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Introduction 
Membranous nephropathy (MN) is the most common cause of the nephrotic 
syndrome in the adult Caucasian population, with an incidence of 
approximately 10-20 per million per year.1 In one third of patients a 
secondary cause for the disease can be identified, such as infections, both 
solid and hematological malignancies, use of drugs, or underlying systemic 
auto-immune diseases.2 In about 70% of patients no underlying cause is 
found and the disease is considered to be idiopathic (iMN). In a majority of 
patients iMN presents as a nephrotic syndrome, with heavy proteinuria (>3.5 
g/day), low serum albumin concentration (<30 g/l) and edema. In most 
patients renal function at presentation is still normal. 
The glomerular lesions in iMN are characterized by thickening of the 
glomerular basement membrane with formation of so called spikes. In 
electron microscopy subepithelial deposits are seen, separated by 
protrusions of newly formed GBM (the spikes). There is foot process 
effacement which reflects severe structural damage to the podocytes. The 
deposits consist mainly of IgG and complement. Passive Heymann nephritis, 
a rat model which histopathologically mimics human iMN, proved to be an 
immune complex glomerulonephritis in which antibodies play an important 
role.3 In this model formation of auto-antibodies to podocyte antigens is 
induced by injecting rats with an extract of proximal tubules. Based on the 
above findings iMN was considered an immune complex disease, resulting 
from binding of antibodies to the podocyte, causing complement mediated 
podocyte injury. For many years the causative antigen in humans has 
remained unknown. Recently, Beck and all were able to show auto-
antibodies in 70% of patients with iMN.4 These antibodies are targeted to the 
M-type Phospholipase A2 receptor (PLA2R), a protein present on the 
podocyte.  These findings will improve our insights in the pathogenesis of 
iMN and indicate that iMN be classified as a true autoimmune disease.  
The natural course of iMN is highly variable: 40-50% of patients develop a 
spontaneous remission whereas 50-60% of patients will eventually develop 
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renal insufficiency.5 To avoid progression of disease, all patients with iMN 
should be treated with optimal supportive care. Dietary salt and protein 
restriction are the first step.6 Furthermore, blood pressure should be lowered 
to values around 125/75 mmHg, preferentially with drugs blocking the renin-
angiotensin system (ACE-inhibitors, angiotensin-receptor blockers) because 
of their anti-proteinuric effects.7 Hypercholesterolaemia should be 
aggressively treated with lipid-lowering drugs, since there is evidence that 
hypercholesterolaemia itself negatively influences podocyte function.8 Since 
there is an increased incidence of thrombo-embolic events in patients with 
iMN and a nephrotic syndrome, oral anticoagulation should be considered in 
patients with serum albumin levels below 20 g/l or those with additional risk 
factors for thrombo-embolic complications. 
In addition to supportive care, patients can be treated with 
immunosuppressive therapy. Although efficacy of immunosuppressive 
therapy with alkylating agents was suggested in two randomized controlled 
trials,9;10 its use in iMN remains heavily debated.11 Opponents in particular 
point to the severe side effects of such therapy and question the overall 
benefits. In the randomized controlled trials that demonstrated the efficacy of 
alkylating agents in iMN, all patients with iMN and a nephrotic syndrome 
were treated. Such a treatment strategy would expose many patients 
unnecessarily to these toxic drugs, since up to half of them would have 
developed a spontaneous remission. Therefore, it was proposed to restrict 
treatment with alkylating agents to patients that would progress to ESRD.11  
Identification of high risk patients then becomes utterly relevant. Other 
authors have advocated use of less toxic agents like calcineurin inhibitors 
(ciclosporin, tacrolimus), mycophenolate mofetil or anti-CD20 antibodies 
(rituximab). However, thusfar the evidence that these agents are effective 
and improve renal outcome is lacking from randomized controlled trials.  
Throughout the years there has been an extensive search for tools to 
differentiate between patients with a favorable or poor prognosis.12 A steady 
rise in serum creatinine concentration and persistent severe proteinuria       
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(8 g/day) proved to be major risk factors for future renal function 
deterioration.13-15 Remission of proteinuria, either spontaneous or after 
treatment, is the most powerful marker of a good long term outcome.16 
However, these factors all require a certain period of observation. In search 
for an early marker, histological markers have been proposed, but appeared 
to be of limited value. A variety of urinary proteins were evaluated as well. 
We have previously shown that urinary beta-2 microglobulin and urinary IgG 
excretion, measured at a single time point after presentation, can predict 
prognosis in iMN with reasonable accuracy.17 This prediction of the 
prognosis in patients with iMN allows restriction of immunosuppressive 
treatment to patients who are at highest risk for end stage renal disease 
(ESRD).   
 
Outline of the thesis 
The studies in this thesis all share a common goal: optimizing the 
management of idiopathic membranous nephropathy in the individual 
patient. The studies address several important questions: can we improve 
predictability of prognosis; is treatment effective; who should be treated and 
when should treatment start; and will the discovery of the anti-PLA2R 
antibodies affect treatment?   
The glomerular filtration rate (GFR, “Renal function”) is the most important 
parameter in any patient with kidney disease. GFR is not only a marker of 
severity of disease, it also is the best predictor of progression to End Stage 
Renal Disease. Preserving GFR is the treatment goal in all patients with 
kidney diseases. GFR can be measured by calculating the urinary clearance 
of exogenous markers, however these procedures are invasive, time- 
consuming and expensive. Therefore, in daily clinical practice we use 
creatinine clearance or formulas based on serum creatinine measurement. 
Altered renal handling of creatinine, which may occur in the nephrotic 
syndrome, will invalidate creatinine based formulas.18 In Chapter 2 we have 
studied the relationship between estimated GFR (MDRD formula), and 
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plasma cystatin C (CysC) and plasma beta-2-microglobulin (β2m) as 
markers of GFR in a cohort of patients with glomerular diseases. 
We previously demonstrated that patients with iMN and a nephrotic 
syndrome who are at high risk for progression of disease, can be identified 
with reasonable accuracy by measuring the urinary excretion of the low 
molecular weight protein β2m, a marker of proximal tubular injury.17 
However, since urinary β2m is technically difficult to measure and not 100% 
specific, the search for alternative markers continues. In Chapter 3 and 
Chapter 4 we evaluated additional urinary biomarkers, which reflect 
proximal but also distal tubular injury. 
We introduced urinary β2m as prognostic marker in 1995 and validated its 
use in the period 1996-2003.12;17;19 Since then, the supportive treatment of 
patients with iMN has improved. Lower blood pressure targets were advised, 
the use of ACE-inhibitors or angiotensin- receptor blockers has become 
standard care, and powerful lipid lowering drugs were introduced. This may 
have altered the natural course of the disease in patients who are not (yet) 
treated with immunosuppressive disease and this may influence the 
predictive properties of urinary β2m measurement at presentation. In 
Chapter 5 we re-evaluated the accuracy of urinary β2m and urinary IgG as 
predictors of outcome in patients with iMN in a large cohort of 129 patients.  
From 1991 onwards we have restricted immunosuppressive therapy to 
patients who were considered to have a high risk for progression: only 
patients with renal insufficiency or a severe intolerable nephrotic syndrome 
were treated with a combination of steroids and cyclophosphamide for 12 
months.1;5 To evaluate the effects of this treatment strategy we studied the 
incidence of ESRD due to iMN in the Netherlands in the period from 1991 to 
2005. The results of this study are presented in Chapter 6. 
  
Urinary β2m measurement allowed us to identify the high risk patients in an 
early stage. This would allow an early start of immunosuppressive therapy, 
before the onset of renal function deterioration. Although early start of 
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therapy may be advantageous, either by reducing the number of 
complications of the nephrotic syndrome, by better preserving renal function 
or by limiting treatment-related side effects, this has not been proven. We 
performed a randomized clinical trial in 26 patients comparing early versus 
late start of immunosuppressive treatment (Chapter 7).  
 
Alkylating agents have proven to be effective in patients with iMN.9;10 
However, due to fear of side effects their use is still debated by some 
authors. In Chapter 8 we shortly comment on the efficacy, side effects and 
areas of uncertainty of the use of both chlorambucil and cyclophosphamide.  
 
Circulating autoantibodies against the M-type phospholipase A2 receptor 
(anti-PLA2R) were recently identified in the majority of US patients with iMN. 
This exciting finding will lead to new insights in the pathogenesis of this 
disease. In Chapter 9 we assessed the prevalence of anti-PLA2R in a cohort 
of 18 Dutch iMN patients and correlated the presence of anti-PLA2R with 
clinical parameters reflective of disease activity. 
 
In Chapter 10 we review the literature and summarize our strategy for 
optimal management of idiopathic membranous nephropathy in the 
individual patient.  
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Abstract 
Background: plasma creatinine concentration and creatinine-based 
equations are most commonly used as markers of glomerular filtration rate. 
The abbreviated MDRD formula is considered the best available formula. 
Altered renal handling of creatinine, which may occur in the nephrotic 
syndrome, will invalidate creatinine based formulas. We have evaluated the 
abbreviated MDRD formula in a large cohort of patients with proteinuria. 
Methods: Data on a cohort of patients with glomerular diseases were 
available from a large database. We have studied the relationship between 
estimated GFR (MDRD formula), and plasma cystatin C (CysC) and plasma 
beta-2-microglobulin (β2m) as markers of GFR. 
Results: The final analysis included 142 patients (93M/49F), age 48 yrs 
(±15), plasma creatinine 101 μmol/l (42-368), plasma albumin 28.0 g/l (10.0-
47.0), proteinuria 6.4 g/day (0.03-37.9), eGFR-MDRD4 64 ml/min/1.73m2 
(15-165), β2m 3.43 mg/l (0.7-13.8), CysC 1.14 mg/ml (0.56-4.00). As 
expected we observed a hyperbolic relationship between eGFR and both 
β2m and CysC. In multivariable analysis plasma albumin concentration 
proved to be the most important predictor of the relationship between eGFR 
and both CysC and β2m. In the presence of hypoalbuminemia eGFR was 
approximately 30-40% higher at equal levels of plasma CysC or β2m. 
Conclusions were similar when using the recently developed CKD-EPI 
formula. Plasma albumin concentration did not affect the relationship 
between eGFR estimated by the 6 variable original MDRD formula and β2m. 
Conclusions: Our data point to discrepancies between eGFR using the 6 
variable MDRD formula and  eGFR using the abbreviated MDRD formula as 
well as the CKD-EPI formula in patients with hypoalbuminemia. One should 
be aware of possible limitations of creatinine based eGFR formulas in 
patients with a nephrotic syndrome. 
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Introduction 
Plasma creatinine concentration is widely used as a marker of glomerular 
filtration rate (GFR). In the individual patient changes in GFR are reflected by 
inverse changes in plasma creatinine concentration. However, plasma 
creatinine concentration is inaccurate for predicting actual GFR since 
creatinine production is highly variable between individuals. Therefore, 
equations have been developed that allow a more accurate estimation of 
GFR. These formulas typically include age and gender to accommodate 
differences in creatinine generation. In recent years the abbreviated MDRD 
formula has been introduced in clinical practice and is considered the best 
available formula.1 This MDRD formula includes the following variables: 
plasma creatinine concentration, age, gender and race. Thus, any condition 
that affects the relationship between plasma creatinine concentration and 
GFR will affect the accuracy of the MDRD formula as estimate of GFR. We 
have previously suggested that renal tubular handling of creatinine is altered 
in patients with a nephrotic syndrome.2  In a pilot study with a limited number 
of patients, we observed that creatinine clearance overestimated GFR 
(measured by inulin clearance) in patients with hypoalbuminemia.  
 
In the present study we have evaluated the abbreviated MDRD formula as 
well as other formulas in a large cohort of patients with proteinuria. We used 
plasma cystatin C (CysC) and plasma beta-2-microglobulin (β2m) as 
markers of GFR. The data suggest that currently used formulas for eGFR 
may be less valid in patients with a nephrotic syndrome. 
 
Subjects and Methods 
In our center, patients with recently diagnosed glomerular diseases are 
evaluated using a standardized protocol as described.3 In brief, blood 
samples and timed urine samples are collected for the measurement of 
plasma creatinine, electrolytes, albumin, urea, β2m, and urinary excretion of 
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creatinine, total protein, β2m, and albumin. In addition aliquots of plasma 
and urine are stored at –70˚ C. Patient data are collected in a database. 
 
For this study we have used data on 180 patients who were entered in the 
database between 1995 and 2006. In addition plasma samples of these 
patients were retrieved, thawed and used for the measurement of CysC and 
plasma creatinine. Methods for the determination of albumin, urea, and β2m 
have been described.3 In our laboratory the creatinine assay was changed in 
2005, and a Jaffé based technique was replaced by an enzymatic method. 
Therefore, plasma creatinine concentration was re-analyzed in all thawed 
samples using the Roche enzymatic method (Roche Diagnostics. Creatinine 
Plus. Indianapolis, IN). CysC was measured using the Dade Behring N latex 
Cystatin C assay.4 Although creatinine and CysC can be reliably determined 
in frozen samples, errors may occur due to effects such as freeze-drying. To 
avoid such errors we regularly measure plasma sodium concentrations in 
thawed samples. Samples with differences in sodium concentration >3% 
compared to the original measurement, are not included for this study. 
 
Calculations and statistics 
Estimated GFR (eGFR) was calculated with the re-expressed 4-variable 
MDRD equation (eGFR-MDRD4) =  175 x (standardized plasma 
creatinine(mg/dl))-1.154 x (age (yr))-0.203 x 1.212 [if black] x 0.742 [if female].5 
We also calculated eGFR using the re-expressed 6 variable MDRD equation 
(eGFR-MDRD6) = 161.5 x (standardized plasma creatinine (mg/dl))-0.999 x 
(age (yr))-0.176 x (BUN (mg/dl))-0.17 x (plasma albumin (g/dl))0.318 x  1.18 [if 
black] x 0.762 [if female].5 We also calculated eGFR by the new CKD-EPI 
equations using serum creatinine, CysC or both (Table 1).6;7 
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Table 1. The CKD-EPI equations for estimating GFR in Caucasians6;7 
 
 
CKD-EPI-Cr 
      
sCr (mg/dl (umol/l))      
 
Female 
 
≤ 0.7 (≤ 62)  
 
eGFR = 144 x (sCr/0.7)-0.329 x(0.993)Age 
 >0.7 (>62) eGFR = 144 x (sCr/0.7)-1.209 x(0.993)Age 
Male ≤0.9 (≤80) eGFR = 141 x (sCr/0.9)-0.411 x(0.993)Age 
 >0.9 (>80) eGFR = 141 x (sCr/0.9)-1.209 x(0.993)Age 
 
CKD-EPI-CysC 
 
eGFR = 127.7 x CysC-1.17 x age-0.13 x (0.91 if female) 
  
 
CKD-EPI-Cr+CysC 
 
eGFR = 177.6 x Scr-0.65 x CysC-0.57 x age-0.20 x (0.82 if female)  
CKD-EPI-Cr = creatinine-based CKD-EPI equation for eGFR; eGFR = estimated 
glomerular filtration rate; sCr = serum creatinine (mg/dl); CKD-EPI-CysC = cystatin 
C-based CKD-EPI equation for eGFR; CysC = serum cystatin C (mg/l); CKD-EPI-
Cr+CysC = CKD-EPI equation for eGFR, based on both serum Creatinine and 
serum cystatin C 
 
 
The correlation between two parameters (non-parametric distributions) was 
analyzed by Spearman’s rank coefficient of correlation.  
To clarify if the relation between the markers of GFR (CysC and β2m) and 
eGFR-MDRD4 was influenced by other parameters, we performed 
univariable and multiple regression analysis. To allow regression analysis, 
non-parametric parameters were transformed. The dependent variable was 
the ratio between inversed CysC or β2m respectively, and eGFR.  
 
The following variables were tested in the regression analysis: age, gender, 
plasma albumin, plasma urea, proteinuria, weight, BMI and body surface 
area (BSA). Multiple regression analysis was performed in forward stepwise 
fashion. 
For comparison between multiple variables, we used a nonparametric 
Kruskall-Wallis test. 
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All data are presented as means (rSD) or medians (range) when 
appropriate. All statistics were performed using SPSS software, version 16.0 
(Chicago, IL). p<0.05 was considered significant. 
 
Results 
Data of 180 patients with a glomerular disease were available. Sixteen 
patients (9%) were excluded from analysis because of differences in plasma 
sodium concentration between original and thawed samples (see Methods). 
Ten patients were treated with immunosuppressive agents including 
steroids, and information on immunosuppressive medication was lacking in 
12 patients. Since the use of steroids clearly affects cellular metabolism and 
lymphocyte survival, and thus will affect production of CysC or β2m, we 
excluded these patients from the analysis. Baseline characteristics of the 
remaining patients (n=142) are shown in Table 2. All patients were 
Caucasian and there were no diabetics. Biopsy proven renal diseases were 
membranous nephropathy (n=66), primary focal segmental 
glomerulosclerosis (n=22), IgA nephropathy (n=23), minimal change 
nephrotic syndrome (n=11) and others (n=20).  Eighty patients had a 
nephrotic syndrome (plasma albumin <30 g/l, proteinuria >3.5 g/day), few 
patients (n=15) had proteinuria <1 g/day. The majority of patients (66%) was 
treated with ACE-inhibitors and/or angiotensin receptor blockers. 
 
As expected we observed a linear relationship between respectively β2m 
and CysC and plasma creatinine (r=0.69 and r=0.86 resp.) and a hyperbolic 
relationship between β2m and CysC and eGFR-MDRD4. In univariable 
analysis plasma urea, plasma albumin, and proteinuria significantly predicted 
the relationship between CysC and eGFR-MDRD4 (respectively p<0.001, 
p=0.003, and p=0.049). In multiple regression analysis both plasma urea and 
plasma albumin remained significant independent predictors (respectively  
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Table 2. Baseline characteristics, n=142 
 
Gender (M/F) 93/49 
Age (yr) 48 r15 
BMI (kg/m2)  25.9 (15.8-42.2) 
BSA (m2) 1.95 r0.21 
Plasma creatinine (μmol/l)  101 (42-368) 
Plasma albumin (g/l) 28.0 (10.0-47.0) 
Plasma CysC (mg/l) 1.14 (0.56-4.00 
Plasma β2m (mg/l) 3.43 (0.7-13.8) 
Proteinuria (g/24hr) 6.4 (0.03-37.9) 
eGFR-MDRD4 (ml/min/1.73m2) 64 (15-165) 
eGFR-MDRD6 (ml/min/1.73m2) 53 (12-128) 
eGFR-CKD-EPI (ml/min/1.73m2) 69 (15-141) 
Treatment with ACE-i/ARB (no.) 94 (66%) 
Data are means rSD or medians (range). CysC = cystatin C; β2m = beta-2-
microglobulin; eGFR-MDRD4 = estimated GFR calculated using the abbreviated 
MDRD formula; eGFR-MDRD6 = estimated GFR calculated using the original 
MDRD formula; eGFR-CKD-EPI = estimated GFR calculated using the CKD-EPI 
formula; ACE-i = ACE-inhibitor; ARB = angiotensin receptor blocker 
 
 
p<0.001 and p=0.016). At equal levels of CysC patients with 
hypoalbuminemia (plasma albumin <25 g/l) had higher eGFR-MDRD4 
(rightward shift of curve, Figure 1).  
We used plasma β2m as a second marker of GFR. In univariable analysis 
only plasma albumin significantly influenced the relationship between β2m 
and eGFR-MDRD4 (p=0.024). In multiple regression analysis plasma 
albumin remained an independent predictor (p=0.027). In the presence of 
hypoalbuminemia there was again a rightward shift of the curve of the 
relationship between β2m and eGFR-MDRD4 (Figure 2). Thus, these results 
suggest that eGFR-MDRD4 provided higher estimates of GFR in patients 
with hypoalbuminemia. 
 
We performed subgroup analyses, limiting the analyses to patients who were 
or were not treated with ACE-inhibitors or angiotensin receptor blockers. 
Results were similar (data not shown). 
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Figure 1.  Relationship between plasma cystatin C and eGFR-MDRD4 for 
different tertiles of plasma albumin (sAlb). Plasma albumin is an 
independent predictor of this relationship (p=0.016). 
 
 
Figure 2.   Relationship between plasma beta-2-microglobulin and eGFR-MDRD4 
for different tertiles of plasma albumin (sAlb). Plasma albumin is an 
independent predictor of this relationship (p=0.027). 
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The original MDRD formula for estimating GFR (eGFR-MDRD6) included 
plasma albumin and plasma urea as variables. Obviously, the relationship of 
eGFR-MDRD6 with eGFR-MDRD4 is thus dependent on plasma albumin 
concentrations.  
We next analyzed the relationship between eGFR-MDRD6 and β2m and 
CysC. In both univariable and multivariable regression the relationship 
between β2m and eGFR-MDRD6 was not influenced by any of the 
parameters, including plasma albumin (p=0.28, Figure 3). Results with CysC 
were different, somewhat to our surprise. We observed a good correlation 
between CysC and eGFR-MDRD6 (r=0.87). In univariable analysis age 
(p=0.043), proteinuria (p=0.002), plasma albumin (p<0.001) and plasma 
urea (p<0.001) significantly influenced the relationship between CysC and 
eGFR-MDRD6. In multivariable analysis both plasma albumin (p<0.001) and 
plasma urea (p<0.001) remained independent predictors, although the effect 
was small. Of note, for plasma albumin the effect was now in the opposite 
direction with a leftward shift of the curve (Figure 4). 
 
We next evaluated the relationship between CysC and β2m. As expected for 
markers of GFR we observed a high correlation between CysC and β2m 
(r=0.87). In univariable analysis age (p=0.005), proteinuria (p=0.002) and 
plasma albumin (p<0.001) significantly influenced the relationship between 
CysC and β2m. In multivariable analysis both age (p=0.01) and plasma 
albumin (p<0.001) remained independent predictors of this relationship. 
Variables included in this analysis were similar to those mentioned in the 
methods section, complemented with eGFR (both eGFR-MDRD4 and eGFR-
MDRD6 were introduced once). At equal levels of β2m patients with 
hypoalbuminemia had lower levels of plasma CysC. The relationship 
between CysC and β2m is depicted in Figure 5. 
 
 
Chapter 2 -------------------------------------------------------------------------------------------------- 
26 
 
 
Figure 3.  Relationship between plasma beta-2-microglobulin and eGFR- MDRD6,   
calculated by using the original MDRD formula, for different tertiles of 
plasma albumin (sAlb). Plasma albumin does not influence this 
relationship (p=0.62). 
 
 
Figure 4.   Relationship between plasma cystatin C and eGFR- MDRD6 for 
different tertiles of plasma albumin (sAlb). Plasma albumin is an 
independent predictor of this relationship (p<0.001). 
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Figure 5.    Relationship between plasma cystatin C and plasma beta-2-
microglobulin for different tertiles of plasma albumin (sAlb). Plasma 
albumin is an independent predictor of this relationship (p<0.001). 
 
 
In recent years other formulas for estimating GFR have been proposed. 
These include formulas based on serum creatinine concentration such as 
the CKD-EPI formula (CKD-EPI-Cr), as well as formulas based on serum 
CysC concentration (CKD-EPI-CysC) or a combination thereof (CKD-EPI-
CysC-Cr). We evaluated these formulas in our patients. In multivariable 
analyses plasma albumin proved an independent predictor of the 
relationship between both CysC and β2m and eGFR calculated by CKD-EPI-
Cr. The relationship between CysC and eGFR calculated by CKD-EPI-CysC 
is invalid for this analysis. Analysing the relationship between β2m and 
eGFR calculated by CKD-EPI-CysC we again found plasma albumin to be 
an independent predictor.  
Tables 3 and 4 summarize the results of eGFR estimates using various 
formulas, for patients with serum albumin levels above and below 30 g/l 
respectively. In these tables patients are grouped according the level of 
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eGFR calculated using the MDRD6 equation. Similar data were obtained 
when using classes of GFR based on serum β2m levels (Tables 5 and 6). 
The tables clearly illustrate that the various formulas provide rather similar 
results in patients with serum albumin levels >30 g/l, although as expected 
the GFR estimated by CKD-EPI formulas was higher in the higher categories 
of GFR. In contrast, the MDRD4 formula as well as the CKD-EPI formulas 
provided higher estimates of GFR in patients with serum albumin <30 g/l, 
when compared to eGFR-MDRD6. 
 
Discussion 
We have evaluated the performance of the MDRD4 and MDRD6 formulas 
for estimating GFR in patients with proteinuric kidney disease. Our data 
indicate that these formulas are not interchangeable in patients with low 
serum albumin levels. Notably, we observed that the relationship between 
eGFR-MDRD4 and the GFR markers CysC or β2m was influenced by 
plasma albumin levels. At equal levels of CysC or β2m, eGFR-MDRD4 was 
higher in patients with hypoalbuminemia. In contrast, the relationship 
between eGFR-MDRD6 and β2m was not dependent on serum albumin 
levels. These discrepancies in performance between the MDRD4 and 
MDRD6 formula are clearly illustrated in Tables 3-6, showing that eGFR 
estimated by the MDRD6 formula is consistently lower than values estimated 
by the MDRD4 formula in patients with low serum albumin levels. Table 3 
and 4 suggests that the MDRD6 formula is biased in patients with 
hypoalbuminemia, since the MDRD4 formula provides values that are 
closest to values derived by CysC based formulas. 
 
Could the MDRD6 formula be invalid in patients with a nephrotic syndrome? 
Integration of serum albumin levels in the MDRD6 formula provided a means 
to account for decreased creatinine generation in patients with malnutrition 
of chronic inflammation. Since hypoalbuminemia in patients with a nephrotic 
syndrome is related to urinary albumin loss and not to malnutrition, the  
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MDRD6 formula may be expected to underestimate GFR in patients with a 
nephrotic syndrome. 
 
However, we suggest that our data indicate that the abbreviated MDRD4 
formula overestimates GFR in patients with a nephrotic syndrome, due to 
altered tubular handling of creatinine. We observed that serum albumin 
levels influenced the relationship between eGFR-MDRD4 and CysC or β2m. 
At equal levels of CysC or β2m, eGFR-MDRD4 was higher in patients with 
hypoalbuminemia. Both CysC and β2m are low molecular weight proteins 
that are filtered in the glomerulus without evidence of tubular secretion. 
Plasma levels of both CysC and β2m correlate well with GFR, both markers 
are used as estimates of GFR, and at least β2m has been validated in 
patients with proteinuria.8-13 Based on these premises, the data indicate that 
eGFR-MDRD4 overestimates real GFR in patients with a nephrotic 
syndrome, which must be attributed to altered tubular handling of creatinine 
in patients with a nephrotic syndrome.  
We have evaluated the recently developed CKD-EPI formulas. Our data 
suggest that also the creatinine based CKD-EPI formula is less valid in 
patients with a nephrotic syndrome. This is not unexpected, since alterations 
in the renal tubular handling of creatinine will affect all formulas that are 
merely based on serum creatinine levels as the sole laboratory parameter. 
 
A closer look at our data and our additional analyses suggest that plasma 
β2m levels are a more consistent marker of GFR than levels of CysC.  
First, the effect of plasma albumin levels on the relationship between plasma 
β2m and eGFR-MDRD4 was quantitatively similar to the effect of plasma 
albumin levels on the relationship between endogenous creatinine clearance 
(ECC) and inulin clearance observed in our previous study.2  In the present 
data an eGFR-MDRD4 of 80 ml/min/1.73m2 equaled a plasma β2m level of 
2.10 mg/l in a patient with a plasma albumin of 40 g/l and 3.32 mg/l in a 
patient with a plasma albumin of 20 g/l (percentage overestimation 37%). In 
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comparison, ECC of 80 ml/min equaled an inulin clearance of  57 
respectively 42 ml/min (percentage overestimation 26%).2 
Secondly, plasma β2m levels correlated with eGFR-MDRD6, independent 
from plasma albumin levels. We have previously suggested that eGFR-
MDRD6 more accurately reflects inulin clearance in the nephrotic 
syndrome.2 Thus far, plasma β2m has received little attention as marker of 
GFR. Older studies observed a very high correlation between plasma β2m 
and GFR.12;13 The performance of β2m was disputed in other studies.14 
However, the latter study included patients with malignancies and systemic 
inflammation, conditions which may be associated with increased 
lymphocyte proliferation and thus generation of β2m. Our data suggest that 
a renewed interest in plasma β2m as a marker of GFR seems warranted. 
 
Although CysC has been used more widely as a marker of GFR, its 
usefulness in clinical practice is debated. In a recent cross-sectional analysis 
of 3418 patients with kidney disease Stevens et al. noted that factors such 
as age, gender, race, BMI, weight, plasma urea, diabetes, proteinuria, and 
blood pressure influenced CysC independent of GFR.15 Of note, in the latter 
study serum albumin was negatively correlated with CysC, in apparent 
contrast with our findings showing lower CysC levels in patients with hypo-
albuminemia. There are clear differences between the studies. We have 
evaluated patients with often severe hypoalbuminemia due to urinary protein 
losses. In contrast, patients in the study of Stevens et al. were normo-
albuminemic (serum albumin 42 g/l). The low serum albumin levels in their 
patients could be due to inflammation or malnutrition, factors that may 
influence cell metabolism. Furthermore, CysC generation is influenced by 
changes in thyroid hormone metabolism.16;17 Our data also point to changes 
in CysC production in patients with hypoalbuminemia. The relationship 
between CysC and eGFR-MDRD6 was shifted to the left in patients with low 
albumin levels. Moreover, at equal levels of plasma β2m CysC levels were 
lower in patients with hypoalbuminemia. Our recent observations that 
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subclinical hypothyroidism is frequent in patients with proteinuria may 
explain these findings.18 
 
Theoretically, formulas based on alternative markers such as CysC might be 
more advantageous. However, this will only be true if the production of this 
alternative marker is not changed in the nephrotic syndrome. Our 
observation of lower CysC levels in patients with hypoalbuminemia already 
suggested that also CysC based GFR formulas could be invalid in patients 
with a nephrotic syndrome. Analysis of the data confirmed this. 
 
Literature data support our conclusions. Based on a study of 42 patients with 
proteinuria we already suggested that creatinine was an invalid marker of 
GFR in patients with a nephrotic syndrome.2 In this study we showed that 
endogenous creatinine clearance as well as eGFR-MDRD4 overestimated 
GFR as measured by inulin clearance in patients with nephrotic syndrome. 
The study can be criticized for its small number of patients. Other studies 
provide supportive arguments. Several studies have reported glomerular 
hypofiltration due to a decreased filtration-coefficient in patients with a 
nephrotic syndrome, despite normal levels of serum creatinine.19;20 Altered 
renal handling of creatinine in patients with proteinuria is supported by an 
analysis of data from the MDRD study, which showed increased tubular 
secretion of creatinine in patients with glomerular diseases. 21 
 
Limitations of the study: 
Our conclusions are based on the assumption that plasma CysC and β2m 
are markers of GFR. We have not used inulin clearance or its alternatives to 
measure GFR. Therefore, our conclusions must be regarded as hypothesis 
generating and need further validation in a larger study in which golden 
standard techniques for measurement of GFR are used. 
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In conclusion, in patients with hypoalbuminemia we propose that estimates 
of GFR using creatinine based formulas may be invalid. As a result a 
clinically significant decrease of GFR may be overlooked in patients with a 
nephrotic syndrome. In daily clinical practice one should be aware of the 
limitations of formulas for estimating GFR in patients with a nephrotic 
syndrome.  
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Abstract 
Background: An accurate prediction of prognosis in patients with idiopathic 
membranous nephropathy (iMN) would allow restriction of 
immunosuppressive treatment to patients who are at highest risk for ESRD. 
Several markers of proximal tubular cell injury have been used as predictors 
of prognosis. In this study we compared the accuracy of urinary beta-2-
microglobulin (Uβ2m) and N-acetyl-beta glucosaminidase (Uβ-NAG) in 
predicting renal insufficiency and remission rates.  
Methods: 57 patients with iMN (38M, 19F; age 48 ±16 yr), a nephrotic 
syndrome, and a serum creatinine level <135 μmol/l were studied 
prospectively. At baseline, a standardized measurement was carried out to 
determine renal function and protein excretion. The end point renal failure 
was defined as a serum creatinine exceeding 135 μmol/l or a rise of serum 
creatinine of >50%. Remission was defined as a proteinuria <2.0 g/day with 
stable renal function.  
Results: Mean follow-up was 80 r36 months. Mean serum creatinine 
concentration was 89 r20 μmol/l, serum albumin 24 r5.3 g/l and proteinuria 
8.9 r4.8 g/24h. Thus far, 28 (49%) patients have reached the predefined 
endpoint of renal failure. Multivariate analysis identified Uβ2m as the 
strongest independent predictor for the development of renal insufficiency. 
Sensitivity and specificity were 81 and 90% respectively for Uβ2m (threshold 
value 54 μg/mmol cr), and 74 and 81% respectively for Uβ-NAG (threshold 
value 2.64 U/mmol cr). Overall remission rate was 44%. A remission 
occurred in 78% of patients with low Uβ2m and in 14% of patients with high 
Uβ2m, and respectively in 71% of patients with low Uβ-NAG and 21% of 
patients with high Uβ-NAG.  
Conclusions: Although both Uβ2m and Uβ-NAG predicted progression and 
remission in iMN, Uβ2m was more accurate. High specificity in predicting 
prognosis should be pursued to avoid unnecessary immunosuppressive 
therapy. We therefore conclude that Uβ2m is superior to Uβ-NAG in 
predicting prognosis in patients with iMN. 
------------------- β2m is superior to β-NAG in predicting prognosis in patients with iMN 
41 
 
Introduction 
Idiopathic membranous nephropathy (iMN) is the most common cause of the 
nephrotic syndrome in adults. Its natural course when untreated is variable: 
14-56% of patients develop a spontaneous remission whereas 34-62% of 
patients develop renal insufficiency.1 Whether patients with iMN should be 
treated with immunosuppressive therapy has been heavily debated in the 
past decades.1-4 Randomized controlled trials showed a treatment benefit 
when treating all patients with iMN and a nephrotic syndrome. Still many 
authors argue against such a strategy, which exposes many patients 
unnecessarily to toxic agents.4 We are also in favor of a restrictive treatment 
strategy, limiting immunosuppressive treatment to patients at highest risk for 
ESRD.1;5 Our group demonstrated that such a strategy is feasible with high 
renal survival rates.6 
 
Evidence of renal function deterioration is probably the most specific marker 
of ESRD.1;7;8 However, postponing the start of treatment until renal 
insufficiency is apparent has unwanted effects: side effects of treatment are 
more frequent and more severe, and renal function may not normalize.1;5 
Therefore, specific markers that allow prediction of prognosis in the early 
phase of the disease are desirable. 
 
We and others showed that patients at highest risk for progressive renal 
failure can be identified by measuring markers of renal tubular injury in the 
urine.9-13 In a previous study we validated the use of the low molecular 
weight (LMW) protein beta-2-microglobulin (β2m) as a highly accurate 
marker in predicting the development of renal insufficiency.10 However, the 
use of β2m poses some problems in daily clinical practice. At first, urinary 
β2m (Uβ2m) can only be measured when urinary pH exceeds 6.0. In more 
acidic urine β2m is unstable and rapidly degrades. In our center patients are 
prepared with sodium bicarbonate before urine samples are collected. In 
spite of this, in about 7% of patients the urinary pH remains below 6.0. 
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Secondly, the methods used for the β2m measurement are not available in 
every clinic and require some experience.14 Thus, although Uβ2m is a 
predictive marker with high sensitivity and specificity, an alternative marker 
could be of use. 
 
Several other markers can be considered to serve as this alternative. The 
excretion of the low molecular weight protein alfa-1-microglobulin (α1m) has 
been studied in patients with iMN.10;12 Although its predictive value was 
similar to β2m, no validation study has been done. Bazzi et al. Used SDS-
PAGE gel electrophoresis and observed that multiple bands in the low 
molecular weight region, evidence of tubular proteinuria, predicted 
prognosis.13 Urinary excretion of IgG also has predictive value in iMN.10;12 
When combining some of the above mentioned markers, specificity can be 
somewhat increased.10 Bazzi et al. evaluated the predictive value of the 
tubular lysosomal enzyme N-acetyl-beta-glucosaminidase (β-NAG) on 
functional outcome and response to therapy in patients with primary 
glomerulonephritis.11 In 36 patients with iMN and a nephrotic syndrome, 
urinary β-NAG (Uβ-NAG) predicted both progression and remission with high 
sensitivity. The measurement of Uβ-NAG does not require special 
precautions for collecting urine samples. Thus, Uβ-NAG may be preferable 
to Uβ2m in daily clinical practice. 
 
In this study we compared the accuracy of Uβ2m and Uβ-NAG in predicting 
functional outcome (renal insufficiency and remission rates) in patients with 
iMN. 
 
Methods 
For this study we have used urine samples collected from patients who 
participated in a prospective study to validate the predictive value of 
Uβ2m.Details of this study have been described.10 In brief, we included 
patients with biopsy proven iMN, a baseline serum creatinine d135 μmol/l, 
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proteinuria t3.5 g/dy and/or serum albumin d30 g/l and a follow-up of at least 
12 months. Patients were excluded when they had been treated with 
immunosuppressive agents other than corticosteroids before the baseline 
measurements.  
 All patients were evaluated at baseline using a standardized protocol of 
urine and blood measurements as described.10 In brief, patients come to our 
ward after an overnight fast. They are instructed to take 4000 mg of oral 
sodium bicarbonate on the evening before their visit to ensure that urinary 
pH exceeds 6.0, which is mandatory for the measurement of Uβ2m. On the 
morning of the measurement, patients are not allowed to take diuretics. 
Upon arrival, 375 to 500 ml tap water is given to enforce diuresis. The 
patients remain supine during two hours except for voiding. Timed urine 
samples are collected, and in the middle of this collection period, a blood 
sample is taken. At baseline two 24-hr urine samples are collected for 
assessment of daily excretion of total protein and creatinine. Techniques for 
the measurements of creatinine, β2m and standard laboratory parameters 
were described before.10 
In addition aliquots of urine were centrifuged and the supernatant was stored 
at -70˚C. In the clinical chemistry laboratory measurement of urinary β-NAG 
was performed at intervals of 2-3 months. Maximal storage time of these 
samples thus was <3 months. For the determination of β-NAG a colorimetric 
assay was performed, using 3-cresolsulfonphthalein-N-acetyl-β-d-
glucosaminide, which is hydrolyzed by NAG with the release of 3-
cresolsulfonphthalein, which is measured photometrically at 580 nm (Roche 
Diagnostics nr. 10875406001). Results of the β-NAG measurements were 
entered in the clinical laboratory files and were not known to the treating 
physicians. After the first evaluation and baseline measurement patients 
were prospectively followed throughout the years and data on treatment, 
remission and survival were obtained.  
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For the current study, the data of the Uβ-NAG were entered in the study 
database. In addition, follow-up of all participating patients was extended 
and completed. The primary aim of the present study was to compare the 
accuracy of Uβ-NAG and Uβ2m for predicting renal survival. The secondary 
aim was to evaluate the value of the different markers for predicting the 
occurrence of a remission, either partial or complete. 
 
Definitions and calculations 
Renal failure was defined as an increase in serum creatinine >50% from 
baseline or an increase of serum creatinine >135 μmol/l In our institution this 
level of renal insufficiency is used to advise start of immunosuppressive 
therapy. Survival was calculated using the date of the baseline 
measurements as t=0.  Partial remission (PR) was defined as proteinuria 
<2.0 g/day with stable renal function. Complete remission (CR) was defined 
as proteinuria <0.2 g/day with a stable serum creatinine concentration. 
Endogenous creatinine clearance (ECC) was calculated from parameters 
measured in 24-hr urine samples, collected at t=0. Besides this, we 
estimated GFR (eGFR) by applying the extended MDRD formula.15  
Uβ2m is expressed as microgram per millimol of urinary creatinine (μg/mmol 
cr), the reference value in healthy volunteers is <22 μg/mmol cr. Uβ-NAG is 
expressed as units per millimol of urinary creatinine (U/mmol cr) and the 
reference value in healthy volunteers is <0.2 U/mmol cr. 
 
Statistical analyses 
The correlation between Uβ2m and Uβ-NAG (non-parametric distributions) 
was analysed by Spearman’s rank coefficient of correlation. Renal survival 
and remission rates were calculated using Kaplan-Meier curves. The 
equality of survival for different groups was assessed by log rank test. 
Predictive accuracy was assessed by making receiver operating 
characteristics (ROC) curves.  We determined the area under the curve 
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(AUC) and calculated the sensitivity and specificity by using the most 
discriminative threshold values for both markers. 
We evaluated the effect of the different parameters in predicting renal 
survival. Univariate analysis and multivariate analysis using Cox proportional 
hazard model with a forward stepwise procedure was performed to identify 
the best independent predictive marker. For this purpose, non-parametric 
values were transformed using log 10 transformation. 
 
All data are presented as means (rSD) or medians (range) when 
appropriate. All statistics were performed using SPSS software, version 
12.0.1 (Chicago, IL). Differences were considered significant with p-value 
<0.05. 
 
Results 
We studied 57 patients (38M, 19F; age 48 ±16 yr) with iMN, who fulfilled our 
inclusion criteria. Baseline characteristics of these patients are given in 
Table 1. Two patients had been treated with prednisone. 
Uβ2m and Uβ-NAG correlated very well (r=0.841). However, there were 22 
patients with a normal Uβ2m level at the baseline measurement, whereas 
Uβ-NAG was elevated in all patients. 
 
Patients have been followed for 80 r36 months (range 12-143 months). 
Thus far, 28 (49%) patients have reached the predefined endpoint of renal 
failure. Overall renal survival rates were 79% at 6 months, 67% after one 
year and 51% after three years. The reason for renal failure was a rise of 
serum creatinine >50% in four patients and a serum creatinine >135 μmol/l 
in 24 patients. 
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Table 1. Baseline characteristics of patients with iMN (n= 57) 
 
Gender (M/F) 38/19 
Age (yr) 48 r16 
MAP (mmHg)  98 r16 
ECC/24hr (ml/min/1.73m2) 88 r 26 
eGFR (ml/min/1.73m2) 71 r 23 
Serum creatinine (μmol/l)  89 r 20 
Serum albumin (g/l) 24 r 5.3 
Serum cholesterol (mmol/l) 8.5 r 2.0 
Interval Bx/measurement (mo) 2 (0-33) 
Follow-up (mo) 80 r 36 
Timed urine sample:  
  β2m excretion (Pg/mmol cr)*  50 (9-6234) 
 β-NAG excretion (U/mmol cr)+ 2.61 (0.60-11.81) 
 Proteinuria (g/24hr) 8.8 (1.1-18.6) 
Data are means rSD or medians (range). iMN: idiopathic membranous nephropathy; 
MAP: mean arterial pressure; ECC-24hr: creatinine clearance calculated from 24h 
urine; eGFR: estimated GFR by extended MDRD formula;  
Bx: biopsy 
* In case of β2m excretion n=56; in one patient, β2m was not measurable because 
pH urine was too low (<6.0).  
+ In case of β-NAG n=53; in four patients β-NAG was not measurable, due to 
technical problems 
 
 
The use of a fixed serum creatinine as end point can be debated.10 
Theoretically, a small increase of serum creatinine concentration may be 
sufficient to cause a patient to fulfil the renal failure criteria. Therefore we 
also assessed the rate of deterioration of renal function. In the 28 patients 
who reached the predefined endpoint of renal failure, serum creatinine had 
increased by an average of 49% from 101 r18 to 149 r23 μmol/l. Estimated 
GFR was 57 r19 ml/min/1.73m2 at baseline and 35 r9 ml/min/1.73m2 at the 
end point. The absolute decrease of eGFR averaged 48 ml/min/1.73m2/ yr. 
For comparison, in the non-failure group the serum creatinine was 0.86 
r0.16 mg/dL at baseline and 0.88 r0.21 at end of follow-up, the average 
change of eGFR was -0.9 ml/min/1.73m2/ yr.   
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A remission occurred in 25 patients (44%); in 12 patients this was a 
complete remission. Remission rates were 9% at 6 months, 14% after one 
year, 36% after three years and 44% after five years. During follow-up four 
patients relapsed (one from CR, three from PR).  
 
ROC curves were made to assess the predictive accuracy of Uβ-NAG and 
Uβ2m. From the coordinate points of the ROC curves sensitivity and 
specificity for both parameters was calculated, using the best discriminative 
thresholds (Table 2).   
Renal survival curves using the risk stratification for Uβ-NAG and Uβ2m are 
depicted in figures 1 and 2. Renal survival was 32% at one year in patients 
with high Uβ2m (>54 Pg/mmol cr) and 93% in patients with low Uβ2m (≤54 
μg/mmol cr). At the end of follow-up the survival rates were 12% and 83% 
respectively. Survival rates at one year in high (threshold >2.64 U/mmol cr) 
and low Uβ-NAG (≤2.64 U/mmol cr) groups were 36% and 89% respectively. 
At the end of follow-up the renal survival was 20% in patients with high Uβ-
NAG and 74% in patients with low Uβ-NAG. All differences in survival were 
highly significant. Calculated sensitivity and specificity were respectively 
82% and 90% for Uβ2m and 74% and 81% for Uβ-NAG. 
 
 
Table 2. Sensitivity, specificity, PPV and NPV of the most discriminative 
thresholds of urinary proteins for the prediction of renal failure in patients 
with iMN. 
 
Parameter AUC Threshold Sensitivity Specificity PPV NPV 
 
β2m excretion 
 
0.906 54 Pg/mmol cr 82% 90% 88% 84% 
β-NAG excretion 
 
0.870 2.64 U/mmol cr 74% 81% 80% 75% 
PPV: positive predictive value; NPV: negative predictive value 
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Figure 1.  Renal survival in patients with iMN with urinary beta-2-microglobulin 
excretion ≤54 μg/mmol cr (Low Uβ2m) and >54 μg/mmol cr (High 
Uβ2m). See methods for definitions of renal failure.  
 
 
 
Figure 2. Renal survival in patients with iMN with urinary N-Acetyl-beta 
glucosaminidase excretion ≤2.64 U/mmol cr (Low Uβ-NAG) and 
>2.64 U/mmol cr (High Uβ-NAG). See methods for definitions of 
renal failure.  
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Figure 3.  Probability of remission (proteinuria <2.0 g/dy) in patients with iMN 
with urinary beta-2-microglobulin ≤40 μg/mmol cr (Low Uβ2m) and 
>40 μg/mmol cr (High Uβ2m).  
 
 
 
Figure 4. Probability of remission (proteinuria <2.0 g/dy) in patients with iMN 
with urinary N-acetyl-beta-glucosaminidase ≤2.50 U/mmol cr (Low 
Uβ-NAG) and >2.50 U/mmol cr (High Uβ-NAG).  
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In univariate analysis, the following parameters were significantly related to 
renal survival: serum creatinine, serum albumin, proteinuria, and urinary 
excretion of Uβ2m and Uβ-NAG (all p<0.001). Multivariate analysis revealed 
that Uβ2m was the strongest independent risk factor (relative risk 2.69; 95% 
confidence interval 1.82-3.98). After Uβ2m, serum creatinine was identified 
as the second independent predictive factor (relative risk 1.04; 95% 
confidence interval 1.00-1.07). 
The probability of reaching a remission using risk stratification with the best 
discriminative thresholds for remission is depicted in figures 3 and 4. A 
spontaneous remission occurred in 78% of patients with low Uβ2m (≤40 
μg/mmol cr) and in 14% of patients with high Uβ2m (>40 μg/mmol cr), and 
respectively in 71% of patients with low Uβ-NAG (≤2.50 U/mmol cr) and in 
21% of patients with high Uβ-NAG (>2.50 U/mmol cr). Calculated sensitivity 
and specificity for predicting a remission were respectively 87 and 83% for 
Uβ2m and 70 and 78% for Uβ-NAG (Table 3).  
 
 
Table 3. Sensitivity, specificity, PPV and NPV of the most discriminative 
thresholds of urinary proteins for the prediction of remission in patients with 
iMN. 
 
Parameter AUC Threshold Sensitivity Specificity PPV NPV 
 
β2m excretion 
 
0.861   40 Pg/mmol cr 87% 83% 78% 86% 
β-NAG excretion 
 
0.851 2.50 U/mmol cr 70% 78% 65% 78% 
PPV: positive predictive value NPV: negative predictive value 
 
 
Discussion 
Our data indicate that Uβ2m is more accurate than Uβ-NAG in predicting 
prognosis of patients with iMN. This conclusion holds for both renal outcome 
parameters, i.e. renal function and remission of proteinuria. 
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Our study may be criticized because we used a fixed value of serum 
creatinine of 135 μmol/l as end point for defining renal failure. We feel that it 
is not justified to withhold immunosuppressive treatment in patients with 
more severe renal insufficiency. However, it has been shown in many 
studies that moderate renal insufficiency with serum creatinine levels of 125-
135 μmol/l are accurate predictors of ESRD.7;16-18 Furthermore, it is evident 
from percentual change in serum creatinine and decrease in eGFR that renal 
function was severely disturbed at the end point. When compared to the 
non-failure group there was a highly significant difference in the decrease of 
eGFR over time, indicating that with this endpoint we are able to identify 
progressors and non-progressors.  
 
The validity of Uβ2m in predicting renal failure was established in our 
previous study.10 The current data show that specificity and sensitivity remain 
similar also after a more prolonged period of follow-up. This is not 
unexpected since most patients with iMN will reach their “destiny” within five 
years after onset of the disease.17 Follow-up beyond this period therefore 
has no major influence on the outcome statistics of renal failure. The value of 
Uβ2m in predicting a remission was not evaluated in our previous study. As 
expected a low urinary excretion of β2m is a prognostic favourable sign, with 
a high sensitivity in predicting the development of a spontaneous remission. 
Late spontaneous remissions can occur up to 75 months after the start of the 
disease. 
In our study Uβ-NAG was less accurate than Uβ2m for predicting 
progressive disease and remission. Bazzi et al. reported a sensitivity and 
specificity of respectively 100 and 72% for Uβ-NAG for predicting 
progression in a subgroup of 36 patients with iMN and a nephrotic 
syndrome.11 The higher sensitivity in Bazzi’s study can on the one hand be 
the consequence of differences between the study populations. More 
important, on the other hand are the differences in endpoints in the two 
studies; in Bazzi’s study progression was defined as progression to chronic 
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renal failure (not otherwise specified), ESRD or doubling of serum creatinine. 
Progression rate after a follow-up of 42 ±23 months was only 19%. We have 
used a less conservative renal endpoint definition and noted a progression 
rate of 49% after 3 years. These differences likely explain the difference in 
reported sensitivities of Uβ-NAG between our and Bazzi’s study.  
 
Both β2m and β-NAG are considered reliable markers of proximal tubular 
cell injury. How can the differences in accuracy be explained? β2m is a 
LMW-protein that is readily filtered through the glomerulus and almost 
completely reabsorbed by the proximal tubulus. When brush border cells in 
the proximal tubulus are damaged, the reabsorption of β2m is impaired, 
leading to an increased urinary β2m excretion. Although in theory 
destruction of a very small number of cells may occur without any 
noteworthy effect on the reabsorptive capacity of the proximal tubulus cells, 
β2m is a reliable early marker of tubulo-interstitial injury. 
β-NAG is an enzyme that is localized in the lysosomes of the proximal 
tubular cells. Severe tubular cell injury, characterized by damage of the cell 
membranes, will lead to losses of cytosolic and lysosomal enzymes in the 
urine. However, the exocytosis-endocytosis pathway is responsible for some 
spilling of β-NAG in the urine, independent of cell injury.19;20 Increased 
activity of the lysosomal pathway may cause increased loss of β-NAG. Since 
proteinuria stimulates lysosomal activity, exocytosis of lysosomal content 
may be responsible for the increased Uβ-NAG excretion in patients with 
proteinuria. Our data are in agreement with these observations. In many 
patients with a normal Uβ2m, Uβ-NAG was already elevated. Thus, Uβ-NAG 
is a less specific marker of tubular injury than Uβ2m.  
 
Are these differences between β2m and β-NAG relevant for daily clinical 
practice? Let us assume an imaginary patient cohort of 100 patients with 
iMN. Based on the natural history of iMN, one would predict that 45 of these 
patients eventually will progress to renal failure.1 Using Uβ2m, with a 
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calculated sensitivity and specificity of respectively 82 and 90%, 5 patients 
will be wrongly classified as high risk and receive unnecessary 
immunosuppressive therapy, where as in 8 patients treatment will unjustly be 
withheld or postponed. The overall accuracy of Uβ2m in predicting renal 
failure is 87%. Based on Uβ-NAG, with a calculated sensitivity and specificity 
of respectively 74 and 81%, 10 patients will receive unnecessary 
immunosuppressive treatment and 12 patients will not receive early 
treatment. The overall accuracy of Uβ-NAG in predicting renal failure is 78%. 
In this imaginary cohort using Uβ-NAG instead of Uβ2m to identify patients 
at risk for renal failure (and thus identify patients for receiving 
immunosuppressive therapy) would have led to overtreatment of 5 additional 
patients (100%). Similar calculations can be made regarding the predictive 
performance of a spontaneous remission. 
 
We feel that an ideal prognostic marker should especially reach a high 
specificity in predicting end stage renal disease, to avoid unnecessary 
treatment in patients who will never progress to renal failure.  Based on both 
specificity and overall accuracy, Uβ2m is superior to Uβ-NAG in predicting 
progression in patients with iMN, although the differences in the AUC’s are 
rather small. Despite its disadvantage of instability in acid urine, Uβ2m 
seems to be more useful in daily clinical practice. The costs of both assays 
are comparable. 
 
In conclusion: both Uβ2m and Uβ-NAG predicted progression and remission 
in iMN. Use of prognostic markers allows identification of high-risk patients at 
an early stage and will lead to better patient selection for treatment. High 
specificity in predicting prognosis should be pursued to avoid unnecessary 
immunosuppressive therapy. As Uβ2m is more accurate than Uβ-NAG, we 
prefer Uβ2m over Uβ-NAG. 
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Abstract 
Background: It is suggested that proteinuria contributes to progressive renal 
failure by inducing tubular cell injury. The site of injury is unknown. Most 
studies have used markers of proximal tubular cell damage. Fatty acid 
binding proteins (FABP’s) are intracellular carrier proteins with different 
expression in the kidney. Liver-type FABP (L-FABP) is found in the 
cytoplasm of proximal tubules, whereas heart-type FABP (H-FABP) is 
localized in the distal tubules. We evaluated the urinary excretion of L-FABP 
and H-FABP in patients with iMN. 
Methods: We have studied 40 patients (27 males, 13 females) with idiopathic 
membranous nephropathy (iMN). Mean age was 48 ±15 yr, serum creatinine 
concentration 89 ±17 μmol/l and proteinuria 8.9 ±5.0 g/24h. Urinary L-FABP 
and H-FABP were measured by ELISA. Renal failure was defined as an 
increase in serum creatinine >25% from baseline with a serum creatinine > 
135 μmol/l or an increase >50% from baseline. 
Results: Urinary L-FABP excretion was detectable in all but one patient. 
Median (range) level was 3.29 (0.7-165.6) μg/mmol creatinine. (Normal 
<0.38 μg/mmol Cr). Urinary H-FABP was undetectable in 9 patients. Median 
level was 1.53 (0.1-90.5) μg/mmol Cr (Normal <0.1 μg/mmol Cr). Both L- 
and H-FABP correlated with urinary β2-microglobulin, urinary α1-
microglobulin and IgG. Urinary H-FABP paralleled L-FABP.  
After a mean follow-up of 75 r32 months, 16 (40%) patients have reached 
the predefined endpoint of renal failure. Both urinary L-FABP and H-FABP 
predicted renal outcome, with calculated sensitivity and specificity of 81 and 
83% for both. 
Conclusions: Urinary L-FABP and urinary H-FABP are increased in patients 
with iMN. There was a high correlation between L-FABP and H-FABP, 
suggesting the concurrent development or existence of proximal and distal 
tubular cell injury. Both L-FABP and H-FABP predicted prognosis in patients 
with iMN. These markers may be of interest as research tools; however, they 
are not superior to more conventional marker proteins. 
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Introduction 
Proteinuria is the hallmark of glomerular disease and an important 
independent predictor of progressive renal injury. Proteinuria is not only a 
reflection of glomerular injury but contributes to renal damage by inflicting 
toxic injury to the renal tubular epithelial cells. Indeed, chronic progressive 
renal failure correlates better with the extent of tubulo-interstitial injury than 
with the severity of glomerular damage.1,2  
The recognition that tubular injury is important in progressive renal injury has 
stimulated the interest in urinary markers of tubular cell injury. Proximal 
tubular cell injury is reflected by an increased urinary excretion of low 
molecular weight proteins such as beta-2-microglobulin (β2m) and alfa-1- 
microglobulin (α1m), brush border enzymes such as Alkaline Phosphatase, 
or cytosolic and lysosomal cellular enzymes such as N-acetyl-beta-
glucosaminidase (β-NAG). We and others have shown that the urinary 
excretion of proximal tubular cell markers can predict prognosis in patients 
with glomerular diseases with reasonable accuracy.3-5 
The above-mentioned proteins are rather non-specific markers of proximal 
tubular cell injury. Little is known on the role of distal tubular injury in 
progressive renal disease. In addition, more specific or pathogenetically 
relevant markers may offer advantages in evaluating various patient groups. 
 
Fatty-acid binding proteins (FABP’s) are intracellular carrier proteins.  Two 
types of FABP’s are localized in human renal tubular cells. Liver-type FABP 
(L-FABP) is found in the cytoplasm of proximal tubules, whereas heart-type 
FABP (H-FABP) is localized in the distal tubules.6;7 An increased urinary 
excretion of FABP’s may simply result from release by structurally damaged 
tubular cells. However, it is suggested that tubular L-FABP expression is 
upregulated by hypoxia and increased excretion may thus occur before the 
occurrence of the actual structural damage.8;9  
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In this present study we evaluated the urinary excretion of L-FABP and H-
FABP in patients with idiopathic membranous nephropathy (iMN).  
 
Material and Methods 
In our center, patients with recently diagnosed membranous nephropathy 
are evaluated using a standardized protocol as described.3 In brief, blood 
samples and timed urine samples are collected for the measurement of 
serum creatinine, albumin, cholesterol, β2m, IgG and transferrin and urinary 
excretion of creatinine, β2m, albumin, IgG, transferrin and α1m.  In addition 
aliquots of urine are centrifuged and the supernatant is stored at –70˚ C. 
Patients are prospectively followed throughout the years, and data on 
treatment, remission and survival are obtained.  
 
For the present study we evaluated urinary samples of 40 consecutive 
patients with a biopsy-proven iMN who fulfilled the following inclusion 
criteria: baseline serum creatinine d135 μmol/l, proteinuria t3.5 g/day or 
proteinuria t2.0 g/day and serum albumin d30 g/l and a follow-up of at least 
12 months. Patients were excluded when they had been treated with 
immunosuppressive agents other than oral corticosteroids before the 
baseline measurements.  
Methods for the determination of serum and urinary proteins have been 
described.3 Urinary L-FABP and H-FABP were measured with ELISA 
assays, using human L-FABP and H-FABP ELISA kits (Hycult biotechnology 
b.v., Uden, The Netherlands).  
 
Calculations 
Endogenous creatinine clearance (ECC) was calculated from creatinine 
measured in 24-hr urine samples. Because 24-hr urine samples were not 
regularly collected during follow up, we calculated GFR by applying the 
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MDRD formula.10 Urinary excretion is expressed as milligrams or 
micrograms per millimol of urinary creatinine (mg/mmol Cr or μg/mmol Cr) 
 
Renal biopsies 
To evaluate the correlation between FABP excretion and the extent of 
tubulo-interstitial damage, renal biopsies were reviewed. We selected those 
biopsies that were obtained within six months of the measurement of the 
urinary markers. The biopsies were reviewed by the renal pathologist (E.J.S) 
without knowledge of neither the amount of FABP excretion nor the clinical 
outcome. In light microscopy, cross sections were evaluated for the extent of 
tubulo-interstitial damage (atrophy, fibrosis) and scored semi-quantitatively 
using a 4-point scale: nil (0 points), mild (1 point), moderate (2 points) or 
severe (3 points).  Furthermore, the tubules themselves were assessed for 
epithelial damage (loss of brush border, loss of continuity of the epithelium, 
activated appearing cell nuclei) in a similar semi-quantitatively manner. A 
distinction was made between proximal and distal tubules and both were 
scored separately. This resulted in three different scores per biopsy: a 
tubulo-interstitial score, a ‘proximal-tubular damage’ score and a ‘distal 
tubular damage’ score. 
 
Statistical analyses 
The correlation between two parameters (non-parametric distributions) was 
analyzed by Spearman’s rank coefficient of correlation. To clarify the relation 
between urinary FABP’s and other urinary parameters, we performed 
multiple regression analysis. This analysis was performed in forward 
stepwise fashion. The following variables were tested: β2m, α1m, IgG, 
proteinuria and eGFR. Variables with evidence of multicollinearity (r>0.8) 
were not put in the analysis at the same time. For comparison between two 
groups (non-parametric distributions) we used the Mann-Whitney U test. 
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Renal survival was calculated by using Kaplan-Meier curves. Renal failure 
was defined as an increase in serum creatinine >25% from baseline with a 
serum creatinine >135 μmol/l or an increase >50% from baseline. Survival 
was calculated using the date of the baseline measurements as t=0. We 
compared renal survival using log-rank tests.  Predictive accuracy was 
assessed by making receiver operating characteristics (ROC) curves.  We 
determined the area under the curve (AUC) and calculated the sensitivity 
and specificity by using the most discriminative threshold values. In this 
analysis lowest measurable level of the FABP’s was taken as value for 
patients with the undetectable levels, in order to make them suitable for risk 
stratification. 
 
All data are presented as means (rSD) or medians (range) when 
appropriate. All statistics were performed using SPSS software, version 
12.0.1 (Chicago, IL). p<0.05 was considered significant. 
 
Results  
Urinary FABP excretion was studied in 40 patients with iMN. Baseline 
characteristics of the patients are shown in Table 1. Thirty-six patients had 
nephrotic range proteinuria, four patients had a serum albumin <30 g/l and 
proteinuria t2.0 g/day. The GFR was below 60 ml/min/1.73m2 in 5 patients.  
 
Urinary L-FABP excretion was measured and detectable in all patients but 
one. Median L-FABP was 3.29 μg/mmol Cr, range 0.7-165.6. In a small 
cohort of non-proteinuric volunteers L-FABP was undetectable in one 
sample, the median level was 0.14 μg/mmol Cr, range 0.13-0.38. 
Urinary H-FABP was undetectable in 9 out of 40 patients. Median H-FABP 
was 1.53 μg/mmol Cr, range 0.1-90.5. In the healthy volunteers H-FABP was 
below the detection limit. 
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Table 1. Baseline characteristics of patients with iMN (n=40) 
 
Gender (M/F) 27/13 
Age (yr) 48 r15 
MAP (mmHg) 99 r16 
Serum creatinine (μmol/l) 89 r17 
Serum albumin (g/l) 25 r5.3 
Cholesterol (mmol/l)  8.0 r1.9 
Follow-up (mo) 75 r32 
ECC-24 hr (ml/min/ 1.73m2) 87 r23 
eGFR (ml/min/1.73m2) 70 r20 
Interval Bx- urine sample (mo) 2 (0-33) 
Timed urine sample:  
 Albumin excretion (mg/mmol Cr) 550 (50-1650) 
 IgG excretion (mg/mmol Cr) 18.0 (1.7-228) 
 β2m excretion (μg/mmol Cr) 44.5 (8.9-6234) 
 α1m excretion (mg/mmol Cr) 3.8 (1.1-38.1) 
 L-FABP excretion (μg/mmol Cr) 3.29 (0.7-165.6) 
 H-FABP excretion (μg/mmol Cr) 1.53 (0.1-90.5) 
 Proteinuria (mg/mmol Cr) 856 (57-2606) 
Data are means rSD or medians (range). iMN: idiopathic membranous nephropathy; 
MAP: mean arterial pressure; ECC-24hr: creatinine clearance calculated from 24h 
urine; eGFR: estimated GFR calculated using the MDRD formula; Bx: renal biopsy; 
mo: months; β2m: beta-2-microglobulin; α1m: alfa-1-microglobulin; L-FABP: liver-
type fatty-acid binding protein; H-FABP: heart-type fatty-acid binding protein. 
Urinary protein excretion is expressed per mmol of urinary creatinine (mmol Cr). 
 
 
Correlation between FABP excretion and other urinary proteins. 
We observed a significant correlation between urinary excretion of L-FABP 
and β2m. (Figure 1, r=0.76)  However, in 15 out of 16 patients with 
completely normal levels of β2m excretion (<24 μg/mmol Cr) L-FABP was 
elevated (median 1.98 μg/mmol Cr, range 0.71-17.2). Urinary L-FABP also 
correlated significantly with urinary IgG (r=0.81), α1m (r=0.77) and total 
protein (r=0.71). Using multiple linear regression analysis L-FABP excretion 
was dependent on β2m excretion (p=0.02) and H-FABP excretion (p=0.04). 
Because of multicollinearity (r=0.81) β2m and α1m were not analyzed at the 
same time. 
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Figure 1. Correlation between urinary L-FABP and urinary β2-microglobulin in 
patients with iMN. Logarithmic scale. r=0.76, p<0.01 
 
 
 
 
Figure 2.  Correlation between urinary L-FABP and H-FABP in patients with 
iMN. Logarithmic scale. r=0.881, p<0.01 In 9 patients urinary H-
FABP was below detection limit.  
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Urinary H- FABP was strongly correlated with L-FABP (Figure 2, r=0.88). As 
depicted in the figure, there were no “outliers” among these patients, i.e. no 
patients with low L-FABP levels but high H-FABP, nor patients with high 
range L-FABP levels without detectable H-FABP. Urinary H-FABP correlated 
with urinary β2m as well (r=0.7). There were 5 patients with elevated urinary 
H-FABP but completely normal urinary β2m. H-FABP also correlated 
significantly with urinary α1m (r=0.78), IgG (r=0.73), β2m  (r=0.7) and total 
protein (r=0.58). Using multiple linear regression analysis H-FABP excretion 
was significantly dependent on β2m excretion (p=0.001) and L-FABP-
excretion (p=0.03). 
 
FABP excretion as a predictor of outcome 
Patients have been followed for 75 r32 months. Thus far, 16 (40%) patients 
have reached the predefined endpoint of renal failure. Overall renal survival 
was 85% at 6 months, 75% after one year and 60% after three years. The 
reason for renal failure was a rise of serum creatinine >25% with a serum 
creatinine >135 μmol/l in 7 patients and a rise of >50% in 9 patients. We also 
assessed the extent of deterioration of renal function. In the 16 patients who 
reached the predefined end point of renal failure, serum creatinine had 
increased by an average of 58% from 100 r17 to 157 r26 μmol/l. Estimated 
GFR was 60 r19 ml/min/1.73m2 at baseline and 33 r7 ml/min/1.73m2 at the 
end point. The absolute decrease of GFR averaged 50 ml/min/1.73m2/ yr. 
For comparison, in the non-failure group, the average change of GFR was 
0.3 ml/min/1.73m2/ yr.  
 
ROC curves were made to assess the predictive accuracy of L-FABP and H-
FABP. From the coordinate points of the ROC curves sensitivity and 
specificity for both parameters was calculated, using the best discriminative 
thresholds (Table 2).   
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Table 2. Sensitivity, specificity, PPV and NPV of the most discriminative 
thresholds of urinary proteins in the prediction of renal failure in patients 
with iMN.  
 
Parameter AUC Threshold Sensitivity Specificity PPV NPV 
 
L-FABP excretion 
 
0.844 5.7 μg/mmol Cr 81% 83% 76% 87% 
H-FABP excretion 
 
0.810 3.1 μg/mmol Cr 81% 83% 76% 87% 
β2m excretion 
 
0.858 95 μg/mmol Cr 81% 88% 81% 88% 
IgG excretion 
 
0.820 26 mg/mmol Cr 75% 88% 80% 84% 
α1m excretion 
 
0.896 4.0 mg/mmol Cr 94% 79% 75% 95% 
PPV: positive predictive value; NPV: negative predictive value; AUC: area under 
the curve; L-FABP: liver-type fatty-acid binding protein; H-FABP: heart-type fatty-
acid binding protein; β2m: beta-2-microglobulin; α1m: alfa-1-microglobulin 
 
 
Renal survival curves using the risk stratification for L-FABP and H-FABP 
are depicted in Figures 3 and 4. Renal survival was 45% at one year in 
patients with high urinary L-FABP (>5.5 μg/mmol Cr) and 96% in patients 
with low urinary L-FABP. At the end of follow-up the survival rates were 16% 
and 87% respectively. Survival rates at one year in high (threshold >3.0 
μg/mmol Cr) and low urinary H-FABP groups were identically to the high and 
low L-FABP groups. At the end of follow-up the renal survival was 15% in 
patients with high urinary H-FABP and 87% in patients with low urinary H-
FABP. All differences in survival were highly significant (log rank test). 
Calculated sensitivity and specificity were respectively 81 and 83% for both 
L-FABP and H-FABP.  
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Figure 3. Renal survival in patients with iMN with urinary L-FABP excretion 
<5.7 μg/mmol Cr (“low”) and t5.7 μg/mmol Cr (“high”). Renal failure 
was defined as an increase in serum creatinine >25% from baseline 
with a serum creatinine >135 μmol/l or an increase >50% from 
baseline.   
 
 
 
 
 
Figure 4.  Renal survival in patients with iMN with urinary H-FABP excretion 
<3.1 μg/mmol Cr (“low”) and t3.1 μg/mmol Cr (“high”). Renal failure 
was defined as an increase in serum creatinine >25% from baseline 
with a serum creatinine >135 μmol/l or an increase >50% from 
baseline. 
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To put these results in perspective, other known predictive markers were 
plotted into ROC-curves in the same way. We calculated sensitivity and 
specificity of β2m, α1m and IgG excretion in this cohort.  
(Data shown in Table 2) 
 
Correlation between FABP excretion and tubulo-interstitial changes in renal 
biopsies. 
In 30 patients the interval between the renal biopsy and the measurement of 
the urinary markers was less than six months. Archival biopsy material of 21 
patients could be retrieved. The biopsies were coming from five different 
pathological laboratories and had been prepared according to local protocol. 
Median interval between the biopsy and measurement of the urinary markers 
was 1.5 months (range 0-4.1). The majority of patients (62%) had only mild 
tubulo-interstitial injury, and few had nil or severe TI-injury (Figure 5). There 
was no significant correlation between L-FABP or H-FABP and the TI- score 
(Figure 5). Next we analyzed more specifically damage of the proximal and 
distal tubules. This analysis also did not reveal a correlation between 
respectively L-FABP and proximal tubular damage and H-FABP and distal 
tubular damage.   
 
Discussion 
Our study demonstrates that urinary excretion of L-FABP and H-FABP is 
increased in patients with iMN. Both L-FABP and H-FABP predicted 
prognosis with high accuracy. Admittedly, in this study neither L-FABP nor 
H-FABP was superior to known proximal tubular markers like β2m in 
predicting progressive disease. 
 
Our study may be criticized because of the definitions of the end-point of 
renal failure. Besides an increase of 50% of serum creatinine we used an 
increase of 25% in combination with a fixed value of serum creatinine of 135 
μmol/l as end point for defining renal failure. We do not consider it justified to  
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Figure 5.  Correlation between tubulo-interstitial damage (TI-score) and urinary 
L-FABP (open symbols) and H-FABP excretion (closed symbols). 
Correlations are not significant. For definition of the TI-score see 
Methods. 
 
withhold treatment with immunosuppressive therapy in patients with higher 
serum creatinine values. From the literature it is well established that a 
serum creatinine >135 μmol/l or a deterioration of renal function is a 
powerful predictor of ESRD.11-14 Furthermore, our analysis shows that GFR 
was severely decreased in the patients who met our end-point criterium as 
compared to the non-failure group. 
 
FABP’s are intracellular carrier proteins that bind and transport free fatty 
acids (FFA’s) to mitochondria or peroxisomes. The family of FABP’s 
presently contains nine distinct types of 15 kDa cytoplasmic proteins, which 
are expressed in tissues with an active fatty acid metabolism.15 Each type is 
named after the tissue in which it was first identified and shows a 
characteristic tissue distribution.  
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The primary function of FABP is the facilitation of intracellular long-chain 
fatty acid transport. Other functions include putative protection against 
detrimental effects of locally high concentrations of long chain fatty acids. 
FABP may act as an endogenous antioxidant by promoting FFA metabolism 
and by binding long-chain fatty acid oxidation products.16 The cellular 
expression of FABP is primarily regulated at the transcriptional level. Gene 
upregulation can occur in response to changes in lipid metabolism as 
caused by (patho-)physiological stimuli that induce oxidative stress, like 
diabetes, hypertrophy, endurance training and ischemia.15  
In humans L-FABP is localized in the liver, the small intestine and in 
proximal renal tubular cells, whereas H-FABP is widespread in the heart, the 
brain, the small intestine, skeletal muscles and distal renal tubular cells. 
Kamijo et al. observed elevated levels of L-FABP in the urine of 48 patients 
with non-diabetic chronic kidney disease (CKD).17;18 Urinary excretion of L-
FABP increased with deterioration of renal function. In these patients with 
various renal diseases urinary L-FABP proved to be more sensitive in 
predicting progression of CKD than proteinuria. Serum levels of L-FABP in 
patients with CKD did not influence the urinary L-FABP excretion.19  
As serum H-FABP is known to be a marker of myocardial ischemia and is 
used as an indicator of myocardial damage, Nayashida et al. studied the 
influence of renal function on serum and urinary H-FABP levels in patients 
undergoing a primary coronary artery bypass.20 In this small group of 19 
patients, the creatinine clearance correlated inversely with the peak levels of 
serum H-FABP, but correlated with the peak levels of urinary H-FABP. It was 
concluded that serum H-FABP, which is deriving from myocardial cells, is 
cleared by the kidney and that this clearance can be impaired when 
creatinine clearance is decreased, resulting in lower urinary levels of H-
FABP. To our current knowledge, urinary excretion of H-FABP has never 
been studied in patients with renal disease.  
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In our study urinary L-FABP correlated well with well-known markers of 
proximal tubular injury such as β2m and α1m. However, while urinary L-
FABP was elevated in all but one of the patients, excretion of β2m was 
normal in about one quarter of patients. These observations lent support to 
the suggestion of Kamijo et al. that L-FABP may be elevated before 
structural tubular damage occurs, due to cellular upregulation of L-FABP 
gene expression in reaction to cellular oxidative stress.8;18 L-FABP could 
therefore be an early sign of tubular stress and its urine excretion may 
increase before other markers do. Studies of the early rise in the urinary 
excretion of L-FABP may be relevant and contribute to our understanding of 
the evolution of tubular stress and injury. However, from a clinical point of 
view our data clearly indicate that measurement of urinary L-FABP is not a 
better marker of prognosis than more conventional markers such as β2m 
and α1m. In retrospect, this may not be a surprise since urinary L-FABP may 
be increased in the early phase in response to stress, before the actual 
“point of no return” is reached. 
 
Urinary H-FABP levels were elevated in most patients. This suggests that in 
patients with iMN and proteinuria both proximal and distal tubular cells are 
involved in the process of tubulo-interstitial injury. We cannot exclude that 
urinary H-FABP, like L-FABP, is increased due to upregulation in the distal 
tubulus in response to stress rather than cell damage. The fact that there are 
patients with increased H-FABP excretion but normal β2m levels may 
support this idea. Thus, the increase of urinary H-FABP may not necessarily 
reflect injury.  
Urinary H-FABP correlated well with the urinary excretion of other proximal 
tubular markers, including L-FABP.  However, H-FABP was never elevated 
in absence of elevation of L-FABP, while there were patients with elevated L-
FABP in absence of an increased H-FABP. Based on this finding one could 
speculate that tubular stress or damage accompanying primal glomerular 
lesions occurs in a sequential way, starting in the proximal tubules and then 
Chapter 4 -------------------------------------------------------------------------------------------------- 
72 
 
progressing to the distal parts. The elevation of the distal tubular marker H-
FABP would then be a sign of more extensive disease. While the exact 
mechanisms of the pathogenesis of tubulo-interstitial injury in glomerular 
diseases remain unclear, further investigation in differences between 
proximal and distal tubular markers like L-FABP and H-FABP may bring new 
insights to the pathogenesis and process of tubulo-interstitial damage.21  
 
We did not observe a correlation between the level of FABP excretion and 
histological characteristics. At first sight this may seem strange. Obviously, 
the study has limitations. The number of biopsies was limited. In most 
patients the renal biopsy and the measurement of the FABP’s was not 
performed at the same moment. We studied biopsies that were performed 
within 6 months of the urine measurement (n=21). Limiting this analysis to 
biopsies performed within 3 months (n=18) did not change the results. 
Furthermore, the renal biopsies were retrieved from five different centers, 
which differ in quality of staining techniques, adding bias. Also, evaluation of 
injury at the cellular level and the distinction between proximal and distal 
tubules is difficult. Lastly, only few biopsies had evidence of moderate and 
severe tubulo-interstitial injury. This is no surprise since our study was 
intended to evaluate prognostic markers and thus excluded patients with 
renal insufficiency. In the latter group of patients high concentrations of 
urinary FABP’s might have been present. However, we have measured 
urinary L-FABP and H-FABP in some patients with IgA nephropathy and 
severe renal insufficiency. In these patients the excretion of the urinary 
FABP’s was increased compared to controls, however values were 
comparable to those in the patients with membranous nephropathy. 
Although the above mentioned arguments may explain the lacking 
correlation between urinary FABP excretion and tubulo-interstitial injury, an 
alternative explanation is more likely. Indeed, our data are in line with the 
notion that FABP expression is upregulated by renal tubular cells even 
before serious injury is present.  
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In conclusion: urinary L-FABP and urinary H-FABP are increased in patients 
with iMN. There is a high correlation between L-FABP and H-FABP, 
suggesting the concurrent development or existence of proximal and distal 
tubular cell injury. Both L-FABP and H-FABP predicted prognosis in patients 
with iMN with the same accuracy. Although they are not superior to more 
conventional marker proteins, measurements of urinary L-FABP and H-
FABP may be of interest as research tools to determine pathogenetic 
mechanisms. 
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Abstract 
Background: Accurate prediction of prognosis in idiopathic membranous 
nephropathy (iMN) allows restriction of immunosuppressive therapy to 
patients at high risk for end stage renal disease. Here we re-evaluate urinary 
low molecular weight proteins as prognostic markers and explore causes of 
misclassification. 
Design, setting, participants & measurements: In a cohort of 129 patients 
with serum creatinine concentration <135 μmol/l and proteinuria ≥3.0 g/10 
mmol, urinary α1- (uα1m) and β2-microglobulin (uβ2m) excretion rate was 
determined. Urinary α1m and uβ2m/creatinine ratio was also obtained. We 
defined progression as a rise in serum creatinine ≥50% or ≥25% and an 
absolute level ≥135 μmol/l.  
Results: Median survival time was 25 months and 47% of patients showed 
progression. The ROC-AUC for uβ2m was 0.81 (95% CI: 0.73-0.89). Using a 
threshold value of 1.0 μg/min, sensitivity and specificity were 73 and 75%. 
Similar accuracy was observed for the uβ2m/creatinine ratio with sensitivity 
and specificity of 75% and 73% at a threshold of 1.0 μg/10 mmol creatinine. 
Similar accuracy was found for uα1m and uα1m/creatinine ratio. Blood 
pressure and cholesterol contributed to misclassification. Repeated 
measurements improved accuracy in patients with persistent proteinuria, the 
positive predictive value of uβ2m increased from 72% to 89% and the 
negative predictive value from 76% to 100%. 
Conclusions: Urinary excretion of α1- and β2-microglobulin predict prognosis 
in iMN. A spot urine sample can be used instead of a timed sample. A 
repeated measurement after 6 to 12 months increases prognostic accuracy. 
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Introduction 
Idiopathic membranous nephropathy (iMN) is an important cause of 
nephrotic syndrome in adults.1 Spontaneous remission of proteinuria occurs 
in 30 to 50% of patients.2;3 Despite treatment with angiotensin converting 
enzyme inhibitors (ACEi), angiotensin-II receptor blockers (ARB) and statins, 
between 25 and 50% of patients show progressive loss of renal function.4;5  
Although alkylating drugs improve outcome in patients with iMN,6-8 these 
agents often have adverse effects such as bone marrow depression, 
infections and increased risk of cancer.8 Therefore one should restrict their 
use to patients at highest risk of progression to end stage renal disease.  
There has been an extensive search for tools that differentiate between 
patients with a favorable and poor prognosis.9 Histological markers 
appeared to be of limited value, whereas the severity of proteinuria is a 
better marker for outcome.2-4;10 Remission of proteinuria or increased serum 
creatinine concentration during follow-up are the most powerful predictors of 
outcome, however these are late events.11;12 In past decades, several 
specific urinary proteins were evaluated as early prognostic markers. 
Candidates such as TGF-β, βNAG, IgG, complement factors, α1- and β2-
microglobulin (uα1m and uβ2m) have been proposed.13-19 In a previous 
study of 57 patients we showed that uIgG and uβ2m can accurately predict 
prognosis.20 Since conservative treatment and prognosis may have changed 
in recent years, we re-evaluated the data. 
Here we report the value of uα1m, uβ2m and uIgG as predictors of outcome 
in a cohort of 129 patients with iMN. In addition we evaluated the role of 
these markers in clinical practice using low molecular weight 
protein/creatinine ratios. We also analyzed possible causes of 
misclassification and the value of repeated measurements. 
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Study Population and Methods 
Population 
Patients with biopsy proven iMN who attended our clinic for urinary analysis 
between January 1995 and June 2009 were assessed for this study. 
Inclusion criteria were normal renal function, defined as serum creatinine 
<135 μmol/l (≈1.5 mg/dL), proteinuria ≥3.0 g/10mmol creatinine, and an 
interval between biopsy and urinary analysis <3 years. Exclusion criteria 
were participation in the intervention arm of an immunosuppressive therapy 
trial,21 follow-up duration <1 year or treatment with immunosuppressive 
drugs prior to urinary analysis. Follow-up was completed until an end point 
was reached or until June 2010. Patients were followed at our hospital or by 
nephrologists in referring centers. Patients were treated with diuretics, given 
dietary sodium restriction, ACE inhibitors and/or angiotensin II receptor 
blockers and statins according to existing guidelines. Immunosuppressive 
therapy was advised only in patients with deteriorating kidney function or 
severe untreatable nephrotic syndrome. Patients with persistent proteinuria 
were invited for a repeated evaluation after 6 to 12 months. 
 
Data collection 
Details of our protocol for the evaluation of patients with iMN are described 
elsewhere.20 Patients were instructed to fast overnight and take sodium 
bicarbonate on the evening before urinary analysis in order to alkalinize 
urine, because β2m disintegrates in acidic urine. They did not take diuretics 
on the morning of urinary analysis. Timed urine samples were collected and 
blood samples were taken. IgG and uα1m were measured using a BNII 
nephelometer (Behring, Marburg, Germany) and uβ2m was measured using 
ELISA.22 The excretion of total protein and low molecular weight proteins 
was standardized against urinary creatinine concentration, to obtain a urine 
protein-creatinine ratio. Data on serum creatinine concentration, urinary 
protein and creatinine excretion during follow-up and use of 
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immunosuppressive therapy, ACE inhibitors, ARBs and lipid lowering drugs 
were gathered from medical records.  
 
Definition of end-points 
We defined progression as 1) a rise in serum creatinine >50%, 2) a rise in 
serum creatinine >25% and an absolute level ≥135 μmol/l or 3) the need for 
immunosuppressive therapy because of severe nephrotic syndrome as 
judged by the treating physician.23 Partial remission of proteinuria was 
defined by urinary protein excretion <2.0 g/10mmol creatinine with stable 
serum creatinine. We also applied the definition of partial remission as 
suggested by Troyanov et al. (proteinuria <3.5 g/day and a reduction of 
>50% with a stable kidney function).2 Remission was considered complete 
when protein excretion was <0.2 g/10mmol creatinine. Spontaneous 
remission means it occurred without immunosuppressive therapy. 
 
Statistical analyses 
All analyses were performed with Stata 10 (Statacorp LP, TX, USA). Median 
values and inter quartile ranges were calculated. Incidence of patient 
outcomes was plotted using the competing risks method. The area under the 
receiver-operator characteristic curve (ROC-AUC) was calculated to 
compare prognostic value of urinary markers. We determined cut-off values 
so that false positive and false negative rates would be minimal and the 
proportion of correctly classified patients maximized and we calculated 
sensitivity, specificity, positive and negative predictive values. Finally we 
created a logistic model using a backward stepwise algorithm with exclusion 
at p>0.10 and re-inclusion at p<0.05. The model’s ROC-AUC was compared 
to the AUC for either uα1m or uβ2m to evaluate if it added to prognostic 
power. Sources of misclassification were explored by tabulation of baseline 
characteristics by classification and outcome. One way ANOVA or Χ2 tests 
were used to compare the four groups. Classification according to repeated 
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measurements was cross tabulated by outcome to explore the value of 
repeated measurements. 
 
Results 
Population characteristics 
Between January 1995 and June 2009 we evaluated 300 patients with 
biopsy proven iMN. One-hundred-sixty-nine patients met criteria for 
enrollment (Figure 1). In 17 patients follow-up was less than 12 months. No 
follow-up data were available for 23 patients. Thus, 129 patients were 
available for analysis. Baseline characteristics are presented in Table 1. The 
majority of patients was male and middle aged. Median serum creatinine 
concentration was 88 μmol/l (inter quartile range 76-103) and median 
proteinuria 8.0 g/10mmol creatinine (IQR 5.6-10.7). Urinary excretion of low 
molecular weight proteins was increased, with median urinary α1- and β2-
microglobulin excretion of 41 (reference <10) and 0.6 (reference <0.2) 
μg/min, respectively. Virtually all patients (99%) received ACE inhibitors 
and/or ARBs during follow-up and the majority (90%) was treated with lipid 
lowering medication. 
 
Outcomes 
Clinical outcome is reported in Table 1 and illustrated in Figure 2. Sixty 
patients (47%) showed progression. In 30 patients serum creatinine 
concentration increased by >50%, in 24 patients serum creatinine 
concentration increased >25% and reached values ≥135 μmol/l, and 6 
patients started immunosuppressive therapy because of severe nephrotic 
syndrome. Of the patients showing progression, 47% did so within 12 
months, 72% within 24 months and all within 5 years. In 63 patients 
proteinuria spontaneously decreased by >50% and reached values <3.5 
g/day. With the exception of two cases, proteinuria in these patients 
decreased to concentrations <2.0 g/10 mmol creatinine. Twenty three 
----------------------------------------------------- LMW-proteins as prognostic markers in iMN 
83 
 
 
Figure 1.  Flowchart of the inclusion of patients. 
 
 
Figure 2.  Patient outcomes. The black line represents renal survival without 
progression. The speckled lines represents partial remission defined 
as proteinuria <3.5 g/day and <50% since baseline (- y - y); partial 
remission defined as proteinuria <2.0 g/day (− − −), and complete 
remission defined as proteinuria <0.2 g/day (- - - -). 
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percent of patients who developed spontaneous remission (<2.0 g/10 mmol 
creatinine) did so within 12 months, 59% within 24 months, and 97% within 5 
years. Forty three percent of the patients who went into partial remission, 
eventually had a complete remission of proteinuria.  
 
Prognostic value of uα1m and uβ2m 
We plotted a ROC curve for the prognostic accuracy of uα1m, uβ2m and 
uIgG excretion (Figure 3, left panel). ROC-AUC was 0.81 (95% confidence 
interval: 0.73-0.88) for uα1m, 0.81 (0.73-0.89) for uβ2m and 0.75 (0.66-0.84) 
for uIgG. ROC curves for uα1m and uβ2m and uIgG creatinine ratios are 
presented in Figure 3, right panel. The ratios yielded similar ROC-AUCs: 
0.80 (0.72-0.87), 0.80 (0.72-0.88) and 0.74 (0.66-0.83) for uα1m, uβ2m and 
uIgG respectively. The optimal cut off value for the excretion of uβ2m based 
on our current data is 1.0 μg/min (Table 2). At this threshold, the positive 
predictive value (PPV) and negative predictive value (NPV) were 72% and 
76%, respectively. For uα1m, a threshold value was determined at 50 
μg/min, with a PPV of 76% and NPV of 73%. When excretion was 
standardized for urinary creatinine concentration, threshold values were 1.0 
μg/10mmol creatinine and 75 mg/10mmol creatinine for uβ2m and uα1m 
respectively (supplementary Table S1).  
 
Sources of misclassification 
To evaluate potential sources of misclassification we tabulated baseline 
characteristics by classification based on uβ2m excretion rate (Table 3). In 
general, progressors showed higher median serum creatinine (110 and 90 
μmol/l versus 80 and 86 μmol/l) and cholesterol concentrations (8.4 and 8.5 
versus 6.5 and 6.1 mmol/l) than non-progressors. MAP (94 mmHg versus 93 
mmHg) and proteinuria (5.5 versus 6.2 g/10mmol creatinine) were 
remarkably similar between misclassified progressors and correctly   
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Figure 3.  Left Panel: ROC curves for prognostic accuracy of urinary excretion 
rate of α1- (− − −), and β2-microglobulin (black line) and IgG (- y - y).  
Both α1- and β2-microglobulin excretions rates are expressed in 
μg/min and IgG in mg/24h. Areas under the curve were: uα1m: 0.81 
(0.73-0.88), uβ2m: 0.81 (0.73-0.89) and IgG: 0.75 (0.66-0.84).  
Right Panel: ROC curves for the prognostic accuracy of α1- (− − −), 
and β2-microglobulin (black) and IgG (- y - y). When expressed as 
mg / 10mmol creatinine. Areas under the ROC curve were: 
uα1m/creat: 0.80 (0.72-0.87), uβ2m/creat: 0.80 (0.72-0.88) and 
uIgG/creat: 0.74 (0.66-0.83). 
 
 
classified low risk patients, whereas serum albumin levels were markedly 
higher in non-progressing patients whose uβ2m was <1.0 μg/min than in 
progressors (27 g/l versus 23 g/l). To further improve prognostic accuracy 
we created two models, one based on uβ2m, the other on uα1m. We 
included baseline MAP, serum cholesterol, serum creatinine, serum albumin 
and proteinuria. All predictors were log transformed and a stepwise 
backward selection algorithm was used. The model including uβ2m also 
retained serum cholesterol and creatinine as independent predictors. Its 
ROC-AUC was 0.85 (0.79-0.92). A similar model including uα1m had a 
ROC-AUC of 0.86 (0.80-0.93). The final models are presented in 
Supplementary Table S2. 
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Table 2. Test characteristics for urinary low molecular weight protein    
excretion to predict progression in 129 iMN patients. 
PPV: positive predictive value, NPV: negative predictive value, uβ2m: urinary β2-
microglobulin, uα1m: urinary α1-microglobulin. Test positives are the number of 
patients with a urinary α1- / β2-microglobulin excretion greater than the threshold 
value. 
 
 
We questioned if tubule-interstitial damage could be of value. In 95 patients 
the interval between kidney biopsy and urine analysis was <3 months. 
Biopsies of 47 were available for review. Tubulo-interstitial injury (scored 0-
3) correlated with uβ2m (r=0.58). However the tubule-interstitial injury score 
did not improve the predictive accuracy in individual patients and did not 
explain discordances (Supplementary Table S3). 
 
  
threshold  
value 
sensitivity specificity PPV NPV 
false 
positives  
(n) 
false 
 negatives 
 (n) 
test  
positives  
(n) 
β2m 
≥ 0.5 μg/min 80% 67% 68% 79% 23 12 71 
≥ 1.0 μg/min 73% 75% 72% 76% 17 16 61 
≥ 1.5 μg/min 65% 83% 76% 73% 12 21 51 
≥ 2.0 μg/min 58% 83% 76% 70% 12 24 47 
≥ 2.5 μg/min 55% 84% 75% 68% 11 27 44 
α1m 
≥ 40 μg/min 77% 71% 70% 78% 20 14 66 
≥ 50 μg/min 65% 83% 76% 73% 12 21 51 
≥ 60 μg/min 57% 86% 77% 69% 10 26 44 
≥ 70 μg/min 45% 88% 77% 65% 8 33 35 
≥ 80 μg/min 42% 90% 78% 64% 11 27 44 
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Table 3. Baseline characteristics for progressors and non-progressors 
classified according to initial excretion of β2-microglobulin ≥1.0 μg/min 
 
  Progressors 
β2m≥1.0 β2m<1.0 
n (% male) 44 (75%) 16 (62%) 
Age at time of biopsy (years) 57 (47 - 64) 49 (44 - 58) 
Time between biopsy and urine analysis (months) 2 (1 - 4) 2 (0 - 2) 
Survival time (months) 11 (6 - 25) 16 (7 - 25) 
MAP  (mmHg) 100 (89 - 112) 94 (81 - 105) 
Laboratory:  serum creatinine (μmol/l) 110 (97 - 119) 90 (68 - 95) 
                       serum albumin (g/l) 20 (17 - 24) 23 (18 - 26) 
                   serum cholesterol (mmol/l) 8.4 (7.0 - 9.8) 8.5 (5.7 - 9.3) 
                   eGFRMDRD4 (ml/min/1.73m2) 58 (53 - 67) 75 (65 - 97) 
Urine samples: 
   proteinuria (g /10 mmol creatinine) 10.7 (9.3 - 12.7) 5.5 (4.8 - 8.7) 
   β2-microglobulin (μg/min) 7.8 (2.3 - 13.8) 0.3 (0.1 - 0.5) 
   α1-microglobulin (μg/min) 106 (61 - 131) 31 (20 - 44) 
   IgG (mg/24h) 511 (356 - 776) 157 (74 - 217) 
   Selectivity Index 0.27 ±0.08 0.11 ±0.05 
Medication 
    ACEi/ARB use at time of biopsy   36% 20% 
ACEi/ARB use during follow-up 100% 100% 
Statin use at time of biopsy  20% 7% 
Statin use during follow-up 93% 93% 
Outcomes 
Progression 100% 100% 
50% rise in serum creatinine (n) 18 12 
25% rise and serum creatinine >135 μmol/l (n) 24 0 
clinical progression (n) 2 4 
Spontaneous remission 
    partial remission:< 2.0 g/10 mmol 0% 0% 
partial remission: <3.5 g/10 mmol & ≥50% reduction 0% 0% 
complete remission 0% 0% 
Data are presented as mean ±SD or median (interquartile range). MAP: mean 
arterial pressure. ACEi: angiotensin converting enzyme inhibitor. ARB: angiotensin-II 
receptor blocker.  
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Table 3. continued 
 
 
 
Non-progressors 
β2m<1.0 β2m≥1.0 p 
52 (65%) 17 (65%) 0.69 
49 (38 - 60) 56 (51 - 64) 0.02 
1 (1 - 4) 2 (1 - 4) 0.88 
53 (28 - 84) 41 (24 - 54) 
93 (86 - 104) 99 (92 - 104) 0.16 
80 (70 - 87) 86 (82 - 91) <0.001 
27 (23 - 31) 22 (17 - 25) <0.001 
6.5 (5.5 - 7.7) 6.1 (5.3 - 7.3) 0.004 
85 (78 - 93) 75 (67 - 80) <0.001 
6.2 (4.7 - 8.5) 9.1 (5.9 - 11.0) <0.001 
0.1 (0.2 - 0.4) 2.6 (1.3 - 7.7) 
22 (12 - 37) 50 (39 - 83) 
119 (62 - 219) 351 (158 - 607) 
0.15 ±0.07 0.21 ±0.08 <0.001 
16% 6% 0.03 
98% 100% 0.68 
10% 6% 0.26 
84% 94% 0.43 
0% 0% 
- - 
- - 
- - 
90% 82% 
94% 82% 
40% 29% 
Misclassified progressors are those patients who did show progression but had 
uβ2m <1.0 μg/min. ANOVA was used to compare continuous data between the four 
groups and X2 tests to compare medication use and gender. 
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Repeated measurements 
We analyzed data of 44 patients with persistent proteinuria who underwent 
repeated urinary measurements. Baseline characteristics did not differ from 
total study population characteristics (Supplementary Table S4). At the time 
of repeated measurements, patients generally had lower blood pressure 
(MAP 95 versus 89 mmHg) and serum cholesterol values (7.8 versus 6.0 
mmol/l) compared to baseline, likely due to intensified conservative 
treatment. Median serum creatinine concentrations (85 versus 97 μmol/l) 
and uβ2m (0.5 versus 1.1 μg/min) were higher. We tabulated uβ2m at 
baseline and repeated measurement by outcome in Table 4. Patients with 
an uβ2m above 1.0 μg/min at both measurements invariably showed 
progression (n=11). In contrast, none of the 17 patients with uβ2m <1.0 
μg/min at two measurements showed progression. Fifteen (88%) of them 
went into spontaneous remission. Four patients with uβ2m >1.0 at baseline, 
had uβ2m below the threshold at the repeated measurement. Three of them 
did show progression.  In all three patients blood pressure was greatly 
reduced at the time of the repeated measurement, with a decrease in MAP 
of 7, 16 and 22 mmHg respectively, leading to very low MAP of 69 and 81 
mmHg in two of them. In summary, when uβ2m was ≥1.0 μg/min in at least 1 
of two measurements, PPV for progression was 89% and when uβ2m <1.0 
μg/min at both occasions, the NPV was 100%. 
 
Discussion 
We evaluated urinary excretion of α1- and β2-microglobulin as prognostic 
markers in a cohort of 129 iMN patients with nephrotic range proteinuria and 
normal serum creatinine concentration. Approximately half of the patients 
showed progression and the other half went into spontaneous remission. 
This illustrates that the “rule of thirds” does not apply to iMN patients who 
present with the nephrotic syndrome and normal kidney function.24 The 
majority of patients (61%) reached either disease progression or partial 
remission within 24 months and 92% within 5 years of follow-up. 
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Table 4. Classification according to uβ2m excretion at baseline and 
repeated measurement versus patient outcome in 44 patients with repeated 
measurements. 
 
Measurement Outcome (n) 
Baseline Repeated Progression No progression 
uβ2m ≥ 1.0 μg/min uβ2m ≥ 1.0 μg/min 11 0 
uβ2m ≥ 1.0 μg/min uβ2m < 1.0 μg/min 3 1 
uβ2m < 1.0 μg/min uβ2m ≥ 1.0 μg/min 10 2 
uβ2m < 1.0 μg/min uβ2m < 1.0 μg/min 0 17 
The positive predictive value for patients with a least one measurement ≥1.0 μg/min 
was 89%.The negative predictive value for patients with both measurements <1.0 
μg/min was 100%. Of the 11 patients who were classified as progressors and had 
uβ2m >1.0 μg/min, 3 had a 50% rise in serum creatinine, 7 had a 25% rise and 
serum creatinine >135 μmol/l and 1 patient had severe nephrotic syndrome. 
 
 
Our data indicate agreement between two commonly used definitions of 
partial remission, i.e. proteinuria <2 g/day versus 3.5 g/day and a decrease 
>50% from baseline.2 In our population concordance between the two 
definitions was almost perfect, only time to remission varied slightly. Patients 
with high baseline proteinuria tend to achieve remission sooner when the 
latter definition is used, whereas patients with limited baseline proteinuria 
have proteinuria less than 2 grams per day before a reduction of 50% is 
achieved. Thus our data support the use of the definition proposed by 
Troyanov et al.2  
We confirmed the prognostic value of uβ2m. However the AUC was lower 
than reported in our previous study, 0.81 (95% CI: 0.73-0.89) versus 0.94 
(0.87-1.00).20 This difference may be caused by a distinction in the definition 
of endpoints. In our previous study renal death was defined as a rise in 
serum creatinine ≥50% or an absolute level over 135 μmol/l. In the current 
study, the second criterion also included a 25% rise in serum creatinine, 
since an absolute value could lead to biased results.19 Secondly, we used 
stricter inclusion criteria in the current study; excluding patients with limited 
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proteinuria. Furthermore, when we inspected baseline characteristics of 
patients in our current cohort by year of referral, we noted a decline in 
baseline serum creatinine, albumin and cholesterol, a lower MAP over time 
and shortened time between biopsy and urine analysis (Supplementary 
Table S5). Higher referral rates and lower baseline ACEi/ARB use in recent 
years point toward earlier referrals by participating nephrologists. 
Timed urine samples are not routinely taken in all hospitals and uβ2m should 
be measured after alkalinization of urine by overnight bicarbonate intake. 
Our current data suggest that a timed measurement of low molecular weight 
protein excretion may not be necessary. Both α1m and β2m related to 
urinary creatinine concentration had the same prognostic power as the timed 
excretion. Contrary to uβ2m, uα1m measurement does not require 
alkalinization and it can be measured using a nephelometric assay, thus a 
spot urine taken at the out-patient clinic for measurement of uα1m/creatinine 
ratio may be sufficient to predict prognosis.  
We attempted to find explanations for the discordance between predicted 
and actual progressive disease by comparing patient characteristics 
stratified for prediction and outcome. We observed notable differences in 
serum cholesterol, creatinine and the ratio between serum albumin and 
proteinuria. A model that included these variables slightly improved 
prognostic power. We hypothesize that the higher cholesterol values reflect 
increased hepatic synthesis and are indicative of higher unmeasured protein 
losses due to tubular hypermetabolism. Alternatively, the high cholesterol 
levels may contribute to progressive renal injury. Although based on a 
limited number of biopsies, our data suggest evaluation of tubulo-interstitial 
damage is of no added value. 
We evaluated if repeated measurements of uα1m and uβ2m would improve 
prognostic accuracy. Repeated measurements were done in patients with 
persistent proteinuria. When one of the measurements was above the uβ2m 
threshold value of 1.0 μg/min 89% of patients showed progression. 
Conversely, when both measurements were <1.0 μg/min none of the 
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patients showed progression (NPV=100%). Noteworthy, the data show that 
changes in blood pressure can influence the results. Low levels of uβ2m and 
uα1m in the face of very low blood pressure cannot be used with confidence. 
Alternatively the opposite may also hold true, although we do not have hard 
data to confirm this. 
Our study has several limitations. Our end point to define renal failure can be 
criticized. However, we feel that it is not justified to delay start of 
immunosuppressive therapy until doubling of serum creatinine. If we 
calculate eGFR using the abbreviated MDRD formula 88% of the patients 
who fulfilled our definition of renal failure had an eGFR value below 60 
ml/min/1.73m2. We performed additional analyses with occurrence of eGFR 
<60 ml/min/1.73m2 as end point. ROC-AUCs for uβ2m and uα1m remained 
similar and were 0.84 (0.77-0.92) and 0.84 (0.76-0.92) for uβ2m in μg/min 
and μg/10 mmol creatinine respectively. For uα1m ROC-AUCs were 0.82 
(0.74-0.89) and 0.82 (0.75-0.90) for μg/min and μg/10 mmol respectively. 
Many patients were referred to our centre for urinary analysis, but followed 
and treated elsewhere, and we were unable to collect follow up data for all 
patients. Also, the data we presented on repeated measurements have to be 
interpreted with some caution as these were performed on a subset of 
patients with persistent proteinuria. Finally, we were not able to calculate a 
proteinuria risk score for the cohort, which requires multiple measurements 
of serum and urine creatinine and proteinuria during each 6 month period 
during follow-up.4 These data were not available. 
 
Conclusions 
We have advocated that treatment decisions in the individual patient with 
iMN must be based on an individualized assessment of risks and benefits.21 
The risks of prolonged nephrotic syndrome should be balanced against 
those of progression and treatment related complications. Urinary α1- or β2-
microglobulin measurement can be of value in this balanced decision since 
they allow an early prediction of prognosis in iMN. A spot urine sample can 
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be used instead of a timed sample. Blood pressure may affect excretion 
rates. A repeated measurement after 6 to 12 months increases prognostic 
accuracy. 
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Supplementary Table S2. Regression coefficients of the predictive model 
for the progression of idiopathic membranous nephropathy. 
 
  regression coefficient 95%CI 
Model 1: uβ2m 
ln(uβ2m) 0.54 [0.22 - 0.86] 
ln(screat) 3.06 [0.33 - 5.8] 
ln(schol) 2.53 [1.00-4.05] 
Intercept -18.82 [-32.10 - -5.53] 
Model 2: uα1m 
ln(uα1m) 1.19 [0.49 - 1.91] 
ln(screat) 3.67 [1.05 - 6.28] 
ln(schol) 2.32 [0.81 - 3.83] 
Intercept -25.59 [-37.89 - -13.28] 
95%CI: 95% confidence interval, ln: natural logarithm (elog), uβ2m: urinary excretion 
of β2-microglobulin (μg/min), uα1m: urinary excretion of α1-microglobulin (μg/min), 
screat: serum creatinine (μmol/l), schol: serum cholesterol (mmol/l). 
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Supplementary Table S3. Classification of patients according to uβ2m, 
outcome and tubulo-interstitial lesions. 
 
Classification TI lesions Total 
None  Few Moderate Severe 
No progression, uβ2m < 1.0 μg/min 9 10 1 0 20 
No progression, uβ2m ≥ 1.0 μg/min 1 4 0 0 5 
Progression, uβ2m < 1.0 μg/min 4 2 1 0 7 
Progression, uβ2m ≥ 1.0 μg/min 0 7 6 2 15 
Total 14 23 8 2 47 
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Supplementary Table S4. Patient characteristics at baseline and repeat 
measurement. 
 
  Baseline  
n (% male) 44 (64%) 
age at time of biopsy (years) 49 (38 - 59) 
time between biopsy and urine analysis (months) 2 (1 - 3) 
Survival time (months) 29 (15 - 53) 
MAP  (mmHg) 95 (85 - 107) 
Laboratory 
serum creatinine (μmol/l) 85 (75 - 95) 
serum albumin (g/l) 23 (19 - 28) 
serum cholesterol (mmol/l) 7.8 (6.2 - 9.4) 
eGFR-MDRD4 (ml/min/1.73m2) 77 (66 - 91) 
Urine samples: 
proteinuria (g /10mmol creatinine) 7.6 (5.1 - 10.4) 
β2-microglobulin (μg/min) 0.5 (0.1 - 1.4) 
α1-microglobulin (μg/min) 33 (21 - 45) 
IgG (mg/24h) 229 (121 - 349) 
Outcomes 
Progression 55% 
50% rise in serum creatinine (n) 13 
25% rise and serum creatinine ≥ 135 μmol/l (n) 8 
clinical progression (n) 3 
Spontaneous remission 
partial remission: <2.0 g /10mmol 41% 
partial remission: <3.5 g /10mmol and ≥50% reduction 41% 
complete remission 16% 
 
Data are presented as median (interquartile range). MAP: mean arterial pressure. 
ACEi: angiotensin converting enzyme inhibitor. ARB: angiotensin-II receptor blocker. 
eGFR-MDRD4: estimated GFR calculated with the abbreviated MDRD formula. P 
values are given for the comparison of baseline characteristics for the total 
population and the 44 patients with repeated measurements. T- or X2 tests were 
used.  
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Supplementary Table S4. continued 
 
 
Repeated 
Measurement 
Total study 
population 
p 
44 (64%) 129 (68%) 0.58 
49 (38 - 59) 51 (43 - 61) 0.25 
12 (8 - 15) 2 (1 - 4) 0.74 
29 (15 - 53) 25 (13 - 51) 0.55 
89 (84 - 102) 97 (86 - 106) 0.72 
  
97 (81 - 113) 88 (76 - 103) 0.19 
25 (20 - 30) 23 (19 - 28) 0.93 
6.0 (5.0 - 7.3) 7.3 (5.7 - 9.2) 0.26 
68 (55 - 82) 75 (60 - 87) 0.32 
  
6.8 (4.3 - 10.4) 8.0 (5.6 - 10.7) 0.41 
1.1 (0.3 - 2.9) 0.6 (0.2 - 4.8) 0.05 
30 (15 - 69) 41 (23 - 72) 0.10 
182 (92 - 341) 257 (116 - 490) 0.07 
  
55% 47% 0.36 
13 30  
8 24  
3 6  
47% 0.46 
41% 61  
41% 63  
16% 26  
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Abstract 
Background: The efficacy of immunosuppressive therapy in preventing 
ESRD in patients with idiopathic membranous nephropathy (iMN) is 
debated. From 1991 onward, we have advocated a restrictive treatment 
strategy in our University Hospital and regional referring hospitals. We 
advised the use of immunosuppressive therapy, consisting of a combination 
of steroids and oral cyclophosphamide for 12 months, in patients with iMN at 
high risk for ESRD. 
Methods: Primary renal diagnosis of all patients who start renal replacement 
therapy in the Netherlands is registered in the RENINE database. We 
studied the incidence of ESRD due to iMN in the Netherlands in the period 
1991-2005. We mailed a questionnaire to all nephrology centers that entered 
a patient with ESRD and iMN in the RENINE database after 2000. 
Results: The introduction of the cyclophosphamide-based treatment strategy 
in the Nijmegen region resulted in a significant 70% reduction in the 
incidence of ESRD in patients with iMN as compared to an unchanged 
incidence in other parts of the Netherlands. Response rate to the 
questionnaire was 65%. There were 45 patients (34 M, 11 F) with a mean 
age at diagnosis of 49 ±17 yrs and a median serum creatinine of 138 μmol/l 
(range 60-1798). Overall, only 22 patients (49%) had been treated with 
immunosuppressive therapy, consisting of prednisone monotherapy in 7.  
Conclusions: our data suggest that the introduction of a cyclophosphamide-
based restrictive treatment policy has reduced the risk of ESRD in iMN. The 
questionnaires reflect the differences in opinion on the optimal treatment of 
high-risk patients with iMN. 
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Introduction 
Idiopathic membranous nephropathy (iMN) is one of the most common 
causes of the nephrotic syndrome in adults. If left untreated, 14-56% of 
patients develop a spontaneous remission whereas 34-62% of patients 
develop renal insufficiency.1 Whether patients with iMN should be treated 
with immunosuppressive therapy has been heavily debated in the past 
decades. Several therapeutic measures have been studied, including 
corticosteroids, cyclosporine, alkylating agents, mycophenolate mofetil, anti-
B-cell antibodies (rituximab) and synthetic adrenocorticotropic hormone. In a 
randomized controlled trial Ponticelli et al. showed a treatment benefit when 
treating all patients with iMN and a nephrotic syndrome with 
methylprednisolone and chlorambucil.2 In two cohort studies we and others 
also demonstrated that alkylating agents increased remission rate and 
improved renal survival.3;4 However, some authors still doubt the efficacy of 
this therapy, pointing to a Cochrane meta-analysis which could not 
document a beneficial effect of alkylating agents on total mortality or risk of 
ESRD.5 Many authors therefore argue against the use of 
immunosuppressive treatment with alkylating agents in patients with iMN 
and a nephrotic syndrome.  
We have developed a restrictive treatment strategy, limiting 
immunosuppressive treatment to patients at highest risk for ESRD.1;6  From 
1991 onward immunosuppressive therapy was advised only in patients with 
renal insufficiency or a severe intolerable nephrotic syndrome. Treatment 
consisted of a combination of steroids and cyclophosphamide for 12 months.  
To evaluate the effects of this treatment strategy we studied the incidence of 
ESRD due to iMN in the Netherlands in the period from 1991 to 2005. In 
addition, we have retrieved information on the use of specific 
immunosuppressive therapy in patients with iMN who developed ESRD from 
2000 onward. 
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Subjects and Methods 
From 1991 we have used a combination of oral cyclophosphamide and 
steroids in our hospital for the treatment of patients with iMN.7 Our treatment 
regimen has been described in detail before.3;7 Briefly, cyclophosphamide 
was administered orally during one year in a target dose of 1.5 to 2 mg/kg 
body weight per day. In addition patients received intravenous pulses of 
methylprednisolone, 1 g each on 3 consecutive days at the beginning of the 
first, third, and fifth month, and oral prednisone 0.5 mg/kg bodyweight every 
other day for 6 months. Treatment was restricted to patients at highest risk 
for ESRD, i.e. patients with established renal insufficiency (defined as a 
serum creatinine of >135 μmol/l, or an increase of serum creatinine >50%). 
In addition, a few patients were treated because of a severe, intolerable 
nephrotic syndrome.  This restrictive treatment strategy was used in our 
University Hospital and in 6 regional referring hospitals (the study region: 
Hospital Gelderse Vallei, Ede; Canisius Wilhelmina Hospital, Nijmegen; 
Jeroen Bosch Hospital, Den Bosch; Hospital Rijnstate, Arnhem; Maxima 
Medical Center, Veldhoven; St.Elisabeth Hospital, Tilburg) 
 
The primary renal diagnosis of all patients who start renal replacement 
therapy (RRT) in the Netherlands is registered in the RENINE database. 
This database is an initiative of the Dutch societies of nephrologists and 
transplantation specialists and data are available to all researchers after 
anonymisation of patient characteristics. We have studied the incidence of 
ESRD due to iMN in the Netherlands and separately in our region in the 
period from 1991 to 2005. In the RENINE database iMN is by definition a 
biopsy proven diagnosis (ERA-EDTA PRD-code 14). We have analyzed the 
data for periods of five years, which are 1991-1995, 1996-2000 and 2001-
2005. For comparison, we have studied the incidence of ESRD due to focal 
segmental glomerulosclerosis and histologically examined glomerulo-
nephritis (ERA-EDTA PRD-codes 17 and 19). 
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To estimate changes in the overall incidence of iMN in the study period we 
used data from PALGA, the nationwide registry and network of 
histopathology and cytopathology in the Netherlands. In the PALGA 
database all histological diagnoses made by pathologists are entered after 
anonymisation of patient characteristics. Results of second biopsies and of 
biopsies in transplant kidneys are included, therefore the data will somewhat 
overestimate the true incidence of iMN. 
 
The databases of RENINE and PALGA are unrelated and cannot be linked. 
The regions defined by the participating dialysis facilities and pathology 
laboratories do not match. Therefore, to analyze the incidence of iMN in the 
Nijmegen region we used the PALGA data of the pathology department of 
the University Medical Center. This department serves three hospitals and 
approximately 50% of the population in the inner circle of the Nijmegen 
region.  
 
A questionnaire was mailed to all nephrology centers that entered a patient 
with the diagnosis iMN in the RENINE database since 2000.  We chose to 
evaluate only those patients who started RRT since 2000, because of the 
time lag between diagnosis and/ or treatment of iMN and the occurrence of 
ESRD.  Several studies have shown that most cases of ESRD due to iMN 
occur within 10 years.3;8 Thus, we started the evaluation of patients ten years 
after the introduction of our cyclophosphamide-based treatment strategy (in 
1991). 
The questionnaire included questions about patient characteristics such as 
sex, age at diagnosis and at start of renal replacement therapy, serum 
creatinine and use of specific immunosuppressive therapy. 
 
Data are presented as means (±SD) or medians (range) when appropriate. 
Pearson's chi-square test was used for comparison of proportions. Poisson 
regression was used to compare per capita incidence rates. Statistics were 
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performed with SPSS software, version 12.0.1 (Chicago, IL) and SAS 
software, version 8.2 (Cary, NC). Differences were considered significant 
with p-value <0.05. 
 
Results 
We have analyzed the incidence of ESRD for periods of 5 years. As 
expected the incidence of patients needing RRT increased over this time 
period. In our region 1038 patients started renal replacement therapy in the 
period 1991-1995, increasing to 1152 in the period 1996-2000, and 1215 in 
the period 2001-2005. For the Netherlands (after exclusion of the Nijmegen 
region) these figures are 5118, 6292 and 7190 respectively. 
In the Nijmegen region the number of patients with ESRD due to iMN 
decreased by 70% when comparing the periods 1991-1995 and 2001-2005. 
In contrast, the number of patients with ESRD due to iMN in the other parts 
of the Netherlands did not change (Figure 1a, χ2 for trend p=0.012). We next 
evaluated the incidence of ESRD due to iMN on a per capita rate (Table 1). 
Poisson regression revealed a significant difference in the change in 
incidence rates between the regions (p=0.004).  
Of note, in the first period (1991-1995) the incidence rate of ESRD due to 
iMN was higher in the Nijmegen region than in the other parts of the 
Netherlands. We therefore questioned if there might be differences in the 
overall incidence of iMN. From the PALGA database we retrieved the total 
number of the histological diagnosis membranous nephropathy for the study 
period. In the Nijmegen region the diagnosis MN was indeed encountered 
more often than in the other parts of the Netherlands (Table 1). Most 
importantly, the incidence of membranous nephropathy based on the 
PALGA database did not change in either region.  
 
Although the PALGA database overestimates the number of patients with 
iMN (see methods) the data provide the best estimate for the overall 
(change in) incidence of iMN. If we compare the incidence rate of ESRD due 
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to iMN with the rates of the histopathological diagnosis of membranous 
nephropathy the difference between the regions can be even better 
appreciated (Table 1, Corrected incidence of ESRD) 
 
We next questioned if the observed decreased incidence of ESRD due to 
iMN in the Nijmegen region was indeed specific for iMN. We therefore 
analyzed the incidence of ESRD due to FSGS and histologically proven 
glomerulonephritis (EDTA codes 17 and 19). The results are depicted in 
Figure 1b and Table 1. It is evident that there are no differences between the 
Nijmegen region and the other parts of the Netherlands for these diagnoses. 
 
 
 
Figure 1a.   Number of patients with ESRD caused by idiopathic membranous 
nephropathy (iMN) in the Nijmegen region (grey bars) versus the other 
parts of the Netherlands (black bars) over time. χ2- test for trend 
p=0.012 
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Figure 1b.   Number of patients with ESRD caused by FSGS and histologically 
examined glomerulonephritis (ERA-EDTA codes 17 and 19) in the 
Nijmegen region (grey bars) versus the other parts of the Netherlands 
(black bars) over time. χ2- test for trend p=0.89  
 
 
Overall 81 questionnaires were mailed to nephrology centers that entered a 
patient with the diagnosis iMN in the RENINE database since 2000. We 
received 53 responses (65%). Eight patients were excluded because of a 
wrong diagnosis (n=4) or missing data (n=4). Our analysis thus included 45 
patients (34 M, 11 F) with a mean age at diagnosis of 49 ±17 yrs and a 
median serum creatinine of 138 μmol/l (range 60-1798). Other 
characteristics are shown in Table 2. For comparison we have added the 
characteristics of 65 patients from the Nijmegen region who were identified 
as high risk for progression to ESRD and received treatment in the period 
from 1991-2002. There were no significant differences between the groups. 
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Of the 45 patients included in our analysis, 22 patients (49%) have received 
some form of immunosuppressive therapy. There were no major differences 
with respect to age, serum creatinine concentration and proteinuria at 
diagnosis between treated and untreated patients (Table 2). The median 
serum creatinine concentration was 214 μmol/l (range 60-1798) at start of 
treatment. Many different treatment strategies have been applied (Table 3). 
Eight of the 22 treated patients received prednisone monotherapy as the 
initial treatment. During follow-up, only one of these patients received rescue 
treatment (cyclosporine). Thus, seven patients received prednisone 
monotherapy as only treatment. In 14 patients the initial treatment consisted 
of an other immunosuppressive agent (Table 3). Eight of these patients 
received rescue treatment afterwards, three of them with two different 
agents. Thus, overall 15 patients (33%) were treated with non-steroidal 
immunosuppressive agents in the course of their disease. In sum, four 
patients received prednisone and chlorambucil according to the original 
Ponticelli protocol. Eight patients received cyclosporine, two patients were 
treated with azathioprine and three received mycophenolate mofetil. Seven 
patients received cyclophosphamide: five of them as initial treatment, two of 
them as rescue therapy. Of these seven patients treated with 
cyclophosphamide, two patients were treated for a period of 3 and 8 weeks, 
three patients for 3 months and only two patients received 
cyclophosphamide for 12 months.  
 
Discussion  
Our epidemiological survey demonstrates a significant decrease in the 
incidence of ESRD due to iMN in the Nijmegen area compared to the other 
regions of the Netherlands. The decrease paralleled the introduction in our 
region of a restrictive treatment strategy.6 Using this strategy we observed 
high renal survival rates, which were better than in historical controls.3  
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Table 3. Immunosuppressive therapy used in 22 treated patients  
 
Initial therapy 
n=22 
Rescue therapy 1 
n=9 
Rescue therapy 2 
n=3 
Prednisone (8) CsA (1) 
 
 
Cyclophosphamide (5) Chl (1) 
CsA (2) 
Aza (1) 
 
MMF (1) 
CsA (1) 
Chlorambucil (3) 
 
MMF (1) 
 
 
Cyclosporine (5) 
 
CP (1) 
CsA (1) 
MMF (1) 
 
 
CP (1) 
Azathioprine (1) -  
Number of patients treated with the given immunosuppressive drug. Alkylating 
agents and cyclosporine were mostly given in combination with steroids. CP= 
cyclophosphamide; Chl = chlorambucil; CsA = cyclosporine; Aza = azathioprine; 
MMF = mycophenolate mofetil. MMF was used only as rescue therapy. All treatment 
given after the first period of immunosuppressive therapy is considered rescue 
treatment. Some patients have received a second rescue therapy. See results 
section for explanation. 
 
 
The present data extend our observations and support the efficacy of our 
treatment strategy. Admittedly, epidemiological data can be biased and the 
observed differences may be unrelated to differences in treatment protocols. 
We have performed additional analyses that support our conclusions. First, 
we have excluded variations in the overall incidence of membranous 
nephropathy as cause of our findings. Data retrieved from the PALGA 
database clearly indicated that there was no change in the reported 
incidence of MN between the time periods. Therefore, the decreased 
incidence of ESRD due to iMN in the Nijmegen region cannot be explained 
by changes in the epidemiology of MN. Of note, the reported incidence of 
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membranous nephropathy was consistently and approximately 1.5 fold 
higher in the Nijmegen region. Differences in the characteristics of the 
populations are the most likely explanation for this finding. The Nijmegen 
region, located in the Southeast of the Netherlands, has more native 
inhabitants and fewer immigrants than the Western part of the Netherlands.  
  
To document that the decreased incidence of ESRD due to iMN in the 
Nijmegen region was specific for iMN we also have analyzed the incidence 
of ESRD due to other glomerular diseases (EDTA codes 17 and 19). Here, 
we did not observe differences between the Nijmegen region and other parts 
of the Netherlands. 
 
To further explore the explanatory role of immunosuppressive therapy we 
have mailed questionnaires to all nephrologists who have registered a 
patient with ESRD due to iMN in the RENINE database since 2000. 
Response rate was good and amounted 65%. Most patients had not been 
treated or only had received prednisone monotherapy, which is 
ineffective.9,10 Thus, the data clearly show that only 33% (15/45) of the 
patients who developed ESRD due to iMN received a potentially effective 
immunosuppressive agent such as cyclophosphamide, chlorambucil, 
cyclosporine, or mycophenolate mofetil. 
Admittedly, the 35% non-response rate could have biased our conclusions. 
However, since the use of immunosuppressive therapy and its relationship 
to outcome was the leading study question, we feel that it is unlikely that 
non-responders have preferentially used immunosuppressive therapy. 
However, even if all non-responding doctors (35%, n=28) had treated their 
patients with immunosuppressive agents, still only 59% of the high risk 
patients would have received potentially effective therapy. 
 
 In our previous study we have shown that in our region more than 90% of 
high risk patients received immunosuppressive therapy with an alkylating 
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agent.6 Thus, the observed differences between the Nijmegen region and 
other parts of the Netherlands in the incidence rate of ESRD due to iMN are 
likely explained by the differences in the use of immunosuppressive therapy.  
Admittedly, although unlikely we cannot exclude that other factors such as a 
change in supportive therapy or earlier detection of iMN could explain the 
differences between the regions.  
 
Obviously, one could speculate that death from immunosuppressive related 
causes in the Nijmegen region could have led to the lower number of 
patients with iMN needing RRT. Our previous studies clearly argue against 
this idea. We have described a cohort of 65 patients with iMN treated 
according to our restrictive cyclophosphamide-based treatment strategy.3 
Patient survival was 84% after seven years of follow-up. No patient died 
from renal failure. Out of the five patients who have died, in one patient, who 
died from bladder carcinoma, death may have been related to treatment. 
The other patients died after the end of treatment, most frequently from 
cardiovascular disease. We are not informed about the survival rates in the 
other regions in the Netherlands. However, if theoretically spoken, patient 
survival would have been 100% in those regions, the difference of 16% can 
still not explain why the incidence of ESRD due to iMN has decreased with 
70% in our region, compared to a stable incidence in the other regions. 
 
Our treatment regimen consists of cyclophosphamide and prednisone. Our 
data thus support  the findings of the randomized controlled trial of Ponticelli 
et al., and the cohort studies of Torres et al. and Du Buf-Vereijken et al. 
which demonstrated the efficacy of a immunosuppressive regimen 
consisting of a combination of steroids and an alkylating agent.2,4,6 A recent 
study provided additional evidence. Jha et al. conducted a randomized 
controlled trial.8 Forty seven patients with iMN and a nephrotic syndrome 
were treated with a 6-months course of alternating prednisolone and 
cyclophosphamide. Outcome was compared to the control group of 46 
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patients that received only supportive treatment. In this study, 
immunosuppressive therapy more often induced a remission, arrested 
progression of renal insufficiency and improved quality of life compared to 
supportive treatment. Based on these data, we feel that it is no longer 
justified to withhold treatment to patients with iMN who are at risk for ESRD. 
Admittedly, our data do not prove that cyclophosphamide is more effective 
than other immunosuppressive agents. Several trials have evaluated 
calcineurin inhibitors, mycophenolate mofetil, ACTH, or rituximab and 
reported short term efficacy.1  
From our questionnaire it is evident that many physicians are reluctant to 
use immunosuppressive therapy in patients with iMN. Almost all reported 
patients presented with renal insufficiency and thus must be considered at 
highest risk for ESRD. Often, further deterioration of renal function is 
awaited, and immunosuppressive treatment is started at a time point that 
renal function is even more impaired. Of note, immunosuppressive therapy 
may be least effective and more toxic when used in patients with more 
severe renal insufficiency.  
The answers to the questionnaire are not unexpected. There is still ongoing 
debate on the optimal treatment of patients with iMN, with discussion on the 
type of agent and the duration of therapy. Although alkylating agents are 
considered effective many physicians and patients fear their side effects. 
The ongoing debate apparently often results in a wait and see policy.  In our 
view this must be a concern since many patients unnecessarily develop 
ESRD and are thus exposed to the morbidity and mortality risks associated 
with dialysis and transplantation. Although side effects of alkylating agents 
are a major problem, our studies have shown high patients survival rates in 
treated patients. Of note, in the study of Jha et al. side effects occurred at 
comparable rates in patients treated with cyclophosphamide or supportive 
treatment.8 
In conclusion: our data suggest that the introduction of a cyclophosphamide-
based restrictive treatment policy has reduced the risk of ESRD in Dutch 
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patients with iMN. The questionnaires reflect the differences in opinion on 
the optimal treatment of high-risk patients with iMN. Implementation of 
treatment guidelines for patients with iMN seems indicated. 
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Abstract 
Background: Immunosuppressive therapy in iMN is debated. Accurate 
identification of patients at high risk for ESRD allows early start of therapy in 
these patients. It is unknown if early start of therapy is more effective and/or 
less toxic than late start (i.e. when GFR deteriorates). 
Methods: We conducted a randomized open label study in patients with iMN, 
a normal renal function, and a high risk for ESRD (Urinary β2m >0.5 μg/min, 
UIgG >125 mg/day). Patients started with immunosuppressive therapy 
(cyclophosphamide for 12 m, and steroids) either immediately after 
randomization or when renal function deteriorated (ΔsCr ≥+25% and sCr 
>135 μmol/l or ΔsCr ≥+50%). End points were remission rates, duration of 
the nephrotic syndrome (NS), renal function, and complications. 
Results: The study included 26 patients (24M/2F), age 48 ±12 yr; sCr 96 
μmol/l [range 68-126]; and median proteinuria 10.0 g/10mmolCr. Early 
treatment resulted in a more rapid onset of remission (p=0.003) and a 
shorter duration of the NS (p=0.009). However, at the end of follow-up (72 
±22 m) there were no differences in overall remission rate, sCr (93 vs 105 
μmol/l), proteinuria, relapse rate, and adverse events. 
Conclusions: In high-risk patients with iMN immunosuppressive treatment is 
effective in inducing a remission. Early treatment shortens the duration of the 
nephrotic phase, but does not result in better preservation of renal function. 
Our study indicates that treatment decisions must be based on risk- and 
benefit assessment in the individual patient. 
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Introduction  
Idiopathic membranous nephropathy (iMN) is one of the most common 
causes of the nephrotic syndrome in adults. The natural course of the 
disease is highly variable; 14-56% of patients develop a spontaneous 
remission whereas 34-62% of patients develop renal insufficiency.1 The role 
of immunosuppressive therapy in iMN is heavily debated, and very recent 
reviews have doubted the efficacy of immunosuppressive therapy.2-4  
 
Until recently only one randomized controlled trial supported the efficacy of 
immunosuppressive therapy on hard end-points.5 This study favored 
treatment of all patients with iMN and a nephrotic syndrome with 
chlorambucil and prednisone. Implementation of this treatment strategy in 
daily clinical practice has the potential to cause harm, since approximately 
50% of patients will be exposed unnecessarily to immunosuppressive 
therapy. Therefore, most authors advocate to restrict immunosuppressive 
therapy to patients with established renal insufficiency, the best predictor of 
ESRD.6-8 When compared with historical controls, patients with renal failure 
benefited from immunosuppressive therapy.9 Unfortunately, patients with 
renal insufficiency are more prone to develop treatment-related 
complications.1;10 
 
It is now possible to identify patients with iMN at high risk for ESRD at an 
early stage. Cattran et al. developed an algorithm which comprises clinical 
parameters like duration and level of proteinuria and creatinine clearance to 
calculate a predictive score in the individual patient.11 We and others showed 
that high-risk patients can be identified with high accuracy by measuring 
markers of renal tubular injury in the urine.12-15    
 
The identification of high risk patients should enable to improve treatment. 
First, treatment could be restricted to high-risk patients, thus avoiding that 
patients are unnecessarily exposed to toxic therapy. Second, treatment 
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could be started in an early stage, i.e. before the onset of renal failure. 
However, it is undetermined if such a treatment strategy is feasible It is 
questioned if immunosuppressive therapy is really effective in high risk 
patients. Furthermore, it is unknown if early start of therapy is advantageous 
by reducing the number of complications of the nephrotic syndrome, by 
better preserving renal function and by limiting treatment-related side effects.  
 
Our study was aimed to answer some of these questions. Our study also 
was intended to evaluate the potential of a larger study directed at 
evaluation of the Cost-Efficacy of two treatment strategies. 
 
Subjects and Methods 
We conducted a prospective, randomized controlled, open label study from 
May 1998 till May 2005. This study was registered at clinicaltrials.gov (NCT 
00135954). The study protocol met criteria required by the Declaration of 
Helsinki and was approved by the ethics committee of our center. Patients 
were recruited in our university hospital or one of the referring regional 
hospitals. All patients gave written informed consent.  
 
The study included adult patients (age 18-75 years) with biopsy proven iMN. 
Eligible patients had to have a nephrotic syndrome (proteinuria ≥3.5 g/day 
and serum albumin ≤35 g/l with normal renal function (defined as serum 
creatinine <135 μmol/l) and a high risk for ESRD. High risk for ESRD was 
defined as an urinary β2m >0.5 μg/min and urinary IgG >125 mg/24hr. The 
threshold for Uβ2m is based on our previous observations.13 For UIgG we 
adapted the threshold from Bazzi’s et al.,14 which is lower than we observed 
(125 versus 250 mg/day), because our data derived from the pre-ACE-
inhibitor era.  
We excluded patients in whom a secondary cause of MN was suspected 
based on clinical or laboratory criteria and patients who had previously been 
treated with immunosuppressive drugs. Other exclusion criteria were 
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systemic diseases, pregnancy or inadequate contraception, active infection, 
unstable angina pectoris, diabetes mellitus, clinical evidence of renal vein 
thrombosis, liver function test abnormalities (>2 times the upper limit of 
normal), use of NSAIDs, active peptic ulcer disease, and gastrointestinal 
diseases that could impair the resorption of oral medication. 
 
Patients were randomized to receive early or late immunosuppressive 
treatment. Group A started immunosuppressive therapy immediately after 
randomization. Group B started treatment when renal function deteriorated. 
Renal function deterioration (RFD) was defined as an increase of serum 
creatinine with ≥25% reaching a level of ≥135 μmol/l or an increase of serum 
creatinine with ≥50%.  
 
The immunosuppressive treatment regimen has been previously 
described.16 In brief, therapy consisted of oral cyclophosphamide (CP) 1.5 
mg/kg BW/day for 12 months, methylprednisolone 1 g intravenously on days 
1,2,3, 60,61,62, 120,121, and 122, and oral prednisone 0.5 mg/kg BW every 
other day for 6 months, subsequently tapered by decreasing the dose with 5 
mg/wk. For prevention of gastric symptoms famotidine 20 mg once daily was 
added. From 1999 onward, we also added trimethoprim-sulfamethoxazole, 
480 mg/day in the first 4 to 6 months, to prevent Pneumocystis jiroveci 
pneumonia. In young patients in their fertile years the treatment regimen was 
modified because of the infertility risk associated with the use of 
cyclophosphamide: in those patients after three months of 
cyclophosphamide treatment we switched to azathioprine 1.5 mg/kg BW/day 
for the remaining nine months. 
 
All patients were aggressively treated to decrease blood pressure (target 
value 130/80 mmHg), primarily by using angiotensin-converting enzyme 
inhibitors and/or angiotensin receptor blockers. 3-Hydroxy-3-methylglutaryl 
coenzyme A reductase inhibitors were used to decrease serum cholesterol 
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levels in case hyperlipidemia persisted 6 months after randomization. 
Anticoagulant drugs were not routinely prescribed. All patients were advised 
to use a moderately salt-restricted diet.  
 
Follow-up time started from the moment of randomization. Patients who 
started treatment were seen at least every 4 to 8 weeks during the treatment 
year. Patients who were randomized to “late“ treatment were seen every 2 to 
3 months. Blood pressure, laboratory data, and side effects of therapy were 
registered. To be included in the final analysis, at least one year of follow-up 
after randomization was required. 
 
The main outcome parameter was the incidence of remissions as a primary 
event (either complete or partial). An important secondary outcome 
parameter was the time to the first remission. Other outcome parameters 
were the period of nephrotic proteinuria, the serum creatinine,  estimated 
GFR (eGFR) , and proteinuria at end of follow-up, and major side effects 
(hospitalizations, infections). 
 
Definitions and calculations. 
To correct for inappropriate 24-hour urine collections, amount of proteinuria 
was expressed as a protein-creatinine index (grams per 10 mmol of 
creatinine).  
Partial remission (PR) was defined as protein-creatinine index <2.0 
g/10mmolCr and complete remission (CR) was defined as a protein-
creatinine index ≤0.2 g/10mmolCr.  In case of remission, renal function 
should have improved or at least stabilized. Nephrotic range proteinuria was 
defined as a protein-creatinine index ≥3.5 g/10mmolCr. Relapse was 
defined as nephrotic proteinuria (≥3.5 g/10mmolCr) after a period of 
remission (proteinuria <2 g/10mmolCr). We estimated GFR by applying the 
4-variable MDRD equation.17  
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Sample size 
Early treatment seems justified, when there are large differences in the first 
years after the start of therapy. Sample size calculation was made assuming 
a rate of partial or complete response to therapy of 80%,9;18 and a rate of 
spontaneous remissions of 30% in the group with postponed treatment.1 To 
detect the estimated differences with a one-sided test with a type I error of 
5% and a power of 80%, about 13 patients per group are needed. To 
anticipate a 10% loss to follow up, we aimed to include a total of 30 patients. 
 
Statistical analyses 
For descriptive statistics, data are presented as means (rSD) or medians 
(range) when appropriate. Analyses were made on an intention-to-treat 
basis; thus, in case of a second course of therapy, results of the new 
treatment were incorporated in the calculations of the last follow-up data. T-
Test, Mann-Whitney U test, and Wilcoxon signed-rank test were used for 
comparison between and within groups. 
Cumulative probabilities of a clinical event (e.g. partial or complete 
remission) were estimated according to Kaplan and Meier. Generalized 
Wilcoxon (Breslow) test was used to compare the interval for the 
appearance of these events. All statistics were performed using SPSS 
software, version 14.0 (Chicago, IL). Differences were considered significant 
with p- value < 0.05 
 
 
Results 
From May 1998 till May 2005 we evaluated 162 patients with iMN; 57 
patients met criteria for enrollment. Of these, 29 agreed to participate in the 
study. Fifteen patients were randomized for early treatment (group A) and 14 
for postponed treatment (group B). During the first year of the study 3 
patients were excluded because of the following reasons: discovery of a 
malignancy and withdrawal from the study within 3 months; protocol violation 
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(start of prednisone by a physician in another hospital); loss to follow-up due 
to emigration 7 months after randomization (Figure 1). Thus, the final 
analysis included 26 patients. There were no significant differences in 
baseline characteristics between groups (Table 1).  
 
 
Figure 1. Flow- chart of enrollment procedure 
 
Fourteen patients received early treatment (group A). Early treatment was 
started 2 weeks after randomization (range 0-5 weeks). In group A, three 
patients were treated according to the modified treatment scheme with 
azathioprine (see Methods).  
Group B (postponed treatment) comprised 12 patients. During follow-up 8 
patients (67%) needed therapy (median 14 months after randomization  
[range 2-35]) because of deterioration of renal function. Mean creatinine at 
start of immunosuppressive treatment was 159 ±21 μmol/l, mean GFR was  
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Table 1. Baseline characteristics 
 
 Group A 
Early treatment 
(n=14) 
Group B 
Postponed 
treatment (n=12) 
Sex (male/female) 13/1 11/1 
Age (y) 48 ±13 49 ±10 
Time from renal biopsy to study start (mo) 5 (1-16) 7 (1-19) 
Serum creatinine (μmol/l) 94 (68-122) 101 (75-126) 
Serum albumin (g/l) 22.6 ±4.8 22.3 ±3.8 
eGFR (ml/min/1.73m2) 81 ±17 76 ±13 
Proteinuria (g/10 mmolCr) 9.6 (5.9-14.4) 12.0 (5.6-17.2) 
Mean arterial pressure (mmHg) 92 ±18 88 ±14 
ACE inhibitor and/or ARB at study start 14 (100%) 10 (83%) 
Lipid lowering drugs at study start 13 (93%) 8 (67%) 
   
Values are expressed as median (range), mean ±SD, or number (percent). There 
were no significant differences in baseline characteristics between groups. 
eGFR = estimated glomerular filtration rate (by MDRD4 equation); ACE = 
angiotensin-converting enzyme; ARB = angiotensin receptor blocker 
 
 
 
44 ±7 ml/min/1.73m2. Two patients received modified treatment with 
azathioprine after three months. 
 
Remissions 
In the first year of the study remission occurred significantly (p<0.001) more 
often in group A (71%) than in group B (8%).  
The course of the disease in both groups is depicted in Figure 2.Overall, 
early treatment induced a remission in 13 out of 14 patients in group A. 
Remission was partial in 4 patients (29%) and complete in 9 patients (64%). 
The cumulative incidence of a partial or complete remission as a primary 
event was 93%.  In group B 4 patients reached a spontaneous complete 
remission of proteinuria (33%). The other 8 patients were all treated because 
of RFD and remission occurred in seven of them (3 partial, 4 complete). The 
overall cumulative incidence of remission was 92%.  Although there was no  
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Figure 2. Flow-chart of treatment and events during follow-up in the two 
groups. CR = complete remission, PR = partial remission, NS = 
nephrotic syndrome, ESRD = end stage renal disease 
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Figure 3. Cumulative incidence of partial remission of proteinuria in patients 
with early (group A) or late (group B) start of treatment. Time to 
remission is significantly different between groups (p=0.003, 
Breslow test). 
 
 
 
difference in overall remission rate, early treatment resulted in a more rapid 
onset of remission (p=0.003) as depicted in Figure 3. 
The duration of the nephrotic syndrome in the time period between the start 
of the study and the occurrence of the primary remission was significantly 
shorter in group A (6 months, range 1-25) than in group B (15 months, range 
2-46, p=0.009). 
 
Renal function 
A (temporary) increase of serum creatinine of 25% at any time point during 
follow-up occurred in 3 patients (21%) in group A and in 9 patients (75%) in 
group B (p=0.005). Within both groups, mean serum creatinine and GFR at 
start and at the last follow-up did not differ significantly, indicating that renal 
function in group B improved during treatment.  
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Relapse rate/ retreatment 
In group A 3 patients (23%) relapsed to nephrotic syndrome 36 months after 
treatment (range 25-106 months). One patient achieved a spontaneous 
complete remission, another was retreated with CP and steroids for 6 
months, followed by a course of azathioprine. With this regimen a partial 
remission was achieved.  In the third patient, the relapse was only recently 
diagnosed. In group B also 3 patients (27%) relapsed to nephrotic syndrome 
38 months after treatment (range 13-76 months). Two of them were 
retreated. The first patient received 6 months of CP and steroid therapy, 
followed by azathioprine for 1 year and achieved a complete remission. The 
second patient started retreatment with 3 months of CP and steroids, 
followed by mycofenolate mofetil. At end of follow-up he had just started this 
treatment and nephrotic proteinuria still persisted. The third patient has not 
been retreated yet, as the relapse was diagnosed shortly before the last 
follow-up date. 
 
Last Follow-up 
At last follow-up (72 ±22 months) the one patient in group A that never 
reached a remission had progressed to ESRD. Another patient in group A 
had nephrotic proteinuria due to relapse. All others were in stable remission 
(Table 2). In group B one patient had died of unknown cause, while in 
complete remission 16 months after treatment. One patient had persistent 
proteinuria despite treatment and another two patients had relapsed at last 
follow-up.  Eight patients were in stable remission. There were no 
differences in serum creatinine (93 vs. 105 μmol/l), eGFR or proteinuria 
between groups (Table 2). 
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Table 2. Clinical status and laboratory parameters at last follow-up 
 
 Group A 
Early treatment  
(n=14) 
Group B 
Postponed treatment 
(n=12) 
Follow-up (mo) 73 ±20 71 ±26 
Clinical status   
     Remission 12 (86) 8 (67) 
         Complete 6 (43) 7 (58) 
         Partial 6 (43) 1 (8) 
     Persistent proteinuria 0 1 (8) 
     Relapse* 1 (7) 2 (17) 
     ESRD 1 (7) 0 
     Death 0 1 (8) 
Serum creatinine (μmol/l) 93 (64-487) 105 (79-264) 
Serum albumin (g/l) 37.9 ±5.4 40.5 ±6.9 
Proteinuria (g/10 mmol Cr) 0.77 (0.08-5.41) 0.18 (0-7.12) 
eGFR (ml/min/1.73m2) 76 ±25 68 ±18 
Values are expressed as median (range), mean ±SD, or number (percent). There 
were no significant differences in outcome parameters between groups. 
* Relapse: nephrotic proteinuria (≥3.5 g/day) after a period of remission (proteinuria 
<2 g/day). 
eGFR = estimated glomerular filtration rate (by MDRD4 equitation) 
 
 
Adverse events 
An overview of reported adverse events is listed in Table 3. We listed 
adverse events as most probable due to treatment (e.g. infections, 
leucopenia) or most probable due to nephrotic syndrome (e.g. thrombo-
embolic events). Overall, 9 patients in group A and 6 patients in group B 
developed 1 or more adverse events (p=0.48). Respectively 2 patients in 
group A and 6 patients in group B needed hospitalization. Dose reduction of 
the immunosuppressive drugs because of side effects were necessary in 4 
patients in group A and in 6 patients in group B. Infections seemed to be 
more frequent in patients in group B, and they appeared to be more severe, 
based on data of hospitalization and dose reduction. In group A 1 patient did 
not complete treatment with azathioprine because of suspicion of  
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Table 3. Adverse events 
 
 Group A, n=14 Group B, n=12 
 No. of 
patients (%) 
Dose 
reduction 
No. of 
patients (%) 
Dose 
reduction 
Treatment related     
Bone marrow depression     
 Leukocytopenia  2 (14) 2 1 (8) 1 
 Anemia    3 (21) 1 0 (0) - 
Infections     
 Respiratory 1 (7) - 1 (8) 1 
 All others 4 (29) 1 5 (42) 3 
Malaise/Arthralgia 3 (21) - 0 (0) - 
Liver test abnormalities/ 
hepatitis 
0 (0) - 2 (17) 2 
Steroid-induced diabetes  1 (7) - 0 (0) - 
Other  1 (7) 1 0 (0) - 
     
Related to nephrotic 
syndrome 
    
Renal vein thrombosis 1 (7) - 1 (8) - 
Other venous 
thromboembolism  
1 (7) - 0 (0) - 
Myocardial infarction 0 (0) - 1 (8) - 
 
Overall     
No. of patients with 1 or 
more AE 
9 (64)  6 (50)  
No. of patients needing 
dose decrease 
4 (29)  6 (50)  
No. of hospitalizations 2 (14)  6 (50)  
Note: Numbers do not add up because 1 patient can have more than 1 adverse 
event. There were no significant differences in adverse event rates between groups. 
AE = adverse event 
 
 
azathioprine-induced hypersensitivity. In group B two patients did not 
complete treatment with CP because of respectively CP-induced hepatitis 
and severe CMV-alveolitis. 
Although differences between groups were not statistically significant 
(intention to treat analysis), patients in group B, when treated, tended to 
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have more frequent and more severe side effects. In a per protocol analysis 
75% of treated patients in group B needed dose reduction (versus 14% of 
patients in group A) and 75% was admitted to the hospital at least once 
because of a severe side effect (versus 29% of patients in group A). These 
data support the notion that immunosuppressive therapy is more toxic in 
patients with renal insufficiency. 
 
Discussion 
Our study provides firm support for the efficacy of a cyclophosphamide-
based treatment regimen in patients with iMN at high risk for ESRD. 
Immunosuppressive treatment resulted in a higher remission rate, when 
compared to a supportive approach. Our study thus confirms the 
conclusions from the randomized controlled trials that proved the superiority 
of immunosuppressive therapy with alkylating agents over standard care, 
when used in all patients with iMN and a nephrotic syndrome.5;19 Our data 
indicate that treatment efficacy is maintained when restricting treatment to 
high risk patients with iMN. 
 
When comparing early versus late start of therapy, there is no difference in 
the overall remission rate during follow-up. Still, early start of treatment 
resulted in a marked reduction of the time of the nephrotic phase. Since the 
nephrotic syndrome is associated with complications such as thrombosis 
and infections, early start of treatment may offer benefits. 
 
On the other hand, we did not observe differences in clinical status at the 
end of follow-up, nor in complication rate or adverse events between early 
and late treatment start. Admittedly, our study lacks sufficient power to 
exclude small differences. Our findings with respect to renal function are in 
line with our observations in a larger patient cohort that cyclophosphamide 
based therapy was able to improve renal function in more than 90% of 
treated patients.9 
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Our study was partly intended to evaluate the prospect of a larger, 
multicenter study aimed at performing a rigorous cost-efficacy analysis of 
early versus late treatment. In such an analysis various outcome parameters 
should be accounted for such as complications of the nephrotic syndrome, 
complications of the treatment, including infertility and malignancies, and 
proteinuria and renal function during follow-up. 
 
However, our experience with the current study has provided arguments 
against such an endeavor. First, many patients refused to participate in this 
study. The main reason was that patients did not want to be randomized for 
aggressive versus non-aggressive therapy.  
Second, and most importantly, we feel that the average outcome of a larger 
study is not applicable to the individual patient. It is evident that the risk to 
develop complications of the nephrotic syndrome versus the risks of 
treatment varies to a large extent between patients. These risks are largely 
dependent on individual patient characteristics: it seems impossible to take 
these into account in the setting of a randomized trial. We feel that our data 
provide sufficient support for an individualized treatment strategy where the 
timing of start of immunosuppressive therapy is guided by the patient 
characteristics. 
 
An assessment of risks and benefits in the individual patient should be 
performed to make a decision about the start of therapy (Table 4). The risks 
of prolonged nephrotic syndrome, i.e. thrombo-embolic and infectious 
complications, will favour early start of treatment in patients with a past 
history of thrombosis, cardiovascular disease and infections, especially in 
case of severe hypoalbuminemia. On the other hand the risk of treatment 
related complications, i.e. infertility, infections and steroid associated side 
effects, favours late start of treatment in patients with planned parenthood, a 
past history of diabetes mellitus, osteoporosis or respiratory infections. 
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Finally, age must be taken into account. Elderly patients are more prone to 
develop treatment-related complications, whereas the likelihood to develop 
ESRD during lifetime is often small. 
 
Table 4. Start of immunosuppressive therapy in membranous nephropathy: 
factors relevant for the decision in the individual patient. 
 
 Favours  
early treatment 
Favours  
late treatment 
Age   
 Younger X  
 Older     X 
Comorbidity   
 COPD/ Respiratory  X 
 Cardiovascular disease X  
 Diabetes mellitus  X 
 Osteoporosis  X 
Previous thrombo-embolism X  
Previous exposure to cytotoxic agents  X 
Serum albumin <20 g/l X  
Planned parenthood  X 
 
 
What else can be learned from our study?  
Obviously, we were able to identify high-risk patients with iMN since two-
third of initially untreated patients developed RFD within 3 years after 
randomization. The predictive accuracy, based on the threshold value of 0.5 
mg/min for Uβ2m and 125 mg/day for UIgG is reasonable. If we had used 
250 mg/day as threshold value for UIgG only 2 out of 10 patients would have 
developed a spontaneous remission. We advocate the latter threshold value, 
which when combined with Uβ2m results in a predictive accuracy of 90%.13  
Of note, the mean Uβ2m excretion tend to be higher in the 8 patients in 
group B who progressed to RFD compared to the 4 patients who developed 
a spontaneous remission ( 3.8 versus 0.9 mg/min, p=0.06), indicating that  
the chance of a spontaneous remission is related to the level of Uβ2m 
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excretion. Other baseline characteristics did not differ between progressors 
and non-progressors in group B. 
 
Of note, thrombo-embolic complications occurred in two patients randomized 
for early start of treatment. In these patients the thrombo-embolic event 
occurred shortly after the administration of intravenous methylprednisolone. 
It has been suggested before that corticosteroids can be thrombogenic in 
nephrotic syndrome.20 Therefore, we suggest to use low-molecular weight 
heparin in the first months of treatment. 
 
Finally, although side effects of treatment were not significantly different 
between the groups the data support the notion that immunosuppressive 
therapy is less well tolerated in patients with renal insufficiency. 
 
Our study has several limitations. The number of patients included is 
relatively small. However, all patients included had a high-risk for 
progression to renal insufficiency, and a low chance of spontaneous 
remission, which provided enough power to evaluate remission rates. Next, 
the frequency of follow-up visits was different in the two groups, as patients 
in group A who immediately started immunosuppressive treatment were 
seen more often during this treatment. Finally, the treatment schedule of oral 
cyclophosphamide during 12 months might be questioned, as previous 
studies reported good effect of a 3 months course.5;19 Of note, those studies 
included not only high-risk patients, but also patients with a high chance of 
spontaneous remission, so the results might not be applicable to our current 
study population. Our current treatment schedule was based on previous 
experience in high risk patients.9 
 
In conclusion, treatment efficacy is maintained when restricting 
cyclophosphamide based treatment to high risk patients with iMN and a 
nephrotic syndrome. In these patients treatment can safely be postponed 
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until renal function deteriorates. However, there might be a larger risk of 
treatment related sight effects. Our study suggests that treatment decisions 
in the individual patient must be based on an individualized assessment of 
risks and benefits. 
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Introduction 
Idiopathic membranous nephropathy (iMN) is one of the most common 
causes of the nephrotic syndrome in adults. The clinical course of patients 
with iMN is quite variable. Untreated, approximately 40-50% of patients with 
iMN and nephrotic proteinuria will develop ESRD.1  
According to data of registries in the US, Europe and Australia & New 
Zealand MN was the cause of ESRD in 0.47-1.71% of patients who started 
renal replacement therapy in the period 1980-1994.2  
The treatment of iMN is heavily debated. Although several studies have 
claimed success of immunosuppressive therapy,3-6 a meta-analysis and 
Cochrane review published in 2004 concluded that there is insufficient 
evidence of the efficacy of immunosuppressive therapy.7 The perception that 
immunosuppressive therapy is of limited benefit is fostered by recent 
reviews and research articles which explicitly state that the prognosis of 
membranous nephropathy has hardly improved in recent years with up to 
40% of patients reaching ESRD.8-10 This ongoing debate may lead to 
therapeutic nihilism. The uncertainty on the use of immunosuppressive 
therapy in patients with iMN is reflected in our recent study, in which we 
evaluated by questionnaire the immunosuppressive strategies that had been 
used in 45 patients with iMN who started renal replacement therapy in the 
period 2000-2005.11 The majority of patients ( 23; 52%) had not received any 
immunosuppressive therapy, initial immunosuppressive treatment consisted 
of prednisone monotherapy in 7 patients (16%), cyclosporine and 
prednisone in 5 patients (11%), cyclophosphamide and prednisone in 
another 5 patients (11%), chlorambucil and prednisone in 3 patients (7%), 
and azathioprine and prednisone in one patient (2%). 
We summarize the evidence that immunosuppressive therapy using 
alkylating agents is effective in iMN and improves renal survival. We discuss 
the risks associated with this treatment and touch upon areas of uncertainty. 
The introduction of new immunosuppressive agents and biologicals has 
provided hope for effective and safer treatment of patients with iMN. These 
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new agents must be evaluated in randomized trials. Since alkylating agents 
are proven effective, these agents should be considered the golden standard 
of therapy and used as comparator drug in such trials.  
 
Why is immunosuppressive therapy in iMN heavily debated? 
It is no surprise that immunosuppressive therapy is heavily debated in 
patients with iMN. First, there are very few randomized trials in patients with 
iMN, precluding to provide guidelines with grade A levels of evidence. 
Second, the natural history of iMN is quite variable, and many studies have 
reported a relatively good outcome in untreated patients.12 Of note, as 
discussed elsewhere1 the favorable outcome in these studies can be 
explained by the inclusion of patients with non-nephrotic proteinuria. 
Obviously, patients with non-nephrotic proteinuria have an excellent 
prognosis and should not be exposed to immunosuppressive therapy. Third, 
the immunosuppressive agents have serious side effects, and it is quite 
difficult to balance the risks and benefits.10 Following the adagium “primum 
non nocere” (first do no harm), many physicians when in doubt, will opt to 
not expose patients to the side effects of immunosuppression. 
To obliviate this doubt, it is important to be able to predict outcome in the 
individual patient with high accuracy. In recent years we have made 
considerable progress in this area. Both the use of a model, that 
incorporates the duration and magnitude of proteinuria and the change in 
serum creatinine level over a 6 month period, as the measurement of urinary 
low molecular weight proteins can predict outcome with an accuracy of 
>85%.13-15 These models allow a more restrictive treatment policy. 
Obviously, it is impossible to categorize all patients with a model. If a patient 
cannot with certainty be categorized as high risk, an expectative treatment 
policy should be advised.   
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Alkylating agents are effective and have improved prognosis in iMN. 
The efficacy of alkylating agents was until recently only supported by the 
results of one randomized, controlled clinical trial conducted in Italy.3 This 
study recruited patients with recent onset iMN, a nephrotic syndrome and 
normal renal function. Treatment consisted of chlorambucil, prednisolone 
and i.v. methylprednisolone for 6 months in an alternating schedule. 
Treatment increased remission rate and improved renal survival (Table 1). 
The efficacy of immunosuppressive therapy with an alkylating agent was 
recently confirmed in a new randomized, controlled trial by Jha et al.16 These 
investigators used a similar treatment schedule, but replaced chlorambucil 
by cyclophosphamide. Study participants had normal renal function. This 
study provided further evidence that an alkylating agent increased remission 
rate and improved renal survival (Table 1). Obviously, both trials included 
patients with normal renal function who are not at highest risk for developing 
ESRD. Indeed, approximately 35% of patients were exposed unnecessarily 
to immunosuppressive therapy (see Table 1: spontaneous remission rate in 
the untreated controls). Therefore, many authors advise against adopting 
such a treatment strategy and advocate to restrict treatment to high-risk 
patients only. Although the efficacy of immunosuppressive therapy in 
patients with established renal insufficiency is not proven in randomized 
trials two recent cohort studies provided strong support for the efficacy of 
alkylating agents in these high-risk patients.4;5 In these studies by Torres et 
al. and Du Buf et al. a historical control group was used for comparison. Both 
studies showed better renal survival in the treated patients. Table 1 
summarizes the results of the above mentioned studies, all with a high level 
of evidence and clinical significant end points (dialysis free survival).  
The efficacy of a restrictive treatment policy (i.e. treating only patients with 
established renal insufficiency) was demonstrated in another study by Du 
Buf et al., who evaluated outcome in a cohort of patients with iMN and a 
nephrotic syndrome.17 All patients diagnosed with iMN in the study period 
were identified by using the central pathology registry, thus excluding any 
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selection bias. In the study period a restrictive treatment policy was advised, 
thus limiting immunosuppressive therapy to patients with renal insufficiency 
or patients with a severe, longstanding nephrotic syndrome. During an 
average follow-up of 66 months, 22 of 60 patients developed a spontaneous 
remission. Overall 33 patients (48%) received immunosuppressive therapy, 
which consisted of the combination of an alkylating agent and prednisone in 
28 patients. Patient survival after 7 years was 100% and renal survival 88%. 
This study thus indicates that a restrictive treatment strategy which avoids 
unnecessary exposure to alkylating agents in approximately half of the 
patients results in a favourable prognosis in patients with iMN. We recently 
provided additional evidence that the use of a restrictive treatment strategy 
and cyclophosphamide as alkylating agent alters outcome in patients with 
iMN. In an epidemiological study we analyzed the incidence of ESRD in the 
Netherlands and observed that the incidence of ESRD due to iMN 
decreased in our region by 75% when comparing the period 1991-1995 with 
the period 2000-2005.11 By contrast, the incidence of ESRD due to iMN had 
remained unchanged in other parts of the Netherlands. Only 18% of patients 
with ESRD due to iMN had received treatment with an alkylating agent.  
With regard to the choice of the best alkylating agent, a comparative study 
between chlorambucil and cyclophosphamide was performed by Ponticelli et 
al.18 In this study both agents were equally effective in inducing a remission 
of proteinuria. In our hands, a chlorambucil based regimen was less effective 
and more toxic than a regimen based on cyclophosphamide.19 An overview 
of studies performed in patients with iMN and renal insufficiency treated with 
either chlorambucil or cyclophosphamide, points towards better efficacy of 
cyclophosphamide.1 Moreover, the data suggest that the use of chlorambucil 
is associated with more side effects (see below). 
In conclusion: there is now grade A evidence that alkylating agents are 
effective in patients with iMN. Additional data strongly suggest that treatment
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can be restricted to high-risk patients and that a restrictive treatment strategy 
carries a good prognosis and improves outcome.  
 
Side effects of alkylating agents. 
Obviously, alkylating agents are toxic drugs. The short term side effects of 
both chlorambucil and cyclophosphamide include anemia, leucocytopenia, 
thrombocytopenia, anorexia, nausea, liver test abnormalities, interstitial 
pneumonitis, and sterile cystitis. Macroscopic hematuria and hemorrhagic 
cystitis are mainly associated with the use of cyclophosphamide. As 
discussed elsewhere, chlorambucil is associated with more side effects than 
cyclophosphamide.5;19 The magnitude and relevance of these side effects in 
daily clinical practice can be estimated from the adverse events reported in 
recent clinical trials in patients with iMN. Ponticelli reported side effects in 
29% of patients treated with chlorambucil, most commonly gastro-intestinal 
problems, including peptic ulcers.3 Ten percent of treated patients had to 
stop therapy because of side effects, all patients recovered after adequate 
therapeutic measures. In the study of Torres side effects were observed in 
47% of the chlorambucil treated patients, most accounted for by infections 
(32%).4 Jha reported infections as the most frequent side effects in both the 
group with supportive treatment and the patients treated with 
cyclophosphamide.16 In this latter group, infections were present in 15% of 
patients. We ourselves noted hematological abnormalities in more than half 
of the patients treated with cyclophosphamide, infections in 26%, anorexia 
and nausea in 12%, and liver dysfunction in 3%.5 In 46% of patients the 
dose was reduced, and in 6% of patients treatment was prematurely 
stopped. Although cumbersome these short-term side effects can mostly be 
managed by dose reduction, temporary withdrawal of the alkylating agent, 
and appropriate antibiotic therapy. Of note, we currently use cotrimoxazole 
as standard prophylaxis against Pneumocystis Jiroveci Pneumonia.  
The most important and most feared side effects of chlorambucil and 
cyclophosphamide are infertility and malignancy. Most data are available on 
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the effects of cyclophosphamide. Azoöspermia may occur when 
cyclophosphamide is used in a dose of 2 mg/kg/day for more than 12 weeks 
in men.20 In women the risk of amenorrhea increases when the cumulative 
dose of cyclophosphamide exceeds 10-15 gr. The risk of amenorrhea is 
dependent on the cumulative dose, but also on the age of the patient.20;21 
Thus, in patients with planned parenthood in the future, duration of 
cyclophosphamide treatment should be limited to 3 months. 
Obviously, the most dreaded side effect of cyclophosphamide treatment is 
the development of malignancies. Recent studies have reported a doubling 
of the standardized incidence ratio (SIR) of malignancies in patients treated 
with cyclophosphamide.22;23 The increased incidence was predominantly 
attributable to the occurrence of skin cancer (SIR for squamous skin cancer 
7.3-11.5), bladder cancer (SIR 3.6-4.8) and leukemia (SIR 5.7-59).  
The late effects of cyclophosphamide have been studied in patients with 
rheumatoid arthritis and in patients with vasculitis.22;24-26 The cumulative 
incidence of bladder cancer was reported to be 4 to 15% at 15 years after 
drug exposure. The average latency time was 108 months. There is a clear 
dose dependency, and older studies indicated that bladder cancer occurred 
in patients who had used more than 50 g of cyclophosphamide. Median 
cumulative dose of cyclophosphamide was 113 g in the patients with bladder 
cancer. Based on these criteria treatment with cyclophosphamide, 1.5 
mg/kg/day for 12 months (cumulative dose 35-40 g) was considered safe 
until recently.  
In two recent studies the threshold value of 50 g was questioned.23;27 Travis 
et al. studied the risk of bladder and kidney cancer following 
cyclophosphamide treatment in survivors of non-Hodgkin’s lymphoma.27 
There was no increased risk for malignancies in patients who received a 
cumulative dose of cyclophosphamide of less than 20 g. With higher doses 
an increased risk was observed; respectively a six fold (CI 1.3-29) and 14.5 
fold (CI 2.3-94) increased risk of bladder cancer following cumulative doses 
of cyclophosphamide of 20-49 g and 50 g or more, respectively. However, 
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the contribution of radiotherapy to the increased risk could not completely be 
excluded for patients receiving 20-49 g.  In the second study, Faurschou et 
al. observed a significantly increased malignancy risk in patients who had 
received more than 36 g of cyclophosphamide.23 Interpretation of these data 
is difficult, since many patients were treated with other immunosuppressive 
drugs during follow-up. In fact, the SIR of bladder cancer was markedly 
increased in patients who had received cyclophosphamide and methotrexate 
(SIR 13.8; 95% CI 2.8-40), and non-significantly higher in patients who had 
used cyclophosphamide monotherapy (SIR 3.0; 95% CI 0.4-10.8). 
Thus, there is no doubt that prolonged use of cyclophosphamide 
predisposes to the development of a malignancy. Patients must be well 
informed. However, the risks must not be overrated. First, the actual risk of 
developing a malignancy is not very high. Second, it is unclear if the 
increased risk is merely dependent or fully attributable to the use of the 
alkylating agent. It has been suggested that conditions as Wegener’s 
granulomatosis, are associated with a higher cancer rate independent from 
therapy, indicating a possible carcinogenic effect of the disease process 
itself.26 Likewise, a recent Norwegian study showed increased incidence of 
malignancies in patients with iMN independent of the use of 
immunosuppressive agents.28 Third, we must realize that untreated patients 
are more likely to develop ESRD. Renal replacement therapy is associated 
with increased mortality due to cardiovascular disease.29-33 Moreover, renal 
transplantation, the preferred method of renal replacement therapy in 
patients aged <70 years, carries an significantly increased risk of malignant 
disease, due to lifelong treatment with immunosuppressive agents.34-36 Next 
to the well-known up to twenty-fold increased risks of non-melanoma skin 
cancers and virus-associated cancers, a twofold increase in common 
tumors, including colon, lung, breast, prostate, esophagus and pancreas is 
reported in kidney transplant recipients.34  
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Areas of uncertainty 
x Based on the available evidence we can conclude that alkylating agents 
are effective in patients with iMN. Cyclophosphamide seems to be 
preferable over chlorambucil, based on data on efficacy and toxicity. 
Treatment should be restricted to high-risk patients who can be 
identified by the level and/or the composition of urinary proteins. Several 
unanswered questions remain. The optimal dose and duration of 
therapy with cyclophosphamide is uncertain. We have used 
cyclophosphamide 1.5-2 mg/kg/day for 12 months (cumulative dose 35 
g) in high-risk patients and reported a favourable outcome.5;37 However, 
in light of recent literature, this relatively high cumulative dose should be 
questioned. Since a cumulative dose up to 20 g appears to be safe, a 
treatment period of 6 months could be an alternative. Recent studies of 
Jha et al. and Ponticelli et al. showed benefit of treatment with a 
schedule that included cyclophosphamide in a dose of 2 mg/kg/day for a 
total of 3 months (cumulative dose approximately 13 g for a 70 kg 
patient).3;16;38 These latter studies suggest that the dose and duration of 
cyclophosphamide treatment may be further limited although it must be 
realized that the efficacy of these treatment regimens have not been 
demonstrated when restricted to high-risk patients.  
A recent study suggested that even lower doses of cyclophosphamide 
could be used with success.39 In this study conducted in Asia, all 
patients with iMN and a nephrotic syndrome were treated with 
prednisone (30 mg/day with tapering and withdrawal by 2 years) and 
cyclophosphamide in a dose of 1 mg/kg/day for 3 months, followed by 
0.5 mg/kg/day for another 3 months (cumulative dose approximately 9 
g). The authors reported a cumulative incidence of remission of 94% 
after 8 years. However, the data do not support the conclusion that such 
a low dose cyclophosphamide therapy is effective. First, the study 
population consisted of all nephrotic patients with iMN, with almost 50% 
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females, and well preserved renal function. Without immunosuppressive 
therapy more than 50% of patients would have developed a 
spontaneous remission. Moreover, 38% of patients needed a second 
course of therapy because of initial treatment failure or relapse. Thus, it 
is likely that the high-risk patients actually received a total dose of 
cyclophosphamide of almost 20 g.  
x Treatment with alkylating agents is usually combined with high dose 
steroid treatment. The dose and duration of steroid treatment varies, 
and clinical trials are lacking. Some authors report a benefit of 
intravenous methylprednisolone pulses over oral medication.40 Our 
steroid regimen consists of methylprednisolone 1 gram intravenously on 
days 1,2,3, 60,61,62, 120,121, and 122, and oral prednisone 0.5 mg/kg 
BW every other day for 6 months, subsequently tapered by decreasing 
the dose with 5 mg/wk.  Obviously, this treatment is accompanied by the 
well-known steroid-side effects, including Cushingoid appearance, 
hyperglycemia and osteoporosis.  
x The optimal timing of start of therapy is uncertain. Is it better to start 
early immunosuppressive therapy in high-risk patients or can we wait 
until renal function deteriorates? Recently we have conducted a 
randomized open label trial in patients with iMN and a high risk for 
progression.41 Patients started with cyclophosphamide and prednisone 
immediately after randomization or when renal function deteriorated. In 
these high-risk patients, the treatment regimen was effective in inducing 
a remission (>90%) in both treatment arms. Although early treatment 
resulted in a more rapid onset of remission and therefore shortened the 
duration of the nephrotic phase, it did not result in a better preservation 
of renal function at the end of follow-up. It therefore seems that 
treatment can safely be postponed until renal function deteriorates. 
However, when postponing treatment, there might be a larger risk of 
both nephrotic syndrome-related and treatment-related side effects. We 
suggest that decisions on the timing of start of therapy must be based 
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on an individualized assessment of risks and benefits.41 The risks of 
prolonged nephrotic syndrome, i.e. thrombo-embolic and infectious 
complications, will favour early start of treatment in patients with a past 
history of thrombosis, cardiovascular disease and infections, especially 
in case of severe hypoalbuminemia. On the other hand the risk of 
treatment related complications, i.e. infertility, infections and steroid 
associated side effects, favours late start of treatment in patients with 
planned parenthood, a past history of diabetes mellitus, osteoporosis or 
respiratory infections. Finally, age must be taken into account. Elderly 
patients are more prone to develop treatment-related complications, 
whereas the likelihood to develop ESRD during lifetime is often small. 
Some clinical examples are illustrated in Table 2. 
When risk assessment leads to the decision not to start treatment in an 
individual patient, re-evaluation should take place after 6 months or 
earlier if the clinical condition of the patients changes. 
x Are there suitable alternatives? Many other therapeutic agents are 
available in daily clinical practice, i.e. calcineurin inhibitors, 
mycophenolate mofetil, synthetic ACTH and rituximab. An extensive 
discussion of their efficacy and safety is beyond the scope of this 
manuscript. Recent studies with these newer agents in patients with iMN 
have raised optimism on their efficacy, as indicated by high remission 
rates. However, follow-up was short in most studies and there are 
virtually no studies with hard renal end points such as ESRD or 50% 
decrease of GFR. Long terms RCT’s are needed. We recommend that 
alkylating agents be considered as comparator drugs in such trials. iMN 
is a treatable disease in most patients. We should focus on the 
questions on whom to treat, when to start therapy, and the best 
sequence of the use of the various immunosuppressive drugs.  
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Table 2: Treatment decisions in clinical practice: some examples of 
balancing risks and benefits 
 
* β2m- and IgG excretion: urinary beta-2-microglobulin excretion and urinary IgG 
excretion. These are considered elevated when respectively  >500 ng/min and >250 
mg/24hr. Combined elevated B2m- and IgG excretion is a marker of high risk for 
progression to renal failure. 
DVT = deep venous thrombosis; COPD = chronic obstructive pulmonary disease; 
eGFR = estimated glomerular filtration rate 
  
 Patient 1 Patient 2 
Characteristics:   
Age 
Offspring 
Medical history 
sCreatinine (umol/l) 
sAlbumin (g/l) 
Proteinuria (g/day) 
β2m- and IgG excretion* 
25 25 
none 2 
none 2 x DVT 
90 110 
17 17 
17 17 
↑↑ ↑↑ 
Considerations:   
Favours treatment x High risk of progression 
x Nephrotic syndrome 
x High risk of thrombo-
embolic complications 
x High risk of progression 
x eGFR below normal 
 
Against treatment x Risk of infertility 
x Side effects 
x Normal renal function 
 
 
 
x Risk of infertility 
x Side effects 
Advise: x Supportive treatment 
x Re-evaluation at 3, 6 
and 12 months 
x Start treatment if 
sCreatinine increases 
>25% 
x Start immuno-
suppressive treatment  
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Table 2. continued 
 
 
 
  
 Patient 3 Patient 4 
Characteristics:   
Age 
Offspring 
Medical history 
sCreatinine (umol/l) 
sAlbumin (g/l) 
Proteinuria (g/day) 
β2m- and IgG excretion* 
65 65 
2 2 
diabetes, COPD myocardial infarction 
110 180 
21 21 
17 17 
↑↑ ↑↑ 
Considerations:   
Favours treatment x High risk of progression x Sustained renal function 
loss 
x High risk of thrombo-
embolic complications 
x High risk of progression 
Against treatment x Risk of steroid-induced 
hyperglycaemia 
x Risk of respiratory 
infections 
x Side effects with elder 
age 
x Side effects with elder 
age 
Advise: x Supportive treatment 
x Re-evaluation at 3, 6 
and 12 months 
x Start treatment if 
sCreatinine increases 
>25% 
x Start immuno-
suppressive treatment 
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Conclusion 
In patients with iMN alkylating agents increase remission rate and improve 
renal survival. Thus, alkylating agents should be considered the golden 
standard of therapy. Treatment harbours the risk of severe toxicity. 
Therefore, cyclophosphamide should only be given to high-risk patients. If 
possible, a cumulative dose of >20 grams should be avoided. Alternative 
agents with fewer side effects are urgently needed. Still, the efficacy of 
newer immunosuppressants must be proven on renal end points. In 
randomized controlled trials evaluating the efficacy of these agents, 
alkylating agents must be used as comparator drugs. 
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Abstract 
Background and objectives: Circulating autoantibodies against the M-type 
phospholipase A2 receptor (anti-PLA2R) were recently identified in the 
majority of US patients with idiopathic membranous nephropathy (iMN). The 
objectives of this study were to assess the prevalence of anti-PLA2R in a 
separate, European cohort of iMN patients and to correlate the presence of 
anti-PLA2R with clinical parameters reflective of disease activity. 
Design, setting, participants, & measurements: Anti-PLA2R levels were 
blindly assessed by a Western blot immunoassay in 54 serum samples from 
18 patients with iMN collected in various stages of clinical disease. Anti-
PLA2R levels were correlated with other clinical parameters. 
Results: 77.8% of iMN patients in our cohort had antibodies reactive with 
human PLA2R. Antibody level in these patients correlated strongly with both 
clinical status and proteinuria (r=0.73, p<0.01). 
Conclusions: The role of PLA2R as a major antigen in iMN was confirmed in 
an independent, European patient cohort, and levels of circulating anti-
PLA2R revealed a strong correlation with clinical disease activity. We 
propose that detection and measurement of these autoantibodies may 
provide a tool for monitoring of disease activity and treatment efficacy. 
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Introduction 
Idiopathic membranous nephropathy (iMN) is a single organ autoimmune 
disease and a common cause of the nephrotic syndrome in adults. 
Accumulated evidence from the experimental rat model of Heymann’s 
nephritis has advanced the hypothesis that, in human membranous 
nephropathy, a circulating antibody reacts with and binds to a primary 
antigenic target on podocytes.1-4 Further insights into the pathogenesis of 
human disease were established in the past decade, as several podocyte 
target antigens have been proposed based on the presence of circulating 
antibodies in patients with membranous nephropathy.5;6 Recently, we have 
identified circulating autoantibodies against the M-type phospholipase A2 
receptor (PLA2R) in the majority of patients with iMN.5 Cumulative data from 
serum samples obtained in the Northeastern United States have shown that 
greater than 70% of patients with iMN have these autoantibodies, primarily 
of the IgG4 subclass, that are reactive with native and recombinant human 
glomerular PLA2R. We have also documented a preliminary association of 
the presence of circulating anti-PLA2R with clinical disease activity.5 The 
goal of this study was therefore to assess the prevalence of anti-PLA2R in a 
separate, European cohort of iMN patients and to correlate the presence of 
anti-PLA2R with the clinical parameters reflective of disease activity. 
 
Study population and Methods 
In the Nijmegen center, patients with recently diagnosed membranous 
nephropathy are evaluated using a standardized protocol as described.7 In 
brief, blood samples and timed urine samples are collected for the 
measurement of serum creatinine, albumin, cholesterol, beta-2-microglobulin 
(β2m), IgG and transferrin, as well as urinary excretion of creatinine, β2m, 
albumin, IgG, transferrin and alpha-1-microglobulin (α1m). In addition 
aliquots of serum and urine are centrifuged and the supernatant is stored at 
–70˚ C. Patients are prospectively followed with repeated serum and urine 
collections, and additional data on treatment, remission and survival are 
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obtained. This protocol was approved by the ethics committee of our center. 
All patients gave written informed consent.  
 
Serum samples of patients with a biopsy proven iMN and a nephrotic 
syndrome were collected at several time points during their disease and 
treatment course. Membranous nephropathy was considered to be idiopathic 
when no secondary cause of MN was suspected based on clinical and 
laboratory criteria. The samples were categorized by JMH and JFW as: 
nephrotic syndrome (serum albumin <3.0 g/dL and proteinuria >3.5 g/day), 
spontaneous remission (proteinuria reduction of >50% with proteinuria <3.5 
g/day, no treatment with immunosuppressive drugs), treatment-induced 
remission (proteinuria reduction of >50% with proteinuria <3.5 g/day 
following treatment with immunosuppressive agents), persistent proteinuria 
(proteinuria >3.5 g/day or proteinuria reduction <50%), or relapse 
(proteinuria >3.5 g/day after a period of remission).  
 
Coded samples were analyzed by LHB and DMB (Boston University) without 
knowledge of the clinical status for the presence of anti-PLA2R by Western 
blotting against human glomerular proteins under non-reducing conditions. 
Sera were tested at 1:25, which has been shown to be both sensitive and 
specific for iMN,5 followed by detection of human IgG4. For those samples 
that were negative for IgG4-anti-PLA2R, the immunoassay was repeated for 
total IgG anti-PLA2R. Results were standardized with the use of a single 
known reactive MN sample, assayed under identical conditions for each 
experiment. The bands corresponding to PLA2R were scanned on a Hewlett 
Packard flatbed scanner and densitometry was performed using NIH 
ImageJ. The 46 available samples were tested in two separate batches. 
Twenty-four samples were run in both batches to serve as internal controls. 
Correlation between anti-PLA2R levels measured in first and second run was 
0.97. 
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Statistical analyses 
For descriptive statistics, data are presented as means (rSD) or medians 
(range) when appropriate. The correlation between two parameters (non-
parametric distributions) was analyzed by Spearman’s rank coefficient of 
correlation. Mann-Whitney U and Kruskall-Wallis tests were used for 
comparison between groups. All statistics were performed using SPSS 
software, version 17.0 (Chicago, IL). Differences were considered significant 
with p-value <0.05. 
 
Results 
We measured anti-PLA2R levels by a Western blot immunoassay in coded 
serum samples from patients with iMN collected when they were nephrotic, 
in spontaneous or treatment-induced remission, or in relapse (see Study 
population and Methods above). 
 
Fourteen of 18 (77.8%) iMN patients had IgG4 autoantibodies to PLA2R in 
their baseline sample (taken during a period of nephrotic syndrome). One of 
these patients did not show reactivity at presentation, but showed reactivity 
in a serum sample taken 4 months later, while persistently nephrotic. The 
four patients who were non-reactive for IgG4 anti-PLA2R were also negative 
when the immunoassay was repeated with an assay for total IgG anti-
PLA2R. Baseline characteristics of all patients are given in Table 1. In these 
small groups there were no significant differences between the anti-PLA2R-
positive and -negative patients with respect to age, gender, serum 
creatinine, serum albumin, or renal function.  
 
In those patients positive for anti-PLA2R, the level of autoantibodies as 
established by densitometry correlated well with several baseline 
characteristics that are related to the severity of disease.  
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Table 1: Baseline characteristics (n=18) 
 
Gender (M/F) 14/4 
Age (yr) 51 ±10 
sCreat (μmol/l) 122 ±44 
sAlbumin (g/dL) 2.6 ±0.7 
Proteinuria (g/day) 10.2 ±4.7 
β2m-excretion (ng/min) 1786 (99-62000) 
IgG-excretion (mg/day) 249 (21-3082) 
eGFR (ml/min/1.73m2)  50 (25-104) 
sβ2m (mg/l) 3.66 (1.63-12.48) 
sIgG (g/l) 4.34 (1.85-13.35) 
Selectivity Index 0.24 ±0.12 
anti-PLA2R (densitometric units) 10042 (0-30115) 
Data are given as mean ±SD or median (range). Anti-PLA2R = anti-PLA2R 
antibodies; sCreat = serum creatinine; β2m = beta-2-microglobulin; eGFR = 
estimated GFR calculated by extended MDRD formula (MDRD6); Selectivity Index 
(SI) was calculated as IgG clearance/ Transferrin clearance. SI ≤0.2 reflects 
selective proteinuria, whereas SI >0.2 is considered non-selective proteinuria.  
 
  
The anti-PLA2R level correlated positively with proteinuria (r=0.73, p<0.01, 
Figure 1), serum β2m (r=0.72, p<0.01), urinary IgG excretion (r=0.70, 
p=0.03), urinary β2m excretion (r=0.67, p<0.01), and serum creatinine 
(r=0.57, p=0.03). Anti-PLA2R level was negatively correlated with estimated 
GFR (r= -0.53, p=0.049).  
 
Densitometry of the anti-PLA2R Western blot signal also correlated well with 
clinical status during follow-up (Table 2). In 13 patients positive for anti-
PLA2R autoantibodies at baseline, a subsequent sample obtained during 
complete or partial (urine protein <3.5 g/day) remission was available. 
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Figure 1. Correlation between the anti-PLA2R antibody level and 
proteinuria  
    Baseline samples, n=14 
 
 
Median time from presentation till onset of remission was 19 months (range 
11-45).  In 8 of the patients with a remission, there was also a third sample 
obtained after a relapse of proteinuria. Overall, anti-PLA2R levels were high 
in the initial phase of nephrotic syndrome, decreased significantly during 
remission and increased again during relapse (p<0.01 Kruskall-Wallis test; 
Figure 2). In these small groups there were no differences between 
spontaneous or treatment-induced remissions. Of note, an abnormal pattern 
was seen in one patient in whom the anti-PLA2R level did not decrease 
during remission of proteinuria (see Figure 2). In this patient a relapse of 
nephrotic range proteinuria occurred during follow-up and was accompanied 
by progressive loss of renal function. 
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Table 2. Clinical course in anti-PLA2R positive patients (n=14) 
eGFR= estimated Glomerular Filtration Rate by MDRD6 formula; * in ml/min/1.73m2; 
aPLA2R = anti-PLA2R antibodies; dens.units = densitometric units; Time to remission = 
time between presentation and onset of remission;  
# sample 4 months after presentation: in the initial sample anti-PLA2R was not 
detected (see text) 
  
 Presentation  Remission 
Patient Proteinuria eGFR aPLA2R level Time to remission Proteinuria eGFR 
 
  (g/day) * (dens.units) (months) (g/day) * 
1 9.3 77 22273 -  - 
2 3.8 71 3203 24 2.0 77 
3 3.6 62 9251 15 0.2 62 
4 5.8 83 2236 18 2.1 90 
5 10.5 25 17927 13 0.4 48 
6 12.8 51 8802 19 0.4 96 
7 8.8 95 9823 20 2.6 113 
8 8.9 104 10260 45 1.5 86 
9 12.5 66 25116# 20 0.3 83 
10 
 
10.0 44 14510 18 0.7 67 
11 
 
18.0 64 19721 28 1.8 57 
12 
 
10.0 34 10379 11 0.1 61 
13 
 
17.2 31 30115 14 0.8 86 
14 10.9 27 23235 23 0.4 35 
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Table 2. continued 
 
No. = patient number; Time to relapse = time between onset of remission and onset of 
relapse; Spont. = spontaneous remission; Ther. = therapy-induced remission; MMF = 
mycophenolate mofetil; P = prednisone; CP = cyclophosphamide; mo = months 
 
 
 
  
 Remission Relapse  
No. aPLA2R level Type of 
remission 
Treatment Time to 
relapse 
Proteinuria eGFR aPLA2R level 
  (dens.units)   (months) (g/day) * (dens.units) 
1 - - - -  - - 
2 438 Spont. - -  - - 
3 0 Spont. - -  - - 
4 877 Spont. - -  - - 
5 0 Ther. 
MMF + P 
12 mo -  - - 
6 135 Ther. 
MMF + P 
12 mo -  - - 
7 1956 Spont. - 67 8.3 95 3780 
8 8555 Spont. - 51 6.6 99 7416 
9 0 Ther. 
CP + P 
12 mo 75 20.2 71 19757 
10 399 Ther. 
CP + P 
12 mo 104 7.1 50 9491 
11 341 Ther. 
CP + P 
12 mo 69 9.7 50 18373 
12 0 Ther 
CP + P 
12 mo 44 7.9 64 9491 
13 0 Ther. 
CP + P 
12 mo 19 10.0 55 8769 
14 0 Ther. 
CP + P 
12 mo 65 4.9 31 6934 
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Figure 2.  Anti-PLA2R autoantibody levels during the clinical course of 14 
patients that were positive at baseline.  
 Nephrotic; sample taken during period of proteinuria > 3.5 g/day with 
serum albumin <3.0 g/dL; Remission: sample taken during clinical 
remission with proteinuria <3.5 g/day; Relapse: sample taken during 
clinical relapse of proteinuria >3.5 g/day after a period of remission.  
 
 
 
We have recently re-evaluated the eight patients who had a relapse of 
proteinuria after a period of remission. Median follow-up from relapse to final 
evaluation was 26 months (range 12-96). In three patients severe proteinuria 
persisted (median proteinuria 9.3 g/day, range 9.3-14.2) and in these 
individuals, the levels of anti-PLA2R were stable or increased (see 
supplemental Figure e1). In five patients proteinuria decreased from median 
8.3 (range 6.6-10.0) to 4.0 g/day (range 1.2-4.8). In these patients anti- 
PLA2R autoantibody levels decreased or even disappeared (Figure e1). Of 
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note, when plotting all available data of anti-PLA2R levels against 
proteinuria, a significant correlation was again observed ( =0.75; Figure 3). 
 
 
 
 
Figure 3.  Correlation between the anti-PLA2R antibody level and 
proteinuria  
   All samples during clinical course, n=46 from 14 patients with 
positive aPLA2R antibodies at baseline. 
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Figure e1:  Anti-PLA2R autoantibody level during clinical course including 
point of last follow-up.  
 Nephrotic:  sample taken during period of proteinuria >3.5 g/day with 
serum albumin <3.0 g/dL; Remission: sample taken during clinical 
remission with proteinuria <3.5 g/day; Relapse: sample taken during 
clinical relapse of proteinuria >3.5 g/day after a period of remission. 
End of follow-up: samples taken median 26 months after the relapse 
occurred (range 12-96 months), Proteinuria (g/day) at last follow-up 
is depicted in the boxes.  
 
 
Discussion 
We found that 77.8% of iMN patients in our European cohort had antibodies 
reactive with human PLA2R, similar to the proportion of anti-PLA2R positive 
primary MN patients in the US5 and other international iMN patient cohorts 
(LHB, unpublished observations). Although the exact mechanisms and the 
role of PLA2R in pathogenesis of iMN are currently still unknown, our current 
data strengthen the role of PLA2R as the major target antigen in iMN. 
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Other recently described antigens may play a role in our anti-PLA2R 
negative patients.6 
 
Our blinded analysis of samples collected at various stages of clinical 
disease activity revealed a clear association of anti-PLA2R antibodies with 
clinical status as defined by proteinuria. Anti-PLA2R levels were high when 
patients had nephrotic levels of proteinuria, were substantially decreased or 
absent in the setting of spontaneous or treatment-induced remission, and 
were again increased in association with disease recurrence.  Remarkably, 
we observed that the level of anti-PLA2R as semi-quantitatively assessed by 
immunoblotting was positively correlated with the amount of proteinuria. This 
was not only true for baseline samples but also when combining all data 
obtained during follow-up. Although a clear causal relationship cannot be 
established by these data, it is tempting to speculate that higher titers of anti-
PLA2R autoantibodies may lead to more subepithelial antibody-antigen 
immune deposits, greater podocyte damage, and thus increased levels of 
urinary protein. This hypothesis is further strengthened by the observation 
that anti-PLA2R autoantibody levels at baseline also strongly correlated with 
other markers of renal damage such as urinary excretion of β2m and IgG, 
and serum creatinine levels.  Future work is needed to determine if these 
antibodies are directly pathogenic to the human podocyte. 
 
In two patients findings were seemingly inconsistent. In one patient, anti-
PLA2R autoantibodies were absent at first presentation, but clearly positive 4 
months later. In the second patient anti-PLA2R autoantibodies remained 
present during remission, and were absent with increasing proteinuria during 
follow-up.  
 
We have no biologically plausible explanation for the findings in the first 
patient.  Autoantibodies were absent in the sample taken at presentation, 
shortly after a renal biopsy that exhibited all the features typical of an 
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idiopathic membranous nephropathy and at a time when the patient was 
severely nephrotic (proteinuria 12.5 g/day, serum albumin 2.4 g/dL). Since 
the repeated sample was strongly positive, we have to acknowledge the 
possibility of an inadvertent mislabeling of the first specimen. 
 
We have proposed that the immunologically active phase of MN (defined by 
the presence of circulating anti-PLA2R antibodies) must end before a 
corresponding improvement is seen in proteinuria or other clinical features.8 
This makes sense conceptually, since clearance and resolution of the 
subepithelial immune deposits, changes to the glomerular basement 
membrane, and podocyte structural damage need to occur before the 
proteinuria can completely resolve. Residual proteinuria may at times remain 
indefinitely in the absence of immunologic activity, due to tubule-interstitial 
damage or secondary glomerular changes from prolonged disease. For this 
reason, a definition of partial remission based only on urinary protein may be 
flawed, as similar levels of proteinuria can occur with or without the presence 
of immunological activity. It is thus possible that our patient in whom there 
was no anti-PLA2R detectable in the sample at end of follow-up, although 
there was still a persistent proteinuria of 4.8 grams/day, had actually already 
remitted immunologically, but had residual proteinuria based on secondary 
FSGS lesions. Serum albumin level at that moment had slightly increased to 
3.3 g/dL, which in our opinion supports the diagnosis of secondary FGS 
rather than active membranous nephropathy.  
 
Variability in proteinuria due to dosing and compliance with inhibitors of the 
renin-angiotensin system and/or declining renal function may also lead to 
spurious conclusions about remission status that are based only on amounts 
of urinary protein. Thus, in the patient in whom anti-PLA2R antibody levels 
were detected despite a clinically-defined remission, the low level of urinary 
protein may not have been reflective of a true immunological remission. 
Indeed, the patient’s subsequent progressive loss of renal function is 
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consistent with persistent disease activity. This point may become relevant 
in patients with advanced renal failure from iMN who are eligible for 
transplantation, as the presence or absence of anti-PLA2R autoantibodies 
may influence the potential for recurrent disease in the allograft.9  However, 
since a clinical recurrence of membranous nephropathy is observed in a 
minority of patients after transplantation, further studies in this field are 
warranted. 
 
In conclusion, the role of PLA2R as a major antigen in iMN was confirmed in 
an independent, European patient cohort, and levels of circulating anti-
PLA2R revealed a strong correlation with clinical disease activity. 
Furthermore, although anti-PLA2R autoantibody levels correlated strongly 
with proteinuria, we propose that both can also provide independent 
information, especially when they are discordant. In those occasions when 
low or absent anti-PLA2R levels indicate the remission of immunologic 
activity, "residual" proteinuria may reflect as yet unresolved structural 
changes in the glomerulus or interstitial/tubular damage. 
We propose that detection and measurement of these autoantibodies may 
play an important role in the monitoring of disease activity and treatment 
efficacy.  Larger studies are clearly needed to confirm our data and to 
evaluate the sensitivity and specificity of change in anti-PLA2R autoantibody 
level for predicting a change in disease activity in the individual patient. 
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Introduction 
Membranous nephropathy (MN) is the most common cause of the nephrotic 
syndrome in Europe, with an incidence of ~10/million/yr in adults.1 Although 
MN can occur secondary to infections, systemic diseases, use of drugs, or 
malignancies, in most patients no underlying cause is identified (idiopathic 
MN). Recent studies have identified antibodies against the M-type PLA2-
receptor, an antigen present on podocytes, in 70% of patients with iMN, thus 
establishing iMN as an auto-immune disease.2 These findings were 
supported by a Genome Wide Association Study that found an association 
between PLA2R and iMN.3  
In this comment we describe the management of patients with MN (depicted 
in Figure 1).  
 
Exclude secondary causes of MN 
Secondary causes of MN are listed in Table 1. Most causes can be excluded 
by detailed medical history, a review of the patient’s drug history, physical 
examination and laboratory studies (Table 1). Awareness for a malignancy is 
particularly important in the elderly.1;4 The prevalence of a malignancy was 
4.1% in patients <60 years and 19.4% in patients over 60 years of age.5 
Studies have suggested that iMN can be differentiated from malignancy 
related MN. Japanese investigators reported that glomerular staining for 
IgG1 was significantly stronger in malignancy related MN, and equal to IgG4, 
whereas in iMN there was predominant staining for IgG4.6 The French group 
reported an increased  number of inflammatory cells in the glomerulus of  
patients with a malignancy.4 Using a cut-off value of 8 cells per glomerulus 
specificity and sensitivity were 75% and 92% respectively. Although 
promising, these data need validation. Preliminary data indicate that 
antibodies against PLA2R are absent in patients with secondary MN.2 If 
confirmed, there would be no need to search for a malignancy in anti-PLA2R 
positive patients. 
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Figure 1: Flow chart: strategy for the management of patients with 
Membranous Nephropathy 
MN:  membranous nephropathy; GFR: glomerular filtration rate; 
LMW: low molecular weight; D+M: duration and magnitude; ACEi: 
angiotensin converting enzyme inhibitor; CYP: cyclophosphamide; 
CNI: calcineurin inhibitor; MMF: mycophenolate mofetil 
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Table 1. Causes of Membranous Nephropathy and suggested investigations 
in patients with MN 
*It is debated if these studies should be done routinely. We prefer to do this 
selectively, based on results of history, physical examination, laboratory studies etc. 
† in women >40 yrs; †† in men >50 yrs 
 
  
Risk prediction in iMN  
Patients with never-nephrotic proteinuria do not develop renal failure.7 These 
patients should be treated with conservative (non-immunosuppressive) 
therapy only (Figure 1). Alternatively, patients with a deteriorating renal 
function will almost invariably progress to ESRD, and should be considered 
for immunosuppressive therapy. Prognosis is variable in patients with a 
nephrotic syndrome.  Two recent studies showed that 48% - 54% of patients 
with iMN and a nephrotic syndrome needed immunosuppressive therapy 
over a follow-up period of 63-80 months.8;9 Thus, accurate risk prediction is 
needed in these patients.   
Proteinuria is an independent predictor of renal function deterioration in 
patients with iMN.10 However, baseline proteinuria is not an accurate 
Groups Diseases Diagnostic tools  
 
Drugs NSAIDs ╖ 
 Gold ╢  History 
 Penicillamine ╜ 
Auto-immune SLE ANA, anti-dsDNA 
 Thyroiditis TSH, T4  
Infections Hepatitis B Hbs- antigen, Hbe-antigen 
 Hepatitis C anti-HCV 
 Syphilis Treponemal antigen 
Malignancy  Hb, Ferritin, Iron, LDH, Alkaline 
Phosphatase 
 Lung X- thorax 
 Stomach Gastroscopy* 
 Colon Colonoscopy* 
 Breast Mammography† 
 Prostate PSA††, rectal examination 
 Kidney Ultrasound*  
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predictor of prognosis. Up to 21.5% of patients with baseline proteinuria >12 
g/day developed a spontaneous remission.9  Risk factors other than serum 
creatinine or baseline proteinuria are age, sex, HLA, race, blood pressure, 
glomerulosclerosis, tubulo-interstitial fibrosis, selectivity index, and urinary 
excretion of complement C3dg and C5b-9.  All these factors lack clinical 
utility, because of their low sensitivity or specificity (reviewed in 10). Since 
then more promising predictors have been proposed.11-13 Pei et al. showed 
that a model that included the duration and magnitude of proteinuria 
improved predictive accuracy.11  They studied 184 patients; proteinuria was 
>4 g/day in 127 patients. During follow-up 47 patients showed evidence of 
disease progression. A cut-off value of proteinuria >8 g/day for a period of 
>6 months provided a specificity of 88% and a sensitivity of 66%. The 
Toronto group developed a renal risk score, which was based on baseline 
creatinine clearance, the magnitude of proteinuria in the 6 month period with 
minimal persistent proteinuria, and the change in creatinine clearance over 
this 6 month period. This risk score was validated in three independent 
patient cohorts and provided good accuracy of 79-87%.12 The use of the risk 
score has some disadvantages, since patients need to be followed for a 
prolonged period of time, and repeated 24 hr urine collections are needed.  
Bazzi et al. used SDS-PAGE electrophoresis and showed that increased 
excretion of LMW proteins predicted outcome.14 We extended these findings 
by quantitating urinary  E2-microglobulin.15 These data were validated in a 
study that included 57 patients.13 A threshold value of 0.5 Pg/min predicted 
outcome with sensitivity of 88% and specificity of 91%. A recent analysis of 
our data indicates that in the current era sensitivity and specificity are 
between 75 and 80%.  
 
Treatment of iMN 
Conservative therapy 
Patients with edema should be treated with diuretics and sodium 
restriction.16 Drugs that interfere with the RAAS system effectively lowered  
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proteinuria and improved outcome in patients with kidney diseases.17 Thus, it 
is advised that all patients with iMN be treated with ACEi. However, the 
efficacy of ACEi treatment in patients with a severe nephrotic syndrome is 
limited9;18 and the use of ACEi has not dramatically changed the natural 
history of iMN.19;20 Although RCTs are lacking, most authors advise the use 
of cholesterol lowering drugs in patients with longstanding proteinuria. The 
use of statins in patients with CKD is supported by the SHARP study, which 
showed a reduction of cardiovascular events.21  
Patients with iMN are at increased risk for thrombosis. It is advised to 
consider prophylactic anti-coagulant therapy in patients with serum albumin 
<20 g/l. Obviously, risks and benefits must be weighed in the individual 
patient, considering a history of thrombosis, immobilization, increased 
bleeding tendency etc. We advise the use of prophylactic anticoagulation 
with LMW heparin in patients who start treatment with high dose prednisone, 
which might predispose to thrombosis.22 
 
Immunosuppressive therapy  
Many authors are reluctant to advise immunosuppressive therapy in high 
risk patients with iMN. Some doubt the efficacy of such therapy, whereas 
others emphasize the side effects. We recently reviewed the evidence that 
supports the efficacy of alkylating agents in preventing ESRD in patients with 
iMN.23 Two large randomized controlled trials with long follow-up 
demonstrated improved renal survival after treatment with chlorambucil or 
cyclophosphamide alternated with high dose steroids. 24;25 Benefits were 
confirmed in cohort studies.26;27 Cyclophosphamide is preferred over 
chlorambucil.28 Treatment schedules are depicted in Table 2. The optimal 
duration of therapy is debated. A three month regimen of cyclophosphamide 
is effective, however only used in patients in the early stage of disease. We 
have used cyclophosphamide 1.5-2 mg/kg/day for 12 months (cumulative 
dose 36 g) in high-risk patients and reported a favourable outcome.26 
However, recent literature questioned the safety of a cumulative dose of 36 
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g or above.29 Therefore, we now limit the duration of treatment with 
cyclophosphamide to a period of 6 months. We caution against a further 
reduction of the duration of treatment. Based on our experience a 3 month 
course may be too short in high risk patients. This has also been suggested 
in a recent study, that reported resistance to cyclophosphamide used in a 
dose of 1-2 mg/kg/day for 3-6 months.30 Overall, in studies with alkylating 
agents 5 years renal survival is 86 to 92%,  remission rates range from 65-
85%, and relapse rate is 25% after 5 years (Table 3).23 Obviously, the use of 
alkylating agents is complicated by serious side effects, particularly infertility 
and risk of late malignancies. This has stimulated the search for alternative 
treatment modalities.   
 
Calcineurin inhibitors (CNI) are successfully used in patients with iMN and a 
nephrotic syndrome. An overview of clinical trials is provided in Table 4.31-40 
Although remissions occur in 75-88% of patients, the efficacy on renal end 
points remains unproven. Since 50-72% of patients relapses after stopping 
treatment,39-40 and multiple relapses predict ESRD,37 patients may need 
treatment for many years (CNI-dependent).  Mycophenolate mofetil used as 
monotherapy is not effective.41 MMF in a dose of 2 g/day, and combined with 
steroids may induce remissions as effectively as cyclophosphamide or 
chlorambucil.42 However, many (75%) patients relapse within two year after 
end of treatment, and benefits on renal end points have not been 
documented (Table 5).41-46 Therefore, we suggest that MMF be considered 
only in patients who cannot use or are intolerant to cyclophosphamide or 
CNI.  
  
Rituximab has received great interest. This antibody, which targets CD-20 
positive B cells, has been used in different dosing schedules, varying from 
one bolus of 1 g or two biweekly doses of 1 g/day, to 4 weekly doses of 375 
mg/m2. Results from recent clinical trials are depicted in Table 6.47-52 The use 
of rituximab was associated with a high incidence of remissions. However, 
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the  best outcome was reported in female patients with normal renal function 
and moderate proteinuria.53 No benefits were seen in patients with moderate 
tubulo-interstitial fibrosis.51 These data suggested that rituximab may not be 
effective in high-risk patients. However, a recent cohort study in 20 patients 
with iMN, which included 11 patients who had failed prior 
immunosuppressive therapy, showed a remission rate of 89%.50  A recent 
study suggested that rituximab also may allow successful withdrawal in CNI-
dependent patients.52 
 
Several studies showed beneficial effects of synthetic adrenocorticotropic 
hormone (ACTH) in patients with iMN (Table 7).54-57 Its proposed mechanism 
of action is through activation of the melanocortin receptor MCR1 in 
podocytes, leading to reduction of oxidative stress and proteinuria and 
improved podocyte morphology.58  In a randomized controlled trial synthetic 
ACTH proved to be as effective as combined cytotoxic agent/steroid therapy 
in inducing a remission, and was associated with very few side effects.56 A 
recent retrospective case series of 11 patients with iMN that were treated 
with the natural highly purified ACTH gel formulation showed a remission 
rate of 82% in patients who had previously failed a mean of 2.4 
immunosuppressive therapies.57 We argue against the use of ACTH in view 
of the lack of sufficient evidence, the short follow-up in the reported studies 
and the lack of data on hard renal end points. Furthermore, the ACTH gel 
brings enormous costs. 
 
Individualized therapy 
The search for markers that accurately predict prognosis in iMN was based 
on the idea that starting immunosuppressive therapy in the early stage of the 
disease, i.e. at the time of normal renal function, would be beneficial. 
However, this has not been proven. We recently reported data of a small 
randomized study that compared early start of therapy (shortly after renal 
biopsy) with a strategy in which treatment was started at the time that there 
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was evident deterioration of renal function.59 The study included 26 patients 
with iMN, a nephrotic syndrome, and elevated urinary E2M. Early treatment 
resulted in a more rapid onset of remission and a shorter duration of the 
nephrotic syndrome. Four patients randomized for late treatment 
spontaneously improved, and thus were not exposed to immunosuppressive 
therapy. At the end of follow-up there were no differences in eGFR or 
proteinuria. Thus, there is no proof that immunosuppressive therapy should 
be started in the early stage of the disease. We suggest that in the individual 
patient the decision to start therapy must be based on critical weighing 
benefits and risks.  
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Idiopathic membranous nephropathy (iMN) is a glomerular disease that can 
present with variable proteinuria. In patients with non-nephrotic proteinuria 
outcome is favorable. In contrast, in patients with a nephrotic syndrome the 
natural course is highly variable.  Approximately half of the patients will 
develop a spontaneous remission of proteinuria, whereas the other half of 
patients will show deterioration of renal function and progress   to end stage 
renal disease (ESRD). In our opinion, immunosuppressive therapy, which 
has proven to be effective in iMN, should be reserved for this latter group of 
high risk patients. Therefore, it is utterly relevant to identify patients with a 
high risk of progression in an early stage of the disease. Preserving renal 
function (glomerular filtration rate) is the ultimate treatment goal in all 
patients with iMN. 
 
In daily clinical practice glomerular filtration rate (GFR) is estimated by 
creatinine clearance or serum creatinine-based formulas. In a previous study 
we suggested that creatinine based estimates of GFR are invalid in patients 
with a nephrotic syndrome, due to altered renal handling of creatinine.  We 
have analyzed our data to find further support for this finding. In Chapter 2 
we have evaluated the most commonly used formula for estimating GFR 
(abbreviated MDRD formula) in a large cohort of patients with glomerular 
disease. We studied the relationship between estimated GFR (eGFR), and 
plasma cystatin C (CysC) and plasma beta-2-microglobulin (β2m) as 
markers of GFR in 142 patients. Daily proteinuria ranged from 0 to 38 g 
(median 6.4).  As expected, a hyperbolic relationship between eGFR and 
both β2m and CysC was observed. In multivariable analysis plasma albumin 
concentration proved to be the most important predictor of the relationship 
between eGFR and both CysC and β2m. In the presence of 
hypoalbuminemia eGFR was approximately 30-40% higher at equal levels of 
plasma CysC or β2m. Conclusions were similar when using the recently 
developed CKD-EPI formula. These data suggest that the commonly used 
creatinine based methods overestimate GFR in patients with a 
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hypoalbuminemia. As a result a clinically significant decrease of GFR may 
be overlooked in patients with a nephrotic syndrome.  Every physician 
should be aware of the limitations of creatinine based estimates of GFR in 
patients with a nephrotic syndrome. 
 
In a previous study we concluded that urinary β2m excretion predicted 
outcome with a good accuracy. Since then, we have continued the search 
for even better biomarkers. We also have re-evaluated the value of β2m in a 
larger patient cohort. In Chapter 3 we compared the accuracy of urinary 
β2m (Uβ2m) and N-acetyl-beta-glucosaminidase (Uβ-NAG) in predicting 
renal insufficiency and remission rates in a cohort of 57 patients with iMN 
and normal renal function (serum creatinine <135 μmol/l). Twenty-eight 
(49%) patients reached the predefined end point of renal failure after 80 ±36 
months of follow-up. Uβ2m proved to be the strongest independent predictor 
for the development of renal insufficiency. Sensitivity and specificity were 81 
and 90% respectively for Uβ2m (threshold value 54 μg/mmol cr), and 74 and 
81% respectively for Uβ-NAG (threshold value 2.64 U/mmol cr). Remission 
rate was 44%. Remission was also better predicted by Uβ2m than by Uβ-
NAG, leading to the conclusion that Uβ2m is superior to Uβ-NAG in 
predicting prognosis in patients with iMN. 
 
Data on two other urinary markers were presented in Chapter 4. We studied 
the fatty acid-binding proteins (FABP’s) L-FABP and H-FABP, markers of 
proximal and distal tubular damage, respectively. In a cohort of 40 patients 
with iMN and normal renal function, urinary L-FABP excretion at baseline 
was increased in all but one patient. Urinary H-FABP was undetectable in 
nine patients. Both L- and H-FABP correlated with urinary β2-microglobulin, 
and IgG. Urinary H-FABP paralleled L-FABP. After a mean follow-up of 75 
±32 months, 16 (40%) patients had reached the predefined end point of 
renal failure. Both urinary L-FABP and H-FABP predicted renal outcome, 
with a calculated sensitivity and specificity of 81 and 83% for both. There 
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was a high correlation between L-FABP and H-FABP, suggesting the 
concurrent development or existence of proximal and distal tubular cell 
injury. Although neither L-FABP nor H-FABP was superior to known proximal 
tubular markers like β2m in predicting progressive disease, these markers 
may be of interest as research tools. 
 
In Chapter 5, we re-evaluated the accuracy of Uβ2m and urinary IgG in a 
larger patient cohort and explored potential causes of misclassification. In a 
cohort of 129 patients with a serum creatinine concentration <135 μmol/l and 
nephrotic range proteinuria (>3.0 g /10 mmol) urinary α1- (uα1m) and β2-
microglobulin (uβ2m) excretion rate was determined. Urinary α1m and 
uβ2m/creatinine ratio was also obtained. We defined progression as a rise in 
serum creatinine ≥50% or ≥25% and an absolute level ≥135 μmol/l. After a 
median follow-up of 25 months (interquartile range 14-59), 47% of patients 
showed progression to the predefined end point of renal failure and 47% 
went into remission. The ROC-AUC for uβ2m was 0.81 (95% CI: 0.73-0.89). 
Using a threshold value of 1.0 μg/min, sensitivity and specificity were 73 and 
75%. Similar accuracy was found for uα1m, uβ2m/creatinine and 
uα1m/creatinine ratio. Evidently, accuracy was lower than in our previous 
study. This was likely explained by different definitions used, and a change 
in patient characteristics probably reflecting a change in referral pattern. 
Blood pressure and cholesterol contributed to misclassification. Repeated 
measurements after 6 to 12 months improved accuracy in patients with 
persistent proteinuria, the positive predictive value of uβ2m increased from 
72% to 89% and the negative predictive value from 76% to 100%. 
In conclusion, although urinary excretion of both α1- and β2-microglobulin 
still predict prognosis in iMN, overall accuracy has declined in recent years. 
A spot urine sample can be used instead of a timed sample and repeated 
measurements increase prognostic accuracy. 
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Immunosuppressive treatment in patients with iMN is heavily debated. In the 
20th century there has been only one high quality randomized controlled trial. 
This study concluded that treatment of patients with iMN and a nephrotic 
syndrome with an alkylating agent improved outcome and prevented ESRD. 
Based on this data, it was suggested to treat all patients with chlorambucil or 
cyclophosphamide. Opponents argued against such a strategy, claiming that 
prognosis in untreated patients with iMN was better, and that many patients 
would receive unnecessary therapy, which due to its toxicity would only 
increase morbidity.  From 1991 onwards, we have advocated a restrictive 
treatment strategy in our university hospital and regional referring hospitals. 
We advised the use of immunosuppressive therapy, consisting of a 
combination of steroids and oral cyclophosphamide for 12 months, in 
patients with iMN at high risk for ESRD. We evaluated the efficacy of this 
strategy.  In Chapter 6 we studied the incidence of ESRD due to iMN in the 
Netherlands in the period 1991-2005, using data from the RENINE 
database. Incidence data showed that the introduction of the 
cyclophosphamide-based treatment strategy in the Nijmegen region had 
resulted in a significant 70% reduction in the incidence of ESRD in patients 
with iMN as compared to an unchanged incidence in other parts of the 
Netherlands. In addition to this observation, we mailed a questionnaire to all 
nephrology centers that entered a patient with ESRD and iMN in the 
RENINE database after 2000.  Response rate to the questionnaire was 65%. 
There were 45 patients (34 male) with a mean age of 49 ±17 years at 
diagnosis and a median serum creatinine concentration of 138 μmol/l (range 
60-1798). Overall, only 22 patients (49%) had been treated with some form 
of immunosuppressive therapy, and only 8 patients received adequate initial 
treatment with an alkylating agent. The questionnaires reflect the differences 
in opinion on the optimal treatment of high-risk patients with iMN. However, 
incidence data indicate that a cyclophosphamide-based restrictive treatment 
policy reduces the risk of ESRD in iMN. 
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Accurate identification of patients at high risk for ESRD allows early start of 
therapy in these patients. It is however unknown if early start of therapy is 
more effective and/or less toxic than late start (i.e. when GFR deteriorates). 
In Chapter 7 we report the results of a randomized controlled trial in 26 
patients with iMN and a high risk of progression to renal failure, based on 
elevated urinary β2m level >0.5 μg/min and urinary IgG >250 mg/day.  
Patients started with immunosuppressive therapy (cyclophosphamide for 12 
m, and steroids) either immediately after randomization or when renal 
function deteriorated (increase of serum creatinine level ≥25% and serum 
creatinine >135 μmol/l or increase of serum creatinine level ≥50%). End 
points were remission rates, duration of the nephrotic syndrome (NS), renal 
function, and complications. The study included 26 patients (24M/2F), age 
48 ±12 yr; serum creatinine concentration 96 μmol/l [range 68-126], and 
median proteinuria 10.0 g/10mmolCr. Early treatment resulted in a more 
rapid onset of remission (p=0.003) and a shorter duration of the NS 
(p=0.009). However, at the end of follow-up (72 ±22 m) there were no 
differences in overall remission rate, serum creatinine concentrations (93 vs 
105 μmol/l), proteinuria, relapse rate, and adverse events. This study 
confirms that in high-risk patients with iMN immunosuppressive treatment is 
effective in inducing a remission. Early treatment shortens the duration of the 
nephrotic phase, but does not result in better preservation of renal function. 
Therefore, treatment decisions must be based on risk- and benefit 
assessment in the individual patient. 
 
In Chapter 8 we discuss the efficacy of alkylating agents in iMN. There is 
now grade A evidence that alkylating agents are effective in patients with 
iMN and increase remission rate and improve renal survival. Thus, alkylating 
agents should be considered the golden standard of therapy. Treatment 
harbours the risk of severe toxicity. Therefore, cyclophosphamide should 
only be given to high-risk patients. Furthermore, a cumulative dose of >36 gr 
should be avoided. Alternative agents with fewer side effects are urgently 
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needed. Still, the efficacy of newer immunosuppressants must be proven on 
renal end points. In randomized controlled trials evaluating the efficacy of 
these agents, alkylating agents must be used as comparator drugs. 
Meanwhile, the debate should not lead to therapeutic nihilism. 
 
Recent identification of circulating auto antibodies against the M-type 
phospholipase A2 receptor (anti-PLA2R) in US patients with iMN provides 
new insights into the pathogenesis of this disease. In Chapter 9 we 
assessed the prevalence of anti-PLA2R in a cohort of 18 Dutch iMN patients. 
Anti-PLA2R levels were blindly assessed by a Western blot immunoassay in 
54 serum samples from 18 patients with iMN collected in various stages of 
clinical disease. Anti-PLA2R levels were correlated with clinical parameters, 
such as proteinuria and clinical status (nephrotic syndrome, remission, and 
relapse). Seventy-eight percent of iMN patients in our cohort had antibodies 
reactive with human PLA2R. Antibody level in these patients correlated 
strongly with both clinical status and proteinuria (r=0.73, p<0.01). In this 
study the role of PLA2R as a major antigen in iMN was confirmed in an 
independent, European patient cohort, and levels of circulating anti-PLA2R 
revealed a strong correlation with clinical disease activity. Thus, if validated 
in a larger patient cohort, the anti-PLA2R assay may provide a new tool for 
monitoring of disease activity and treatment efficacy. 
 
In Chapter 10, we propose a strategy for optimal management of the 
individual patient with membranous nephropathy based on the studies in this 
thesis and a review of the literature.  
 210 
 
  
 211 
 
Chapter 12 
 
 
Samenvatting 
 
Chapter 12 ------------------------------------------------------------------------------------------------ 
212 
 
Idiopathische membraneuze nefropathie (iMN) is een glomerulaire 
nierziekte, die zich kan presenteren met een wisselende mate van 
eiwitverlies in de urine (proteïnurie). Patiënten met proteïnurie ≤3,5 gram per 
dag hebben een gunstige prognose. Daarentegen is het natuurlijk beloop 
van de ziekte in patiënten met een nefrotisch syndroom (proteïnurie ≥3,5 
gram per dag) zeer variabel. In ongeveer de helft van patiënten met een 
nefrotisch syndroom zal een spontane remissie van de proteïnurie optreden, 
terwijl in de andere helft nierfunctieverslechtering optreedt, leidend tot eind-
stadium nierfalen. Ons inziens zou immuunsuppressieve behandeling, die in 
iMN bewezen effectief is, gereserveerd moeten worden voor deze 
laatstgenoemde groep van hoog risico patiënten. Om die reden is het zeer 
relevant om patiënten met een hoog risico op progressie in een vroeg 
stadium van de ziekte te identificeren. Het behoud van nierfunctie 
(glomerulaire filtratie snelheid) is het ultieme behandeldoel in alle patiënten 
met iMN. 
 
In de dagelijkse klinische praktijk wordt de glomerulaire filtratie snelheid 
(GFR) geschat op basis van de kreatinineklaring of met behulp van formules 
die gebaseerd zijn op de serum kreatinine concentratie. In een eerdere 
studie vonden wij aanwijzingen dat dergelijke formules onbetrouwbaar zijn in 
patiënten met een nefrotisch syndroom. Dit werd toegeschreven aan 
verandering in het transport van kreatinine in de proximale tubulus. Wij 
hebben met behulp van de gegevens uit ons patiëntenbestand geprobeerd 
om deze bevindingen te bevestigen. In Hoofdstuk 2 hebben we de meest 
gebruikte formule voor het schatten van de GFR (de verkorte MDRD 
formule) geëvalueerd in een groot cohort van patiënten met een 
glomerulaire ziekte. We hebben de relatie bekeken tussen de geschatte 
GFR (eGFR) en de plasma cystatine C concentratie (CysC) en plasma beta-
2-microglobuline (β2m), beide markers van de GFR. Wij bestudeerden 142 
patiënten met een proteïnurie van 0 tot 38 gram per dag (mediaan 6,4). Als 
verwacht werd een hyperbole relatie gevonden tussen eGFR en zowel CysC 
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als β2m. In een multivariaat analyse bleek de plasma albumine concentratie 
de belangrijkste voorspeller van de relatie tussen eGFR en zowel CysC als 
β2m. In de aanwezigheid van hypoalbuminemie was de eGFR zo’n 30 tot 
40% hoger bij gelijke waarden van plasma CysC en β2m. De conclusies 
waren hetzelfde wanneer de recent ontwikkelde CKD-EPI formule werd 
gebruikt. Deze data bevestigen dat formules die gebaseerd zijn op de serum 
kreatinine concentratie bij patiënten met een nefrotisch syndroom de GFR 
overschatten. Als gevolg daarvan kan een klinisch relevante afname van de 
GFR in patiënten met een nefrotisch syndroom worden gemist. Iedere 
internist zou zich bewust moeten zijn van de beperkingen van op-kreatinine-
gebaseerde schattingen van de GFR in patiënten met een nefrotisch 
syndroom.  
 
In een eerdere studie toonden wij aan dat de uitscheiding van β2m in de 
urine de prognose van patiënten met iMN vrij accuraat kan voorspellen. De 
betrouwbaarheid was zeker niet optimaal, daarom hebben we de zoektocht 
naar nog betere biomarkers voortgezet. Omdat de conservatieve 
behandeling van iMN de afgelopen 10 jaar is veranderd, hebben we de 
waarde van β2m opnieuw geëvalueerd. In Hoofdstuk 3 hebben we de 
accuraatheid van urine β2m (uβ2m) en N-acetyl-beta-glucosaminidase (Uβ-
NAG) in het voorspellen van nierinsufficiëntie en remissies vergeleken. Wij 
bestudeerden de gegevens van 57 patiënten met iMN en een normale 
nierfunctie (serum kreatinine <135 μmol/l). Achtentwintig (49%) patiënten 
bereikten het vooraf gedefinieerde eindpunt van nierfalen na 80 ±36 
maanden follow-up. Uβ2m bleek de sterkste onafhankelijke voorspeller voor 
het ontwikkelen van nierinsufficiëntie. Sensitiviteit en specificiteit waren 
respectievelijk 81 en 90% voor Uβ2m (afkapwaarde 54 μg/mmol kreatinine), 
en respectievelijk 74 en 81% voor Uβ-NAG (afkapwaarde 2.64 U/mmol 
kreatinine). Het remissie percentage was 44%. Ook remissie werd beter 
voorspeld door Uβ2m dan door Uβ-NAG. Uit deze studie concludeerden wij 
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dat Uβ2m superieur is ten opzichte van Uβ-NAG in het voorspellen van de 
prognose voor patiënten met iMN. 
 
Gegevens over twee andere urinemarkers werden gepresenteerd in 
Hoofdstuk 4. We bestudeerden de vetzuurbindende eiwitten (FABP’s) L-
FABP en H-FABP, markers van respectievelijk proximale en distale tubulaire 
schade. In een cohort van 40 patiënten met iMN en normale nierfunctie, was 
de baseline urine excretie van L-FABP verhoogd in alle patiënten op één na. 
Urine H-FABP was niet detecteerbaar in 9 patiënten. Zowel L-FABP als H-
FABP correleerde met Uβ2m en UIgG. Na een gemiddelde follow-up van 75 
±32 maanden hadden 16 (40%) patiënten het vooraf gedefinieerde eindpunt 
van nierfalen bereikt. Zowel urine L-FABP als H-FABP voorspelde de renale 
uitkomst, met voor beide een berekende sensitiviteit en specificiteit van 81 
en 83%. Er was een sterke correlatie tussen L-FABP en H-FABP, hetgeen 
een gelijktijdig ontstaan of bestaan van proximale en distale tubulaire 
celschade suggereert. Hoewel noch L-FABP noch H-FABP de prognose 
beter voorspelde dan bekende proximale tubulaire markers zoals β2m, 
zouden deze markers in onderzoekssetting van belang kunnen zijn. 
 
In Hoofdstuk 5 hebben we de accuraatheid van Uβ2m en urine IgG 
opnieuw geëvalueerd in een groter patiëntencohort en daarbij gezocht naar 
potentiële oorzaken voor misclassificatie. In 129 patiënten met een serum 
kreatinine concentratie <135 μmol/l en proteïnurie >3.0 g/10mmol kreatinine 
werd de urine excretie van α1- en β2-microglobuline bepaald (uα1m en 
uβ2m). Daarnaast werd een uα1m- en uβ2m/kreatinine-ratio berekend. 
Progressie werd gedefinieerd als een stijging van het serum kreatinine met 
≥50% of een stijging ≥25% met een absolute waarde ≥135 μmol/l. Na een 
mediane follow-up van 25 maanden (interquartiel range 14-59), toonde 47% 
van de patiënten progressie naar het vooraf vastgestelde eindpunt van 
nierfalen, 47% had een remissie van de ziekte bereikt. De ROC-curve voor 
uβ2m had een AUC van 0.81 (95% betrouwbaarheidsinterval 0.73-0.89). 
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Met een afkappunt van 1.0 μg/min, waren de sensitiviteit en specificiteit 
respectievelijk 73% en 75%. Een vergelijkbare accuraatheid werd gevonden 
voor uα1m, uβ2m/kreatinine- en uα1m/kreatinine-ratio. Deze accuraatheid 
was duidelijk minder dan in ons eerdere onderzoek. Dit wordt waarschijnlijk 
verklaard door het feit dat er andere definities werden gebruikt en door een 
verandering in patiëntkarakteristieken, die waarschijnlijk een gevolg zijn van 
een veranderd verwijzingspatroon vanuit de perifere ziekenhuizen. 
Bloeddruk en cholesterol droegen bij aan misclassificatie. Herhaalde 
metingen verbeterden de betrouwbaarheid in patiënten met persisterende 
proteïnurie, de positief voorspellende waarde van uβ2m nam toe van 72% 
naar 79% en de negatief voorspellende waarde van 76% naar 100%. 
Concluderend:  hoewel de uitscheiding in de urine van zowel α1- als β2-
microglobuline de prognose van patiënten met iMN nog steeds voorspelt, is 
de totale betrouwbaarheid de afgelopen jaren verminderd. In plaats van een 
getimed monster kan een willekeurige urine portie worden gebruikt.  
Herhaling van de metingen na 6 tot 12 maanden verbetert de 
betrouwbaarheid van de voorspelling. 
 
De behandeling van patiënten met iMN met immuunsuppressieve medicatie 
is onderwerp van hevige discussie. In de 20e eeuw werd slechts één 
kwalitatief goede gerandomiseerde studie gepubliceerd. De conclusie van 
deze studie was dat behandeling van patiënten met alkylerende middelen de 
prognose van patiënten met iMN en een nefrotisch syndroom verbeterde en 
eind stadium nierfalen voorkwam. Op basis van deze gegevens werd 
voorgesteld alle patiënten met de alkylerende middelen chloorambucil of 
cyclofosfamide te behandelen. Tegenstanders van deze strategie wezen 
erop dat de prognose in onbehandelde patiënten met iMN beter was dan in 
de controlegroep van de betreffende studie en dat veel patiënten onnodig 
behandeld zouden worden. Behandeling met alkylerende middelen zou 
slechts tot meer ziektelast van de daarmee gepaard gaande toxiciteit en 
bijwerkingen leiden. Vanaf 1991 pasten wij in ons academisch centrum en in 
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de meeste regionale, verwijzende ziekenhuizen een restrictieve 
behandelingsstrategie toe. Hierbij werden alleen patiënten met een hoog 
risico op eindstadium nierziekten behandeld met immuunsuppressiva. De 
behandeling bestond in die gevallen uit een combinatie van steroiden en 
cyclofosfamide oraal gedurende 12 maanden. In Hoofdstuk 6 hebben we 
het vóórkomen van eindstadium nierfalen als gevolg van iMN in Nederland 
in de jaren 1991-2005 geëvalueerd, gebruikmakend van de gegevens van 
RENINE. Op basis hiervan konden wij aantonen dat de introductie van onze 
restrictieve, op cyclofosfamide gebaseerde behandelingsstrategie heeft 
geleid tot een significante 70% afname in de incidentie van eindstadium 
nierfalen door iMN in onze regio. In de overige regio’s van Nederland bleef 
de incidentie gelijk. Wij hebben in die periode een vragenlijst gestuurd aan 
alle nefrologische centra die na 2000 een patiënt met eindstadium nierfalen 
als gevolg van iMN bij de RENINE database hadden aangemeld. 
Antwoorden werden gekregen van 65% van de centra. Zij rapporteerden 45 
patiënten (34 mannen) met een gemiddelde leeftijd bij diagnose van 49 ±17 
jaar en een mediane serum kreatinine concentratie van 138 μmol/l (spreiding 
60-1798). In totaal waren slechts 22 patiënten (49%) behandeld met enige 
vorm van immuunsuppressieve therapie, waarvan maar 8 initieel adequaat 
behandeld waren met een alkylerend middel. Deze vragenlijst reflecteert de 
meningsverschillen over de optimale behandeling van hoogrisico patiënten 
met iMN. Het is echter duidelijk dat een op cyclofosfamide- gebaseerd, 
restrictief therapeutisch beleid het risico op eindstadium nierfalen in iMN 
verminderd. 
 
Omdat patiënten met een hoog risico op nierfalen in een vroege fase kunnen 
worden herkend, is het mogelijk om behandeling te starten voordat de 
nierfunctie achteruit gaat. Het is echter niet bekend of vroege start van 
therapie effectiever en/of minder toxisch is dan late start (d.w.z. als de GFR 
afneemt). In Hoofdstuk 7 rapporteren we de resultaten van een 
gerandomiseerd, gecontroleerd onderzoek in patiënten met iMN en een 
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hoog risico op progressie naar nierfalen. Patiënten startten ofwel direct na 
randomisatie met immuun-suppressieve therapie (cyclofosfamide gedurende 
12 maanden en steroïden) ofwel op het moment dat de nierfunctie begon te 
verslechteren (toename van de serum kreatinine concentratie met  ≥25% én 
serum kreatinine concentratie >135 μmol/l of toename van de serum 
kreatinine waarde met ≥50%). Eindpunten waren het percentage remissies, 
de duur van het nefrotisch syndroom (NS), de nierfunctie en complicaties. 
De studie betrof 26 patiënten (24M/2V), leeftijd 48 ±12 jaar; serum kreatinine 
waarde 96 μmol/l [range 68-126] en mediane proteïnurie 10.0 gram/10mmol 
kreatinine. Vroege behandeling leidde tot een sneller ontstaan van remissie 
(p=0.003) en een kortere duur van het NS (p=0.009). Aan het eind van de 
follow-up (72 ±22 maanden) waren er echter geen verschillen in het totale 
aantal remissies, serum kreatinine concentraties (93 vs 105 μmol/l), 
proteïnurie, aantal recidieven en bijwerkingen. Deze studie bevestigt dat in 
hoog risico patiënten met iMN immuunsuppressieve behandeling effectief is 
in het induceren van een remissie. Vroege behandeling verkort de duur van 
de nefrotische fase, maar resulteert niet in een betere preservatie van de 
nierfunctie. Om deze reden moet een besluit over behandeling van de 
individuele patiënt gebaseerd worden op een zorgvuldige afweging van de 
voor- en nadelen. 
 
In Hoofdstuk 8 bespreken we de effectiviteit van alkylerende middelen in 
iMN. Er bestaat nu graad A bewijs dat alkylerende middelen effectief zijn in 
patiënten met iMN: ze doen het aantal remissies toenemen en verbeteren de 
renale overleving. Alkylerende middelen moeten dus als gouden standaard 
van therapie beschouwd worden. Behandeling met deze middelen draagt 
een risico op ernstige toxiciteit met zich mee. Om deze reden zou 
cyclofosfamide alleen gegeven moeten worden aan hoog-risico patiënten en 
bovendien zou een cumulatieve dosis van >36 gram vermeden moeten 
worden. Alternatieve middelen met minder bijwerkingen zijn met zekere 
urgentie gewenst. Voorlopig moet de effectiviteit van nieuwere 
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immuunsuppressiva echter nog bewezen worden op renale eindpunten. In 
gerandomiseerde studies naar de effectiviteit van deze middelen, zouden 
alkylerende middelen in de vergelijkende arm moeten worden gebruikt. 
Ondertussen mag het debat over de beste therapie niet leiden tot 
therapeutisch nihilisme. 
 
Recente identificatie van circulerende auto-antistoffen tegen de M-type 
Fosfolipase A2 receptor (anti-PLA2R) in patiënten met  iMN in de VS, leidt tot 
nieuwe inzichten in de pathogenese van deze ziekte. In Hoofdstuk 9 
hebben we de prevalentie van anti-PLA2R in een cohort van 18 Nederlandse 
iMN patiënten onderzocht. Anti-PLA2R-titers werden blind gemeten middels 
een Western blot immunoassay in 54 serum monsters van 18 patiënten met 
iMN, verzameld gedurende verschillende klinische fases van de ziekte. Anti-
PLA2R-titers werden gecorreleerd met klinische parameters zoals proteïnurie 
en klinische status (nefrotisch symdroom, remissie, recidief). Achtenzeventig 
procent van de iMN patiënten in ons cohort hadden antistoffen die bonden 
aan humaan PLA2R. De antistof titer correleerde in deze patiënten sterk met 
zowel klinische status als proteïnurie (r=0.73, p<0.01). In onze studie werd 
de rol van PLA2R als belangrijk antigeen in iMN bevestigd in een 
onafhankelijk, Europees cohort en toonden de titers van circulerend anti-
PLA2R een sterke correlatie met klinische ziekteactiviteit. Indien gevalideerd 
in een groter cohort, zou de anti-PLA2R assay  een nieuw instrument kunnen 
zijn voor de monitoring van ziekteactiviteit en effectiviteit van behandeling. 
 
In Hoofdstuk 10 stellen we een strategie voor optimale behandeling van de 
individuele patiënt met membraneuze nefropathie voor, gebaseerd op de 
studies in dit proefschrift en een evaluatie van literatuurgegevens. 
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Veel mensen hebben -direct of indirect-  bijgedragen aan het tot stand 
komen van dit proefschrift. Mijn dank aan ieder van hen is groot. Een aantal 
personen wil ik op deze plaats speciaal bedanken: 
 
De patiënten die vanuit heel zuidoost Nederland (en soms van daarbuiten) 
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de behandelstudies ben ik dankbaar. Zonder hen geen proefschrift! 
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Doetinchem, Enschede, Veghel/Oss, Veldhoven, Eindhoven, Roosendaal, 
Zwolle) die patiënten voor een proteïnuriemeting naar Nijmegen verwijzen 
wil ik ook hier graag noemen.  
Dank voor jullie vertrouwen in en bijdrage aan het behouden en uitbreiden 
van de Nijmeegse expertise op het gebied van de glomerulaire ziekten. We 
hopen op een blijvende samenwerking in de toekomst! 
 
Zeer geachte professor dr.J.F.M.Wetzels, beste Jack. Als mijn promotor sta 
jij aan de basis van dit proefschrift. Jij hebt me binnengehaald in het 
glomerulaire onderzoek en begeleid tijdens mijn ontwikkeling als 
onderzoeker. Ik heb onze samenwerking al die tijd als zeer prettig ervaren 
en ontzettend veel van je geleerd. Ik bewonder jouw wetenschappelijk en 
creatieve denken, je onuitputtelijke feitenkennis maar ook zeker je 
betrokkenheid bij je patiënten. Ik heb het je behoorlijk lastig gemaakt (en doe 
dat nu nog) met mijn verlofperiodes en mijn honkvastheid in Nederland. 
Desondanks heb jij mij steeds gestimuleerd om ook na het voltooien van dit 
proefschrift door te gaan met onderzoek. Ik verheug me op onze verdere 
samenwerking en dank je voor jouw vertrouwen in mijn kunnen. 
 
Zeer geachte professor dr. J.H.M. Berden, beste Jo. Als hoofd van de 
afdeling Nierziekten heb jij me de ruimte gegeven voor onderzoeks-
activiteiten, researchbesprekingen en congresbezoek, ook tijdens mijn 
klinische periodes. Hartelijk dank hiervoor.  
 
Secretariaat en staf van de afdeling Nierziekten, sinds 2006 loop ik bij jullie 
rond. Aanvankelijk als zaalarts op E22, daarna in de barak als onderzoeker 
en later op de nefro-gang als NIO. De sfeer op de afdeling is al die tijd goed 
geweest, met een open opleidingsklimaat waarin ik van ieder van jullie veel 
heb geleerd. Dank daarvoor. Ruud, een speciaal woord van dank voor jou. 
In het voorjaar van 2010 sprak jij me aan omdat je zag dat ik het op dat 
moment zwaar had. De paar gesprekken die we toen hadden, hebben er 
mede voor gezorgd dat ik een aantal dingen op een rijtje heb gezet en de 
rust enigszins terugkeerde. Ik vond het bijzonder te merken dat je zo 
opmerkzaam was en heb dat zeker gewaardeerd. 
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Kamergenoten van het eerste uur, Jeroen D. en Jeroen A., als kersverse 
promovendus  belandde ik in de Zeldenrustbarak bij jullie doorgewinterde 
onderzoekers op de kamer. Wat heb ik in het begin veel aan jullie moeten 
vragen. Van reference manager tot SPSS, ik heb veel van jullie opgestoken. 
Dank daarvoor en voor alle gezellige koffiepauzes en lunches. 
Hilde en Jan, jullie werden mijn volgende kamergenoten. Fijn om 
enthousiasme over mooie resultaten te delen, maar ook frustraties over 
missing data, plotseling verdwenen bestanden en bovenal de zoveelste 
revisie van dat ene moeizame artikel. Dank jullie voor een productieve en 
ontspannen tijd en succes met afronden van jullie beider proefschriften. 
 
Alle medeauteurs van de artikelen in dit proefschrift wil ik bedanken voor 
hun  kritische commentaren, zinvolle aanvullingen en bovenal voor de 
prettige samenwerking. 
 
Collega nefrologen in opleiding van de afgelopen jaren: Joy, Jeroen A, Hilde, 
Gerben,Tom, Karin, Jacobien, Martijn, Meint, Eugenie, Pascal, Joan; ik denk 
dat we in alle wisselende samenstellingen een goed team zijn geweest. 
Enthousiaste, kritische dokters met een grote onderlinge collegialiteit. Én 
met de nodige humor, ook zeker niet onbelangrijk in het dagelijks 
standhouden in dit mooie beroep. Dank jullie allen. 
 
Annemiek Polman, Simone Mooren, Yvonne Hooghof: met de 
proteïnuriemetingen hebben jullie je sporen al in heel wat proefschriften 
verdiend! Hoewel jullie inmiddels voor een deel andere werkzaamheden 
hebben, en de metingen nu deels zijn overgenomen door anderen, wil ik 
jullie graag bedanken voor een fijne samenwerking (en voor de vele kopjes 
thee!) 
 
Hilde en Maartje, collega’s en vriendinnen, ik ben blij dat jullie vandaag mijn 
paranimfen willen zijn. Van beginnende assistenten in het Rijnstate zijn we 
“opgegroeid” tot volwassen dokters. Het was prettig om de groeistuipen in dit 
proces samen mee te maken. Jullie patiënten mogen blij zijn met zulke 
vaardige en betrokken dokters, ik ben blij met zulke goede vriendinnen. 
Dank voor jullie steun en aanwezigheid vandaag. 
 
En dan de mensen buiten het ziekenhuis….. 
 
Vrienden en (schoon)familie, ik ben niet altijd even goed in het bijhouden 
van verjaardagen en het afleggen van bezoekjes. Weet dat ik desondanks 
ontzettend blij ben met jullie aanwezigheid in mijn leven! Laten we snel weer 
eens afspreken….. 
 
Lieve Ria en Thea, peettante(s), met dit boekje betreed ik deels jullie terrein. 
Ik schaar mij met trots in de familietraditie van schrijverschap. Ria, dank voor 
al je hulp en tijdsinspanningen bij de uitgave van dit boekje. 
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Lieve Rosa, lieve zus, wat ben ik blij met onze sterke band, die zeker niet 
minder is geworden nu we wat verder van elkaar wonen. Als geen ander wijs 
jij mij regelmatig op de echt belangrijke dingen in het leven. Als grote zus 
kan je het ook nog steeds niet laten om een beetje voor me te zorgen en ik 
koester mij dankbaar in jouw attente aandacht. 
 
Lieve mama en papa, dankzij jullie sta ik hier. Jullie hebben ons altijd 
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emotionele steun. Ik ben zo trots op jullie allebei. 
 
Lieve Robert, jij bent mijn rots in de branding. Sterk, stabiel en met humor 
relativerend tijdens al mijn “piekersessies”.  Dank je voor wie je bent; laten 
we samen heel oud worden..... 
 
Lieve Ruben, lieve Tobias, lief kleintje: dankzij jullie schijnt de zon elke dag 
wel even! 
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